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ABSTRACT
Neurofibromatosis Type I (NFl) is one of the most commonly inherited human disorders,
affecting one in 3,500 newborns worldwide. The mode of disease transmission is believed to be
autosomal dominant, with 100% penetrance. However, the severity of the disease phenotype
varies significantly among NF1 patients. Hallmark lesions of NF1 affect several neural crest-
derived tissues, includes cafe-au-lait spots, Lisch nodules and numerous cutaneous and/or
plexiform neurofibromas. The gene responsible for NF1 was cloned in 1990, and is believed to
function as a tumor suppressor. The protein (neurofibromin) shows close sequence homology to a
family of GTPase Activating Proteins (GAP), which are negative regulators of the ras proto-
oncogene signal transduction pathway.
The focus of this work has been to generate mouse models of NF1 by disrupting the murine Nfl
gene in embryonic stem (ES) cells. We created a strain of mice with a mutant Nfl allele, which
has been shown to produce no functional protein. Initial analysis indicate that heterozygotes are
predisposed to certain NFl-related malignancies, while mice homozygous for the mutation die
around 13.5 days of gestation from cardiac abnormalities. Using the double knockout (DKO)
chimera system, we were able to provide evidence showing that simple Nfl-deficiency may be
sufficient for the induction of neurofibromas. Histological characterization revealed that murine
neurofibromas show close pathologic similarities to the human tumors.
Another serious consequence of the NF1 disease is the malignant progression of benign
neurofibromas into malignant peripheral nerve sheath tumors (MPNST). A potential explanation
for this is that somatic gene mutation must occur in conjunction with Nfl mutations to cause
tumorigenesis in most tissues. To test this model, Nfl-deficient mice were crossed with a p53
mutant strain. Animals harboring mutations in both genes on the same chromosome are
susceptible to malignant sarcomas reminiscent of MPNST. All the tumors have incurred
simultaneous LOH for both genes, suggesting that chromosomal loss or large deletions are the
primary mechanisms for somatic mutations in mice. This could provide a good mouse tumor
model for drugs targeting tumorigenic pathways involving Nfl, p53 or both.
The creation of this Nfl mutant mouse model has also provided a number of useful biological
reagents for the study of Nfl function in various affected tissues, including hematopoietic,
chromaffin and fibroblastic cells, as well as the brain and PNS.
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Chapter 1
Overview of Neurofibromatosis Type 1
Neurofibromatosis Type 1 (NFl, also known as von Recklinghausen neurofibromatosis) is a
common inherited human disorder, affecting one in 3,500 births worldwide (Stumpf et al, 1987).
It is estimated that over 50% of the NF1 mutations are novel mutations (with a mutation rate
approximately one in 10,000 gametes per generation), making it one of the most mutable genes
involved in familial human disorders (Carey et al., 1986). The hallmark lesions of the disease
range from subtle skin pigmentation and eye defects to the development of multiple peripheral
nerve growths that are often disfiguring and painful. Some of these benign lesions may undergo
malignant transformation to become aggressive sarcomas, resulting in poor prognosis of the
patient. The mode of inheritance for NF1 is autosomal dominant, having close to 100% penetrance
(Riccardi, 1992). However, the variable expressivity of the clinical symptoms also makes NF1
one of the most interesting diseases from a tumor etiological standpoint. In this document, I intend
to provide a detailed overview of NF1, including the clinical phenotypes, molecular genetics, and
the creation of animal models to study the fundamental aspects of disease.
The NF1 disease.
The diagnostic criteria for the human NF1 disorder include the appearance of cafe-au-lait spots
(CLS, hyperpigmentation of skin melanocytes), Lisch nodules (hamartomas of the iris),
neurofibromas (benign lesions arising from the cutaneous or plexiform peripheral nerves), and
neurofibrosarcomas (malignant growths typically arising from existing neurofibromas, also known
as malignant peripheral nerve sheath tumors, or MPNSTs) (Riccardi, 1992). To a lesser extent,
some NF1 patients are also predisposed to developing malignancies such as myeloid hyperplasia,
pheochromocytoma (tumors of the adrenal medulla), optic glioma and various sarcomas (Hope &
Mulvihill, 1981; Seizinger, 1993). In addition, facial and long bone abnormalities, as well as mild
learning difficulties are seen with increased frequencies in NF1 patients (Riccardi, 1992). The
current clinical definition for an affected NF1 individual requires meeting two or more of the
following criteria:
* six or more CLS over 5 mm in diameter
* two or more neurofibromas of any time or one plexiform neurofibroma
* freckling in the axillary or inguinal regions
* optic glioma
* two or more Lisch nodules
* a distinctive bone lesion such as sphenoid dysplasia or thinning of the long bone
* a first degree relative with NF1 by the above criteria.
Given the disease definition, it is possible for an individual afflicted with NF1 to show as little as a
few benign skin lesions to over hundreds of palpable neurofibromas. This variability in the
disease spectrum has been an intrinsic feature of NFI: Not only is this evident among unrelated
NF1 patients, the variability is apparent even between affected family members that supposedly
inherited the same NF1 gene mutation (Riccardi, 1993). In fact, studies have shown that identical
twins tend to exhibit a more closely-related set of NF1 phenotypes than fraternal twins and other
more distantly-related individuals (Easton et al., 1993; Huson & Hughes, 1994). These
observations suggest that other genetic (additional mutations) and environmental (biological or
physical) factors must act in conjunction with specific NFI mutations in modulating the severity of
the disease.
While it is almost impossible to precisely predict the occurrence of complications, there are certain
sets of recognized (i.e. empirical) risks for the onset of the NF1 disease. For example, malignant
optic gliomas, brain tumors and myeloid leukemia are found almost exclusively between infant and
adolescent (up to 15 years of age) NF1 patients. Congenital neurofibromas are usually of the
diffuse plexiform variety. Past that stage, patients are typically at-risk of developing increasing
numbers of cutaneous and plexiform neurofibromas. The severity of the disorder (i.e. the risk of
progression from these existing neurofibromas into MPNSTs) typically increases with age and the
onset of hormonal perturbations such as puberty and pregnancy (Riccardi, 1992).
The NF1 clinical heterogeneity story is further complicated by the frequent association of the
disease with two other autosomal dominantly inherited disorders, the Noonan (NS) and Watson
syndromes (WS). NS is characterized by CLS, mental retardation and short stature (Collins and
Turner, 1973), while WS patients present these same features, as well as neurofibromas and Lisch
nodules (Watson, 1967; Allanson et al, 1991). The only WS phenotype not seen in NFl patients
is the 100% penetrance of pulmonary stenosis (valve restriction of the pulmonary artery). It
should be noted that variable expressivity is a trait common to both NS and WS. The extensive
phenotypic overlaps among these three disorders led researchers to hypothesize that NS and WS
either (1) are allelic to NF1 or (2) involve the mutation of genes closely linked to NF1. In fact,
Tassabehji and colleagues (1993) found a perfect, 42 bp, in-frame tandem duplication mutation of
the NF1 gene in a family showing features of NF , NS and WS. Currently, studies have shown
that the NS gene seems to be excluded from chromosome 17 (Sharland et al., 1992), where the
NF1 gene resides (described below), and later localized to chromosome 12 (Jamieson et al.,
1994). The WS disease region has been mapped to chromosome 17 (Allanson et al., 1991), but
the large deletion used for this mapping does not exclude the potential involvement of other genes.
Lastly, the inability to pinpoint the exact chromosomal location for these disease genes may speak
to the multifactorial nature of the disease.
In summary, the variable expressivity of the NF1 disease poses interesting questions about the
genetic and ectopic influences. Given the prevalence and impact of this disorder, my goal is to
create a murine model of NF 1 in an attempt to elucidate such factors.
NF1 neurocristopathy
Many of the affected tissues are derivatives of a transiently-existing cell type during early vertebrate
embryogenesis, the neural crest (NC) (summarized in Table 1). This specialized cell type arises
along the dorsal apex of the newly-fused neural tube in an anterior-posterior fashion. These cells
then quickly detach and begin to migrate through spaces between the neural tube, scleroderm and
the ectoderm. It is believed that the pathways of NC migration is determined by specific
combinations of extracellular matrix (ECM) and cell surface proteins lining each of these spaces,
and that these proteins cause a progressive restriction of developmental fates for each migrating NC
cell (Anderson, 1989). At the appropriate destination, the NC cells cease to migrate (some having
traveled great distances) and assume their appropriate differentiative states. Tissues derived from
the NC include (Le Douarin, 1982):
* melanocytes of the dermis, epidermis and internal organs
* peripheral nerves and nerve sheaths (e.g. sympathetic ganglia)
* adrenal medulla (chromaffin cells)
* the eye (chromaphores of the iris, corneal endothelium)
* the developing heart and connective tissues of large vessels derived from the aortic arches
* cartilage and bones of the face (including nasal and orbital skeleton and the palate)
* connective tissue of the pituitary, thymus, thyroid, parathyroid and salivary glands
Table 1.1. NF1 clinical symptoms involve several neural crest-derived tissues (NC)
Symptoms Tissues affected
cafe-au-lait spots melanocytes (NC)
Lisch nodules iris (NC)
neurofibroma neurons, schwann, fibroblast, perineurial (NC)
neurofibrosarcoma/MPNST neurons, schwann, fibroblast, perineurial (NC)
pheochromocytoma adrenal medulla (NC)
facial bone dysplasia bone derived from NC
myeloid hyperplasia hematopoietic -- myeloid lineage
long bone dysplasia skeletal
mental retardation CNS
The patterns of migration and fates of NC cells were identified by years of experimentation
involving (1) tagging migratory cells with vital dye, radioactivity, antibodies or other genetic
markers and (2) ablation of particular populations of NC cells and assessing their developmental
impact. For example, the NC ablation studies in avian embryos revealed the role of certain cranial
NC cells in the development of embryonic heart. In fact, animals lacking these NC cells developed
a variety of cardiac anomalies, including double outlet right ventricle (DORV), persistent truncus
arteriosis (PTA), aortic defects, and other cardiac inflow abnormalities (Kirby and Waldo, 1990).
However, clinical evidence does not establish a clear correlation between NF1 and congenital heart
defects (Lin and Garver, 1988).
Despite a clear involvement of the NC-derived tissues in various NF1 lesions, explaining why only
these cell types are predisposed to proliferative disorders is more difficult. The fact that some non-
NC cell types are also involved (e.g. mast and endothelial cells) suggest that the mechanism of
disease involves extrinsic agents which acts across cell types and lineages. Do these cells
hyperproliferate due to loss of their terminally-differentiated state, or have they become more
susceptible to growth signal stimulation? This requires an examination of the signals that affect
various NC decisions.
Anderson (1993) compared the mechanism of NC cell differentiation to the process of
hematopoiesis, where proliferating progenitors are generated from stem cells in a single location
and subsequently migrate to peripheral sites of terminal differentiation. The pluripotency of NC
cells are further demonstrated by the identification of environmental and growth signals responsible
for controlling their proliferation, migration and differentiation. For example, NC cells plated on
different extracellular matrix substrates develop into distinctive cell fates (Sieber-Blum and Cohen,
1980), and that these differentiation signals may be further modified by growth factors such as ca-
melanocyte stimulating factor (ca-MSH) (Satoh and Ide, 1987) and glucocorticoid hormones
(Unsicker et al., 1978). The current disease model suggested that the specific genetic mutations
responsible for NF1 confer some kind of growth advantage for these NC cells derivatives, be it a
reversion from their terminally-differentiated state, or acquiring a lower threshold for growth signal
stimulation.
Cloning the NF1 gene.
The cloning of the gene responsible for NF1 was one of the best examples of the positional cloning
technique. The first step is to identify, within multiple affected families, chromosomal regions
and/or polymorphic markers that consistently segregate with individuals showing the disease
symptoms. For NFl, the first linkage was reported by Safarazi et al. (1987), when they localized
the gene to either chromosome 5 or 17. Subsequent narrowing down of the gene locus to the long
arm of chromosome 17 was provided by the efforts of several groups (Seizinger et al., 1987;
Barker et al., 1987; White et al., 1987; Van Tuinen et al., 1987; Skolnick et al., 1987). This
multipoint linkage map was summarized by Goldgar et al. in 1989, where the NF1 disease locus
was localized to a 3 cM region of 17q 11.2.
The detection of two balanced translocation breakpoints from two affected NF1 families was
instrumental to the gene cloning. One translocation occurred between chromosome ip and 17q
(Schmidt et al., 1987), and the other between 17q and 22q (Ledbetter et al., 1989). Given the
correlation between the physical mapping of these two breakpoints to the linkage analysis to
17ql 1.2, these balanced translocation regions were believed to reside within -- and therefore
disrupted -- the NFI gene itself. Using these two guideposts (Figure 1.1), researchers began to
analyze the coding sequences from this region. The first genes identified by walking between the
breakpoints were: EVI2A (Ecotropic viral integration site 2A) (Cawthon et al., 1990), EVI2B
(Cawthon et al., 1991), OMGP (oligodendrocyte-myelin glycoprotein) (Viskochil et al., 1991) and
a pseudogene of AK3 (adenylate kinase 3) (Xu et al., 1992). The EVI2 genes are human
homologs of the mouse Evi2 gene, and have been implicated in the retroviral-induction of myeloid
disorders (Buchberg et al., 1990a). OMGP encoded a glial cell-specific protein, which was
postulated to be a cell adhesion molecule (Mikol et al., 1990). However, these genes were not
considered candidates for NFl, since none of their coding sequences were interrupted by the two
translocation breakpoints, and no NF1 specific mutations were found in these genes (Cawthon et
al., 1990; Cawthon et al., 1991; Viskochil et al., 1991).
The true NF1 gene was finally cloned in 1990 by two groups, led by Dr. Francis Collins (Wallace
et al., 1990a) and Dr. Ray White (Viskochil et al., 1990). Three probes were used to identify the
NF1 transcript: The first probe was a genomic fragment mapping distal to the t(17;22) breakpoint
that was isolated from a cosmid contig that extends through the breakpoint region (Viskochil et al.,
1990). A second probe was a fragment from a jump clone that began between the two breakpoints
Figure 1. 1 The NF1 gene structure
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and extend distal to the t(17;22) breakpoint (Wallace et al., 1990a). The third probe was an entire
yeast artificial chromosome (YAC) encompassing the two breakpoints and extending over 100 kb
toward the telomere (Wallace et al., 1990a). Through the screening of several cDNA libraries,
mRNAs of 11 kb (Viskochil et al., 1990) and 13 kb (Wallace et al., 1990a) were identified. The
coding regions of both these transcripts were found to be disrupted by the t(17;22) translocation
breakpoint, as well as several NFl-specific mutations (Buchberg et al., 1990b).
The NF1 gene structure.
NF1 spans over 350 kb of genomic DNA on chromosome region 17q 11.2 and encodes an mRNA
of 11-13 kb as indicated by its migration on a northern blot, with 59 exons identified to date. The
most prevalent allele of the NF1 transcript (Type I transcript) has an 8454 bp open reading frame,
giving rise to a protein of 2818 amino acids, called neurofibromin. The NF1 protein has an
estimated molecular mass of 327 kDa. A large (2.5 to 4 kb) 3' untranslated region (UTR) is also
present on the NF1 transcript (reviewed in Li et al., 1995).
The NF1 gene sequence predicts a span of 280 amino acid region in the center of the gene that
show homology to the catalytic domain of a family of GTPase activating proteins (GAP), including
p120 mammalian GAP, budding yeast IRA 1 and IRA2, fission yeast sar and Drosophila Gap 1.
This region is known as the NFI GAP-related domain (NFJ-GRD), and spans exons 21 through
27. The importance of this homology will be discussed below. The first alternatively spliced
transcript of NF1 was identified in this region, a 63 bp (or 21 aa) insertion into exon 23 (23a)
called the Type II (or GRD II) transcript (Andersen et al., 1993).
Several other alternative splice variants of the NF1 transcripts have been identified. The summary
of the isoforms is provided below:
* Type I, encoding a 2818 aa protein
* Type II, with a 63 bp (21 aa) insertion into exon 23 (Andersen et al., 1993)
* Type III (3'ALT isoform), with an 54 bp insertion into exon 48 (Gutmann et al., 1993)
* Type IV, containing both the Types II and III insertions (Gutmann et al., 1995)
* N-isoform, producing a 2.9 kb truncated transcript (551 aa protein) (Suzuki et al., 1992)
* 5'ALT2, containing a 30 bp insertion between exons 9 and 10a (exon 9br) (Danglot et
al., 1995)
The expression patterns and potential function for these various neurofibromin isoforms will be
discussed below.
The three genes originally characterized in the search for the true NF1 gene, EVI2A, EVI2B and
OMGP, were found to be embedded in the 40 kb intron 27 of NF1 (Figure 1.1). All three genes
have the opposite transcriptional orientation relative to the NF1 gene, and their exact roles in
regulating the NF1 disease phenotype are yet unknown. However, some have proposed that the
expression of these genes could act to suppress the transcription of NF1 in the opposite DNA
strand by steric hindrance of the RNA polymerase proteins (Wallace et al., 1990b). Along the
same line, loss of NF1 express may allow overexpression of these embedded genes, leading to
disease development. This would be consistent with the reported role of the Evi2 genes in the
development of mouse myeloid leukemia (Buchberg et al., 1990a). More recently, Largaespada et
al. (1995) reported a finding in which murine myeloid leukemia cell lines showing retroviral
integration into Evi2 effectively inhibited the production of neurofibromin. This is consistent with
human data showing a causal relationship between mutations in the NF1 gene and the onset of
juvenile chronic myelogenous leukemia (Shannon et al., 1994).
In addition, eight pseudogenes showing homology to the NF1 gene have been detected in the
human genome. These pseudogene loci have been mapped to chromosomes 2 (with two separate
loci), 20, 21 (Cummings & Marchuk, 1996), 15 (Legius et al., 1992), 14 and 22 (Marchuk et al.,
1992). Using fluorescence in situ hybridization techniques, Purandare et al. (1995) confirmed
these finding and reported an additional NF1 homologous loci on chromosome 18. The locus on
chromosome 12 contains open reading frames homologous to NF1 in at least two exons and is
expressed in a number of tissues (Gasparini et al., 1993). The evolutionary rationale and history
of these pseudogenes are unknown, but many have speculated that they serve as reservoirs of
mutations for the NF1 gene through homologous recombination. However, studies have not
conclusively demonstrated this phenomenon.
The NF1 gene has been found to be evolutionarily conserved (Baizer et al., 1993; Bernards et al.,
1993; Schafer et al., 1993; The et al., 1997), with a majority of the studies focusing on the
similarities between human and mice. Mouse NF1 gene shows close homology not only in the
protein coding region, but also the 5'- and 3'-UTR regions (Bernards et al., 1993). The
neurofibromin proteins for the two species are predicted to have 98.5% sequence identity, with the
NFJ-GRD and the IRA-related domains being the most conserved. The 3'-UTR sequences have
been suggested to play a role in the regulation of gene expression and mRNA stability. In
addition, sequence comparison of the human and murine NF1 promoter regions showed close
sequence homology (over 95% in some regions) as well as the presence of several perfectly
conserved transcription factor binding site motifs, including a cAMP response element and serum
response elements (Hajra et al., 1994). However, the physical binding of these transcription
factors has not been demonstrated in vitro or in vivo. Furthermore, the different NF1 transcript
isoforms (discussed below) are also conserved across the two species (Danglot et al., 1995).
Together, these data suggest not only evolutionary conservation of protein function, but also the
control mechanisms for regulation. In addition, given the high degree of sequence homology
between the two species, mutations in any of these conserved regions may be potentially
significant.
The gene structure for the Drosphila NF1 homolog has also been determined (The et al., 1997).
The gene spans over 13 kb of the fly genome, and produces a transcript of 9750 bp. Further
analysis shows that the Drosophila gene also has sequence similarities in the NFJ-GRD and IRA
domains, while encoding 19 exons, two of which are found to be alternatively spliced. However,
the predicted protein sequence identity is only 60% to human neurofibromin, as opposed to over
90% between human and mouse.
NF1 gene expression.
The NF1 transcript has been detected in many human tissues using RT-PCR, such as the brain,
kidney (Wallace et al., 1990), white blood cell, skin, spleen, lung and muscle (Nishi et al., 1991).
In addition, NF1 expression was found in several normal and tumor cell lines (Wallace et al.,
1990; Nishi et al., 1991; Huynh et al., 1992; Nakamura et al., 1994; Takahashi et al., 1994;
Tokuyama et al., 1995; Metheny and Skuse, 1996). Early studies showed that in development, the
11-13 kb transcript was is expressed ubiquitously in all tissues. As the embryo progresses
through mid-gestation and into adulthood, the expression becomes increasingly localized to several
tissues, including the CNS, PNS and adrenal medulla (but not adrenal cortex) (Daston and Ratner,
1992).
The most interesting studies on NF1 expression in the last few years have focused on the various
isoforms (splicing variants) in terms of their tissue specificity, development and induction patterns.
As described above, 6 distinct isoforms have been identified in various tissues. Type I transcripts
are typically associated with terminally-differentiated CNS tissues, especially in neurons (Suzuki et
al., 1991; Gutmann et al., 1995; Tokuyama et al., 1995), in late development (Gutmann et al.,
1995), and in tumor cell lines that have been induced to cease proliferating (Mantani et al., 1994;
Metheny and Skuse, 1996). Type II transcripts, on the other hand, are expressed at a high level in
undifferentiated tumor cell lines (Suzuki et al., 1991; Takahashi et al., 1994; Tokuyama et al.,
1995) and early in mammalian development (Huynh et al., 1993; Gutmann et al., 1995). Overall,
the available evidence points to the Type II transcript playing a role in promoting cell growth while
Type I functions to induce (or maintain) differentiation. However, one study reported a complete
set of contradictory data, suggesting that Type II is associated with differentiation and Type I is
found in undifferentiated tumors (Nishi et al., 1991). The discrepancy may have resulted from the
different tumor cell lines used in the two experiments.
Type III transcripts are expressed exclusively in muscle tissues as shown by RT-PCR (Gutmann et
al., 1993). Type IV, containing both exons 23a and 48a insertions, is expressed in cardiac muscle
(Gutmann et al., 1995) as well as other tissues (Mantani et al., 1994). The N-isoform has been
found to be equally expressed in normal brain and brain tumor cell lines (Takahashi et al., 1994).
The function of this 551 aa protein, which includes the first 547 aa of neurofibromin, is not
known. The last, and most recently-identified isoform, 5'ALT2, has been found exclusively in the
CNS (Danglot et al., 1995). Since the primary NF1 CNS defects are mental retardation and
learning disabilities, this isoform may have a role in the long-term potentiation of signals in the
brain.
Mutational spectrum and genetic analysis
As mentioned previously, NF1 has one of the highest rates of mutation known for any cancer
gene, with over 50% of the affected individuals believed to have inherited de novo mutation (Carey
et al., 1986). Therefore, it is not surprising to find ample medical literature describing these
mutations (summarized in Shen et al., 1996; Korf, 1995). Many more have attempted to assign a
particular set of NF1 phenotypes to each mutation, with little or no success (Riccardi, 1992; Huson
and Hughes, 1994). The most comprehensive correlative studies have documented specific
phenotypes associated with large deletions spanning the entire NF1 gene. These families of
patients have consistently shown mild facial dysmorphology, mental retardation, and a large
number of cutaneous and plexiform neurofibromas at a young age (Kayes et al., 1994; Cnossen et
al., 1997; Wu et al., 1997). Surprisingly, even though these deletions included the three
embedded genes in intron 27, none of the patients showed signs of leukemia. As a note, these
large deletions (some as large as 700 kb) could potentially involve the loss of other genes adjacent
to the NF1 locus. In contrast, Shen et al. (1993) reported the finding of identical exon 17
mutations in two unrelated NF1 patients that led to different disease features (Shen et al., 1993),
suggesting the involvement of other factors.
The over 100 germline mutations in the NF1 gene covers the spectrum of genetic alterations,
including various missense and nonsense point mutations, large and small deletions, insertions,
translocations, and tandem duplications (Shen et al., 1996). Some researchers have targeted their
mutational search to exons which are believed to be mutational hotspots, including exons in the
NFI-GRD (Marchuk et al., 1991; Gutmann et al., 1993), IRA-related domain (Ballester et al.,
1990; Buchberg et al., 1990b) and exons 31 through 34 (Ainsworth et al., 1993; Dublin et al.,
1995). Others have used techniques to detect mutations in a more comprehensive fashion,
including heteroduplex analysis (HA) and single strand conformation polymorphism analysis
(SSCP). Recently, several novel techniques have been used for NF1 mutation analysis:
denaturing gradient gel electrophoresis (DGGE) (Valero et al., 1994), chemical cleavage of
mismatch (CCM) (Purandare et al., 1994), and protein truncation test, based on the in vitro
transcription-translation of the entire NF1 coding sequence (Heim et al., 1995). However, NFl's
large size (350 kb genomic region), number of exons (59) and non-coding sequence conservation
has traditionally prevented a comprehensive mutational screen for the entire gene.
Several lines of evidence provided potential insights into mechanisms responsible for this high
mutation rate. First, as previously described, the accumulation of mutations in the various
pseudogenes may contribute toward novel NF1 mutations via homologous recombination
(Purandare et al., 1995). Second, CpG dinucleotides show a high mutation rate in the human
genome because of their likelihood to deaminate at the 5-methylcytosine (Cooper and Krawczak,
1990). This has led to the identification of nine substitution mutations at the CpG islands in exon
31 (Cawthon et al., 1990; Estiville et al., 1991; Ainsworth et al., 1993; Valero et al. 1994), as well
as others in exons 10a (Korf, 1995), 29 (in the NFJ-GRD; Valero et al., 1994), 42 (Purandare et
al., 1994) as well as the 5'- and 3'-UTR (Bernards et al., 1993; Rodenhiser et al, 1993). Third,
Rodenhiser et al. (1997) showed that single nucleotide repeats (homonucleotides), short direct
repeats, as well as CpG motifs in NF1 are common sites of small deletions, insertions and
nucleotide substitutions. Lastly, it is possible that the genomic location of the NF1 locus may be
more susceptible to mutations (Krawczak and Cooper, 1991; Wolfe et al., 1989).
The observation that a large number of the germline mutations were inherited from the paternal
allele suggests a possible mutation mechanism for NFl. Using DNA markers, the original reports
suggested that 84%-98% of germline mutations were derived from the paternal chromosome
(Jayadel et al., 1990; Stephens et al., 1992). In fact, one report was able to demonstrate that a
clinically unaffected father carried the de novo NFI mutation in 10% of his sperm (Lazaro et al.,
1994). More recently, however, the same group (Lazaro et al., 1996) examined 470 NF1 families
in order to refine the paternal allele phenomenon in a way that was specific to the types of
mutations. Their report showed that large, intragenic deletions were preferentially detected in the
maternal chromosome, while all other types of mutations were more likely to be inherited from the
father -- suggesting the existence of different mechanisms for mutations during the production of
the egg and the sperm. Rodenhiser et al. (1993) provided evidence showing that specific
methylation patterns for the mutable CpG islands on the paternally-derived NF1 alleles are
responsible for the increased mutation rates.
NF1 protein: neurofibromin.
The NFI gene product encodes a large (2818 aa) protein with an approximate molecular weight of
220-320 kDa. The protein has been identified both in development -- in a manner consistent with
the NF1 transcript expression pattern (Gutmann et al., 1995 -- and in a variety of human and
murine cell lines (DeClue et al., 1991; Gutmann et al., 1991; Daston et al., 1992; Basu et al.,
1992; Hattori et al., 1992; The et al., 1993). Traditionally, neurofibromin antibodies have been
less than ideal in specifically-recognizing the protein. However, a number of immunoprecipitation
and immunohistochemical studies have attempted to determine the cellular and subcellular
localization of neurofibromin. The highest expression of neurofibromin was found in neurons and
glial cells such as Schwann cells and oligodendrocytes (Daston et al., 1992), which is consistent
with the NF1 transcript localization patterns in animals. In addition, two reports (DeClue et al.,
1991; Hattori et al., 1991) independently demonstrated that neurofibromin co-precipitated with the
particulate fraction of cellular proteins in a detergent-extraction/fractionation experiment, while
p120 GAP was primarily in the soluble fraction. This is consistent with findings that
neurofibromin binds to polymerized cytoplasmic microtubules, and that the critical residues for this
interaction is contained within the NFJ-GRD (Gregory et al., 1993). Other subcellular localization
study for neurofibromin found the protein to aggregate upon stimulation of B lymphocytes (Boyer
et al., 1994). This aggregation was inhibited by cytoskeletal disrupting agents such as colchicine
and cytochalasin D, suggesting that microtubule or microfilament structures may be necessary for
the redistribution and normal function of neurofibromin. More recently, Roudebush et al. (1997)
showed that neurofibromin co-precipitated with purified mitochondria. The significance of this
finding is unclear at present.
NFI Protein function
Only a few functions have been suggested for neurofibromin based on its homology with known
protein motifs. The most obvious similarity is neurofibromin's NFl-GRD domain, which shows
close sequence homology to a family of GTPase activating proteins (GAPs) (Hall A, 1990). GAP
proteins function as negative regulators (and possibly as effectors) for the RAS family of small
GTPase proteins. GAP physically interacts with its target and stimulates the hydrolysis of the ras-
bound guanine nucleotides from GTP to GDP, effectively shutting off the ras signaling pathway
(McCormick, 1989).
The ras GTP/GDP cycle
The p21 ras family of proteins function as the master molecular switch in one of the most
elegantly-characterized signal transduction pathways in mammalian systems, starting with the
stimulation of cells by extracellular mitogenic molecules, and ending with increased transcriptional
activation and synthesis of growth genes in the nucleus (reviewed by Egan and Weinberg, 1993).
A variety of extracellular signals induce a rapid and transient increase in the level of active GTP-
bound ras proteins, including ones that promote the growth in fibroblasts (e.g. PDGF, EGF,
FGF), the cycling and differentiation of hematopoietic cells (e.g. IL-3, GM-CSF), and the
differentiation of neuronal cells (e.g. NGF) (Satoh et al., 1992; Khosravi and Der, 1994). All
these factors cause dimerization, phosphorylation and subsequent conformational change of
receptor tyrosine kinases (e.g. PDGF and FGF receptors) or non-receptor tyrosine kinases (e.g.
IL-2 receptor).
This series of events exposes binding sites on the proteins for Grb2, a small adaptor protein whose
only function is to link the tyrosine kinases domains to Sos, a guanine nucleotide exchange factor.
Sos facilitates the dissociation of the inactive ras from GDP, freeing the protein for binding with a
GTP molecule, which causes ras to assume an active conformation (Egan et al., 1993). In effect,
Sos is acting as a positive regulator in the ras GTP/GDP cycle (Figure 1.2). The Grb2/Sos
complex serves to (1) recruit the ras protein to the plasma membrane and (2) increase the level of
active ras-GTP. One of the critical steps to ras signaling is the attachment of the protein to the cell
membrane. This is accomplished by modifying the ras protein by the addition of a hydrophobic
moiety called the farnesyl group, which serves to anchor ras to the cytoplasmic surface of the cell
membrane (Hancock et al., 1991; Kato et al., 1992). The protein which carries out this function is
called the farnesyl protein transferase (FPT).
Once localized to the membrane, activated ras causes the co-localization of the serine/threonine
kinase raf to the membrane. Raf then continues this rapid burst of phosphorylation of signaling
events through a series of proteins called MAP (mitogen-activated protein) kinases, including
MEK, ERKI and ERK2 (Ruderman, 1993; Marshall, 1994), eventually causing the translocation
of some of these proteins into the nucleus, where they activate transcription factors such as c-jun
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and c-fos by phosphorylation (Smeal et al., 1991). This represents the current model explaining
the increase in growth-related gene expression upon mitogenic stimulation.
GAP protein functions
The regulation of active ras level in any cell is crucial, because moderate changes of in the ratio of
active vs. inactive ras would alter the activity of many critical signal transduction pathways. It is
therefore not surprising to find proteins that both positively (e.g. Sos) and negatively (GAP and
NFl) regulate ras-GTP levels (Figure 1.2). In fact, this check and balance mechanism is
conserved across many species: In D. melanogaster, GAPI regulates Ras] activity in eye
development (Barbacid, 1987; Gaul et al., 1992); in S. cerevisiae Iral and Ira2 gene products
regulate RAS 1 and RAS2 in the production of cAMP as a part of a nutrient-response pathway as
well as a mating pathway (Tanaka et al., 1990); the S. pombe sarl gene regulates ras] also in a
mating signaling pathway (Nadin-Davis, 1986).
Mammalian GAPs
In vertebrates, p120 ras-GAP and NF1 share many sequence and functional attributes. The NFI-
GRD homology with GAP involves a 360 aa stretch of the catalytic domain. The introduction of
the NF1 catalytic fragment was able to downregulate the ras pathway in in vitro and in vivo
experiments (Martin et al., 1990; Hattori et al., 1992). Both interact with the same range of ras-
related proteins, as they provide GAP function for H-ras, N-ras, K-ras and R-ras (McCormick,
1995). The GAP binding site has been localized to an N-terminal region of ras, called the "effector
loop" region, a highly-conserved stretch of 8 aa residues on GTPase proteins. Several mutations
in this region drastically reduce GTPase activity without affecting nucleotide binding (Sigal et al.,
1986), probably due to the protein's inability to interact with GAP and neurofibromin (Marshall
and Hettich, 1993). Stang et al. (1996) reported, however, that the Tyr32His mutation on p21 ras
(an effector loop mutation) dissociated p120 GAP but not NF]-GRD. In fact, site-directed
mutagenesis of the NF]-GRD was able to generate variants of the domain that were able to
suppress oncogenic ras (Gutmann et al., 1993; Nakafuku et al., 1993; Poullet et al., 1994). This
observation suggest that NF1 and GAP may be regulating ras activity in slightly different manners.
Other lines of study demonstrate that the two proteins are by no means structurally or functionally
redundant, and are regulated by different molecular mechanisms. First of all, neurofibromin lacks
the SH2 (Src homology 2) domain of GAP, which is crucial for the binding to phosphorylated
protein domains (Settleman et al., 1992). Second, NFl-GRD has between 20-300 fold higher
affinity for ras than GAP, but has approximately 30-fold lower GAP activity (Bollag and
McCormick, 1991). Third, neurofibromin has extended homology with Iral and Ira 2 beyond the
360 aa GAP catalytic domain, a stretch of over 1500 aa (from residue 834 to 2394) (Ballester et
al., 1990). In fact, the NF]-GRD is able to functionally rescue Ira I and Ira2 yeast mutants (Xu et
al., 1990), which function as negative regulators of the yeast-ras cAMP signaling pathway
(Ballester et al., 1990; Buchberg et al., 1990b).
Furthermore, GAP proteins are known to have different sensitivities to inhibition by several
mitogenic lipids (Tsai et al., 1989). For example, arachidonic acid inhibits the catalytic activity of
GAP, NFl-GRD and Ira2 while phosphatidic acid (containing arachidonic and stearic acid) only
inhibits NF]-GRD but not GAP or Ira2 (Golubic, 1992). Interestingly, a major target of MAP
kinase protein is cytoplasmic phospholipase A2 (cPLA2) which, upon mitogenic stimulation, is
recruited to the membrane where it cleaves phospholipids to produce arachidonic acid (Lin et al.,
1993). Not only is arachidonic acid able to regulate ion channel activation in neurons (Freeman et
al., 1991), modulate hormone secretion (Landt et al., 192), and specifically inhibit the catalytic
activity of GAP and neurofibromin, but its prostaglandin derivatives are able to selectively
stimulate GAP activity for p120 GAP, but not neurofibromin (Han et al., 1991). The
prostaglandin stimulatory activity competes with the arachidonic acid inhibitory effects, probably
because of a common binding site on the GAP protein. This suggests another mechanism for
differentially regulating the two GAPs.
Negative regulator or effector?
Schwann cell culture studies provided evidence for cell-type specific regulation of the two GAPs.
In normal cells, 50% of the ras protein is in the GTP-bound form, while only 5% of ras-GTP is
found upon GTPase activation. In Schwannoma cell cultures from NF patients that lack
neurofibromin (but with normal p120 GAP levels), the ras-GTP level again approached 50%,
suggesting little to no GAP activity (Bollag and McCormick, 1992). Other reports have supported
this increase in active ras levels in Schwannoma (DeClue et al., 1992) and neurofibrosarcoma
(Basu et al., 1992) cell lines, as well as in tumor tissues derived from NFl-related neurogenic
sarcomas and neurofibromas (Guha et al. 1996).
The strongest association between the catalytic function of neurofibromin and the development of
cancer comes from studies of the myeloid cell lineage. The suggestion that the NF 1 population are
more at-risk of developing myeloid dysplasia received genetic support when Shannon et al. (1994)
found no functional NF1 in bone marrow of patients suffering from chronic juvenile myeloid
leukemia. This was followed by experiments using mouse hematopoietic cells showing that Nfl-
deficiency causes hypersensitivity to GM-CSF (which signals through ras), raised ras-GTP levels
as well as aberrant growth (Bollag et al., 1996; Largaespada et al., 1996). It is possible that NF1
may confer the primary GAP protein in Schwann and myeloid cell lineages. The inactivation of
NF1 would predispose these cells to malignant growths.
However, this simple model is complicated by experiments in neurofibromin-deficient
neuroblastoma (The et al., 1993) and melanoma-derived cells lines (Johnson et al., 1993) showing
normal levels of ras-GTP. This may simply suggest that NF1 may not confer the primary GAP
activity in these cell types, or that NF1 may have tumor suppressive functions distinct from the
GAP catalytic activity.
A further complication of this model arises from the fact that oncogenic ras proteins (or other
mitogenic stimulation that results in an accumulation of the active GTP-bound protein) cause
growth arrest or differentiation in certain neural cells (Schwann cells and PC12, a
pheochromocytoma cell line) (Greene and Tischler, 1976; Kremer et al., 1991; Li et al., 1992). In
fact, oncogenic ras mutations are almost never found in most type of neural crest derived tumors
(Bos, 1989).
Studies have shown that Type I and Type II NF isoforms interact differently with ras. Type I
(typically associated with later developmental stages and differentiated cell types) shows good
GAP activity toward ras and is found to associate with microtubules. Type II (involved with
primary tumors and early development) on the other hand, is 10-fold less efficient in catalysis and
does not associate with microtubules (Andersen et al., 1993; Gutmann et al., 1995). It is quite
possible that Type I neurofibromin plays a bigger role as a negative regulator of ras in maintaining
differentiation, while Type II proteins serves as an effector for ras signals, be it normal or
oncogenic.
Interacting proteins
Other than ras, one of the few proteins known to interact with neurofibromin is tubulin. Aside
from the localization studies (Gregory et al., 1993), it has also been shown that the GAP activity of
neurofibromin is inhibited during this interaction (Bollag et al., 1993). Since the microtubule
binding domain overlaps with the ras-binding region, this may be a simple case of inhibition by
steric hindrance, sequestration or binding site competition. However, the functional significance
of this interaction is unclear.
Neurofibromin activity may also be regulated by protein phosphorylation. Putative
phosphorylation sites were identified during the initial cloning of the NF1 gene (Marchuk et al.,
1991). However, only recently did one group provide in vitro evidence showing that protein
kinase A (PKA) is responsible for the constitutive phosphorylation at a C-terminal cysteine/serine-
rich domain of neurofibromin (Izawa et al., 1996). This places neurofibromin downstream of the
kinase in the PKA signaling pathway. However, experiments in Drosophila demonstrated that the
loss of NF1 function was not rescued by Ras 1, Sos or Raf, but by the activation of PKA (The et
al., 1997). This data argues for a model where PKA is either downstream of neurofibromin, or
the two proteins act in parallel signaling pathways.
NF1 as a tumor suppressor gene
The genetic components of tumorigenesis can be categorized into three groups: Oncogenes, tumor
suppressor genes and DNA repair genes. Oncogenes normally function as components of
pathways that regulate cell growth, and activating mutations of oncogenes cause an excessive level
of positive signaling to the cell growth machinery (Bishop, 1995). On the other hand, the classic
definition of a tumor suppressor gene is one that normally functions to control cell growth, and the
inactivation of which would lead to the promotion of cancer (Weinberg, 1991).
Genetic and molecular studies of NF1 suggest that its gene is a classic tumor suppressor. Not only
does it function as a negative regulator of a major oncogene, p21 ras, loss-of-function mutations in
the NF1 gene have been found in various NF1 and non-NF1 related tumors (reviewed in
Seizinger, 1993). At the protein level, some NFl-related neurofibrosarcomas (DeClue et al.,
1992), neuroblastomas, Schwannomas (The et al., 1993) and pheochromocytomas (Gutmann et
al, 1995) show reduced or the lack of functional neurofibromin expression . As described above,
a number of these tumors exhibit abnormally high levels of active ras-GTP.
Consistent with this model, the introduction of full-length NF1 gene or its catalytic domain NFl-
GRD was found to suppress growth in a human colon cancer cell line (Li and White, 1996).
Interestingly, this study demonstrated that growth suppression was seen even with the introduction
of an NF1-GRD mutant that shows minimal GAP activity, but still retained normal binding affinity
to ras. Therefore, neurofibromin may function in other non-GAP-related tumor suppressive role.
The most convincing genetic evidence to date in support of NFl's tumor suppressor hypothesis
has been the demonstration of loss-of-heterozygosity (LOH) at the NF1 locus in malignant
neurofibrosarcomas (Legius et al., 1993), malignant melanomas (Andersen et al., 1993b), myeloid
leukemia (Shannon et al., 1994), pheochromocytomas (Gutmann et al., 1994), and more recently,
in benign neurofibromas (Colman et al., 1995; Sawada et al., 1996; Serra et al., 1997). The loss
of both alleles is consistent with the two-hit hypothesis first presented by Knudson (1971) to
explain the variations between familial and sporadic cases of human retinoblastoma. The two-hit
model of oncogenesis stipulates that individuals inheriting one mutated copy of a tumor suppressor
gene is predisposed to cancer. However, this cancer will not arise until the second (wild-type)
copy of the same gene has been inactivated by somatic gene mutation. Indeed, every human NF
patient has inherited one mutant allele of the gene (Huson, 1994) and is therefore constitutionally
heterozygous for the NF1 mutation. This allele may be transmitted from an affected parent
(familial mutation) or unaffected parent (sporadic germline mutation) (Lazaro et al., 1994).
Traditionally, it is believed that the failure in characterizing NF1 LOH in neurofibromas resulted
from the multiple cell types involved in the benign lesion as well as the difficulty in detecting all
NFI mutations. For example, if only one cell type is devoid of functional NFl, sensitive assays
such as PCR commonly used for such analyses would amplify the wild-type allele from adjacent
cells.
The etiology of neurofibromas
One of the hallmark lesions of NF1 is the neurofibroma, a benign growth arising from the
peripheral nerve trunks (either cutaneous or deep plexus) that has the potential to undergo
malignant transformation. Macroscopically, neurofibromas are seen as focal enlargements along
nerves. One of the unmistakable histological features of neurofibromas is the presence of "onion
bulbs," where a neuron or nerve bundle is surrounded by a thick layer of nerve sheath cells.
These lesions typically appear hypocellular, with abundant collagen present between the
hyperplastic cells. The lesion poses another interesting question in tumor etiology: Contrary to the
popular belief that cancer results from the clonal growth of one particular cell type, neurofibromas
always include cells showing different terminally-differentiated states:
* neurons (few)
* Schwann cells (60-85%)
* perineurial cells or fibroblasts (10-20%)
* mast cells
* others such as endothelium, pericytes and smooth muscle cells.
Several genetic and signaling models can be proposed to explain how the multiple cell types
interact to promote neurofibroma development (Figure 1.3). For example, a LOH event may
induce proliferation by rendering a cell more sensitive to growth factor stimulation. On the other
hand, such a mutation may cause a cell to secrete abnormal levels of growth factors that recruits its
(genetically heterozygous) neighbors to divide. Both cases may act in an autocrine or paracrine
fashion, or both. However, it is currently not known which one of these cell types is responsible
for the initiation and growth promotion of the tumor.
Schwann cells
Previous attempts have been made to describe the effects of neurofibromin-deficiency in various
cell types, using cell culture from human NF1 tumors or Nfl-deficient mouse cell lines.
Consistent with previous observation from the introduction of oncogenic ras into these cells,
Schwann cells lacking Nfl function showed increased ras signaling and a tendency to differentiate
Figure 1.3 Mechanisms of neurofibroma formation, neuron, schwann, perineurial
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(Kim et al., 1995). Only when these Schwann cell were provided with increased cAMP pathway
signaling did they begin to proliferate (Kim et al., 1997). Despite this apparent contradiction
between activated ras pathway and proliferation, most still believe Schwann cells to be the mutant
cell type in neurofibromatosis because (1) 40-85% of cells present in these tumors are of this
lineage and (2) most of the cells have lost normal contact with neurons, indicating loss of normal
function (Stefannson et al., 1982; Sheela et al., 1990)
Perineurial cells
Perineurial cells normally form concentric rings surrounding nerve bundles, and are believed to act
as a selective barrier to prevent free diffusion of most macromolecules (e.g. growth factors) from
the nerve fascicle (Olsson and Kristensson, 173). It is possible that NFl-deficiency in perineurial
cells result in the breakdown of this barrier, exposure of the nerve fascicle to aberrant levels of
mitogens, and leading to tumor formation. However, the origin of perineurial cells are still
controversial, with the most direct evidence suggesting a fibroblastic origin (Bunge et al., 1989).
Recent experiments found that NF 1 may play a role in the differentiation of perineurial cells from
fibroblasts, since murine fibroblast lacking neurofibromin fail to form perineurial cells in vitro
(Rosenbaum et al., 1995).
Neurons
The only reports on Nfl-deficient neurons suggested an ability to survive in the absence of
neurotrophic factors (Vogel et al., 1995) and a slight growth advantage in development (Brannan et
al., 1994). In addition, the lack of neurofibromin in conjunction with other gene mutations
implicated in memory has been shown to alter long term potential in the brain (Silva et al., 1997).
Chapter 3 of this thesis describes experiments in which we attempted to identify the critical cell
type(s) involved in neurofibroma formation by creating a mouse composed of both Nfl-deficient
and wild-type cells.
Mouse models of human cancer.
Existing animal models of NF1
A number of spontaneous, chemically-induced and transgenic animal models showing various
phenotypes involving neural crest-derived tissues (i.e. neurocristopathy) have been described.
For example, a population of Holstein cows shows predisposition to the development of multiple
cutaneous neurofibromas which are histologically similar to the human lesions (Sartin et al.,
1994). An NF1 model of the bicolor damselfish (P. partitus) has been described by Schmale et al.
(1986) to show lesions such as pigmentation defects, neurofibromas, Schwannomas and
neurofibrosarcomas. The genetics underlying this set of phenotype is unclear, but the seemingly
transmissible pattern of the lesions (Schmale and Hensley, 1988) suggest the involvement of a
possible infectious oncogenic agent.
Transplacental and neonatal ethylnitrosourea (ENU) mutagenesis experiments in hamsters
(Riccardi, 1988; Nakamura et al., 1989) and rats (Cardesa et al., 1979; Cardesa et al., 1989) have
produced animals that develop a number of NF l-related lesions, such as neurofibrosarcomas and
Schwannomas. Nakamura et al. (1989) found full-length neurofibromin expression in 7 out of 14
neurofibromas isolated from hamsters. The possibility that ENU mutated genes other than Nfl
was supported by the detection of several activating mutations in the neu oncogene (Nikitin et al.,
1991; Nakamura et al., 1994; Perantoni et al., 1994).
Mouse models of neurocristopathy have been generated by the ectopic expression of various viral
oncogenes, including HTLV-1 tax (Hinrichs et al., 1987; Nerenberg et al., 1987; Green et al.,
1992), HIV-1 tat (Corallini et al., 1993) and SV40 large T antigen (Jensen et al., 1993; Messing et
al., 1994; Mazarakis et al., 1996). Lesions were found in neural crest tissues such as the
peripheral nerve, the iris and adrenal medulla. However, the introduction of viral proteins has a
major shortcoming because they usually alter several cellular pathways at once. For example,
SV40 large T antigen and HTLV-1 tax are able to simultaneously transactivate growth factor genes
(Green, 1991) and oncogenes (Duyao et al., 1992; Ejima et al., 1993), while inactivating the Rb,
p53 (reviewed in van Dyke, 1994) and NF1 tumor suppressor genes (Feigenbaum et al., 1996).
Therefore, these models do not allow a careful dissection of the minimal genetic pathways
responsible for tumor formation.
Knockout mouse models
Using gene targeting and homologous recombination to disrupt mouse genes implicated in human
tumor suppression provides several advantages: First of all, the models provide mammalian
systems with pre-defined genetic mutations. Not only are these animals useful as in vivo models
for studying pathways in which these tumor suppressor genes act, the various primary and tumor
cell lines that may be derived provide invaluable reagents for detailed in vitro molecular assays.
Secondly, mouse and human chromosomes have regions of synteny that would allow the
conservation of any transcriptional interplay between adjacent genes or regulatory elements (e.g.
activation or silencing of gene expression).
Another advantage to using mouse models of cancer is the ability to study various combinations of
tumor suppressor and oncogene mutations that may be required for the development of specific
types of cancer. This multi-step nature of tumorigenesis has been suggested for many types of
cancer, but the most comprehensive model to date is that for colorectal carcinogenesis (Fearon and
Vogelstein, 1990). The ability to study multifactorial/multigenic diseases using mouse knockouts
is further enhanced by the opportunity to breed mutations onto different inbred genetic
backgrounds of mice. This has significant implications for studying the role of modifier genes in
carcinogenesis, which has been implicated to modulate the phenotype for tumors of the intestines
(Dietrich et al., 1993), mammary (Moser et al., 1995), ovarian (Phelan et al., 1996), skin
(Sundberg et al., 1997) and lung (Obata et al., 1996). It is not surprising that most of these
modifier genes have been identified through the use of the densely-mapped chromosomal
polymorphic markers in mice.
Tumor suppressor knockout models
Several mouse homologs of human tumor suppressor gene have been disrupted by homologous
recombination. A sample of the models are provided in table 1.2:
Table 1.2. Summary of representative mouse tumor suppressor knockouts (adapted from Jacks T,
Annu Rev Genet 30, 1996).
Gene Protein features +/- phenotype -/- phenotype
Rb nuclear phosphoprotein, pituitary tumor embryonic lethality (E13.5-15.5),
binds transcription factors erythropoiesis defect
p53 nuclear phosphoprotein, sarcoma, 10% embryonic lethality due to
transcription factor lymphoma, others excencephaly, lymphoma,
sarcoma
Wtl zinc fingers, transcription none embryonic lethality (E13.5),
factor cardiac & urogenital defects
Apc coiled-coil motif, binds b- intestinal polyps pregastrulation lethality
catenin (E5-6)
Nfl ras-GAP activity Chapter 2 Chapter 2
Nf2 membrane cytoskeletal sarcoma pregastrulation lethality (-E7)
attachment
Brcal zinc finger, secreted ? pregastrulation lethality
granin? nuclear protein? (E5-6)
Brca2 association with RAD51, a ? pregastrulation to embryonic
DNA repair protein lethality (E8.5-9.5) with defects in
cellular proliferation; hypomorphic
allele mutants survive and show
cancer predisposition*
p107 Rb-family none none
p130 Rb-family none none
p16 inhibit cyclin D-dependent ? predisposition to lymphoma and
kinases sarcoma
*Hypomorphic Brca2 allele reference (Connor et al., 1997).
Judging from the number of mutant strains exhibiting embryonic lethality, many of the tumor
suppressor genes are required for normal mouse development. In many of those cases, inheriting
one mutant copy of the gene predisposes the animal to certain lesions, which is consistent with
Knudson's "two-hit" model, requiring the inactivation of the second, wild-type tumor suppressor
allele (Knudson, 1971).
While the Rb mutant mice show increased risk to pituitary tumors, it is nonetheless an inadequate
model for retinoblastoma, the hallmark malignancy associated with the familial disease (Clarke et
al., 1992; Lee et al., 1992; Jacks et al., 1992). The Apc and p53 mutant strains, however, do
show predisposition to a spectrum of malignancies characteristic of their respective inherited
human diseases, i.e. familial adenomatous polypolis coli ( Miyaki et al., 1995) and Li-Fraumeni
syndrome (Levine, 1992; Greenblatt et al., 1994).
The p53 mutant mouse strain is worthy of note both in a clinical and mechanistic sense. An
estimated 50% of all cancer cases show mutations in this gene (Greenblatt et al., 1994).
Furthermore, p53 is responsible for initiating Gi-phase cell-cycle arrest (Kastan et al., 1992) or
programmed cell death (apoptosis) (Clarke et al., 1993; Lowe et al., 1993) in response to DNA
damaging agents or other insults, depending on the cell type involved. The role of p53 in tumor
suppression is furthered by experiments demonstrating that many tumor viruses produce proteins
that bind and inactivate p53, and that this event is a required step in viral transformation (Moran,
1993).
In the case of the NF1 disease, the inactivation of p53 has been suggested as a required step for
malignant transformation from benign lesions (Greenblatt et al., 1994). One study found p53
mutations in 100% of DNA samples extracted from malignant neurofibrosarcomas associated with
NF 1 patients (Menon et al., 1990). Therefore, it would be of particular interest to study the effect
of combining both the NF1 and p53 mutations in a mouse model (Chapter 4).
Lastly, not all tumor suppressor mouse knockout models develop the expected phenotype.
However, if the animal model does indeed recapitulate the human disease, then it becomes an
invaluable model for further genetic and mechanistic studies on the etiology of the tumor.
Eventually, they may be used as critical preclinical animal models to test the safety and efficacy of
potential anti-cancer drugs.
Conditional gene knockout models
Given that many tumor suppressor proteins are required for embryogenesis, it is not surprising to
find germline tumor suppressor null mutations to result in embryonic lethality. However, in order
to generate mouse models of cancer, we must be able to assay the loss of tumor suppressor
function in the context of an adult animal. The question then becomes: Is it possible to create
mouse models that maintains gene function throughout development (or only in critical tissues) --
allowing it to bypass the embryonic lethality stage -- yet still be able to show the consequences of
losing that particular gene function as an adult animal?
One possible alternative to straight knockouts is the generation of double knockout (DKO)
chimeras. In this approach, engineered embryonic stem (ES) cells lacking both copies of a
particular tumor suppressor gene are injected into mouse blastocysts and allowed to contribute
toward the developing animal. The resulting "chimera" will be composed of cells derived from
both the wild-type blastocyst as well as the DKO (tumor suppressor-deficient) ES cells. If the
level of mutant cell contribution to critical tissues fall below a threshold range, the animal will be
able to escape the developmental bottleneck seen in completely null animals. In fact, the efficacy of
this approach in bypassing embryonic lethality has been demonstrated for the Rb mutant mice
(Maandag et al., 1994; Williams et al., 1994). There is one drawback, however, since the extent
of mutant cell contribution cannot be regulated except through the number of ES cells injected, a
high level contribution may still cause developmental abnormalities in chimeric embryos.
In recent years, several new techniques have been described which offers better control over the
specificity of knockouts.
* Cre-lox conditional knockout: The use of the bacteriophage P site-specific recombination
machinery has been effectively demonstrated in murine cell culture and animal systems. The two
required components are (1) a pair of 34 bp loxP (locus of crossing-over) sequences and (2) the 38
kDa cre (causes recombination) recombinase (Kilby et al., 1993). The presence of cre in cells
causes the two loxP sites to recombine, excising the sequences between two loxP sites in the same
orientation, or causes an inversion if the two loxP sites are in opposite orientations. One of the
first studies utilizing this system in ES cells demonstrated T cell specific deletion of the DNA
polymerase 3 gene (Gu et al., 1994). It is therefore possible to analyze the function of a tumor
suppressor gene only in certain cell types by introducing cre in a tissue-specific manner. Such an
option is beneficial given the fact that many tumor suppressor genes are required for normal mouse
development. Therefore, by maintaining normal gene function in all but one tissue type, the mouse
embryo is then more likely to survive beyond the developmental bottleneck. Many other uses for
the cre-loxP recombinase system have been reported. For example, a mouse lens tumor model
was created by a targeted activation of oncogenes with cre recombinase driven by the aA-crystalline
promoter (Lasko et al., 1992).
* Tetracycline inducible gene expression: Control elements of the antibiotic tetracycline-resistance
operon from the E. coli transposon Tn 10 have been utilized to establish a tightly-regulated system
in mammalian cells. The primary regulatory mechanism is the tetracycline-controlled transactivator
(tTA), which is a hybrid protein containing a tet regulatory element and a viral transactivator
domain. This protein drives gene expression from a promoter that specifically recognizes tTA
(Gossen and Bujard, 1992). Transgene transcription can then be selectively activated by
introducing the antibiotic into cell culture or by feeding the mice. Removal of the antibiotic quickly
shuts down gene transcription. This gives researchers to tight control over the temporal induction
of gene expression, because tetracycline can be introduced to pregnant females in order to cause
transgene expression during various stages of development, or to adult mice at any age.
The work presented in this thesis describes my efforts in characterizing the effects of murine Nfl
mutations in various genetic and physiological contexts. The primary goals are to develop mouse
models that closely recapitulate the various human NF1 disease symptoms. These models will
provide valuable biological systems from which to better understand the the genetic and
environmental events that are necessary and sufficient for tumor development. Chapter 2 will
summarize the effect of the germline Nfl mutation in development and in the adult animal. Chapter
3 will describe the first genetic mouse model of neurocristopathy specifically addressing the role of
Nfl deficiency. Chapter 4 will address the cooperation between the Nfl and p53 tumor
suppressor genes in tumor progression into malignant peripheral nerve sheath tumors.
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Chapter 2
Tumorigenic and developmental consequences of
a targeted Nfl mutation in the mouse
Introduction
Neurofibromatosis type I (NFl) is a dominantly inherited genetic disorder affecting
approximately I in 3500 individuals (Stumpf et al., 1987). The major symptoms of the disease
are benign neurofibromas, pigmentation defects termed cafe-au-lait spots, Lisch nodules
(hamartomas of the iris), skeletal abnormalities, and learning disabilities (Riccardi, 1992). NF1
patients are also at increased risk of developing certain malignancies including optic glioma,
neurofibrosarcoma, pheochromocytoma and myeloid leukemia (Hope and Mulvihill, 1981), thus
classifying the disease as a familial cancer syndrome. Since many of its lesions involve cells of
neural crest origin, NF1 has been described as a neurocristopathy (Bolande, 1974).
The NF1 gene was cloned in 1990 (Cawthon et al., 1990; Viskochil et al., 1990; Wallace et al.,
1990) and shown to encode a member of the GAP family of ras regulatory proteins (Xu et al.,
1990). The GAP-related domain of the NFl-encoded protein (neurofibromin) can stimulate the
GTPase activity of p2lras in vitro (Martin et al., 1990; Xu et al., 1990) and functionally
complement yeast IRAl and IRA2 mutants in vivo (Xu et al., 1990; Ballester et al., 1990),
suggesting that neurofibromin normally functions in a ras-dependent signal transduction
pathway. Accordingly, the pathological consequences of inherited mutations in NF1 may result
from defects in ras signaling, particularly in certain cell types derived from the neural crest.
However, the expression of NFI is not restricted to cells of this lineage. NF1 mRNA has been
detected in a wide range of human tissues and cell lines (DeClue et al., 1991; Basu et al., 1992),
and the gene is ubiquitously expressed during early development in the rat (Daston and Ratner,
1992; Huynh et al., 1994). Expression at later stages of gestation and in the adult is largely
restricted to neuronal tissues (Huynh et al., 1994; Daston et al., 1992).
Several lines of evidence implicate NF1 as a tumor suppressor gene. First, the majority of
mutant alleles of NF1 isolated to date from neurofibromatosis patients cause gross alterations in
the gene (reviewed in Seizinger, 1993)) , indicating that the disease is caused by the inheritance
of a single loss-of-function allele. Consistent with Knudson's "two-hit" model for inactivation of
tumor suppressor genes (Knudson, 1971), some malignant tumors from NF1 patients have shown
either the absence of the wild-type NFI allele (Legius et al., 1993) or reduced neurofibromin
activity (Basu et al., 1992; DeClue et al., 1992). In addition, the NF1 gene is inactivated in a
variety of sporadic tumors which are not normally associated with NF1 (Li et al., 1992; Andersen
et al., 1993; Johnson et al., 1993; The et al., 1993).
Here, we describe the construction and characterization of a mouse strain with a germline
mutation in the Nfl gene. The mouse and human NF1 genes are highly related (Bernards et al.,
1993), suggesting a conservation of function across species. The predicted amino acid sequence
of the human and mouse neurofibromin proteins are 98% identical, and there is also significant
similarity in the 3' non-coding region of the mRNAs (Bernards et al., 1993). Recently, Brannan
et al. (Brannan et al., 1993) described their analysis of homozygous embryos lacking the Nfl
gene, in which they found widespread developmental abnormalities. We have constructed a
similar targeted mutation, provided a detailed characterization of its molecular effects, and
examined the resulting phenotype in both homozygous and heterozygous mutant mice. Our
extensive analysis of Nfl heterozygotes over a period of more than two years reveals an
enhanced predisposition to various tumors including phaeochromocytomas and myeloid
leukemias, tumors that are also evident in human NF1 patients, and the strongest evidence to date
that Nfl acts as a classical tumor suppressor gene.
Methods
Nfl Gene Targeting.
The Nfl knock-out vector (pNflKO) was constructed from a 16.6 kb mouse genomic fragment
(isolated from a strain 129/sv genomic DNA library, a generous gift of R. Jaenisch). The library
was screened with a probe from human NF1 exon 31. This DNA fragment was found to span
exons 30, 31 and 32, as determined by hybridization with oligonucleotide probes specific for
each exon (data not shown). In pNflKO, the neo gene was flanked by two regions of homology:
a 5.1 kb fragment extending from an HindIII site in intron 29 to a EcoRV site in intron 30 and a
1.4 kb fragment from an NcoI site in exon 31 to the PstI site in intron 31 (Figure 2.1). The MCI-
neo expression cassette (Thomas and Capecchi, 1987) replaced a 2 kb fragment between the
EcoRV site in intron 30 to the NcoI site in exon 31. The HSV-TK gene (under the control of the
pgk promoter) and the MCJ-neo cassette are transcribed in the opposite transcriptional
orientation to Nfl. The targeting scheme and the restriction map of the wild-type (Nflwt) and
mutant (Nfln 3 1 ) alleles are depicted in Figure 2.1. Electroporation of pNflKO into D3 ES cells
(Gossler et al., 1986), subsequent drug selection, and Southern blot analysis were performed as
described previously (Xu et al., 1992). The wild-type and the mutant Nfl alleles in ES cells can
be distinguished by Southern blotting as described in Figure 2.1.
Generation of chimeras and testing for germline transmission were done essentially as described
in Jacks et al. (1992). Genotype analysis was performed by Southern blotting (Figure 2.1) or
polymerase chain reaction (PCR). The Nflwt allele was amplified by PCR using primers
directed against exon 31 (5'-GGTATTGAATTGAAGCAC-3') and an intronic sequence (NfX4I:
5'-TTCAATACCTGCCCAAGG-3'), while the Nfl n 3 1 allele was amplified using a primer
directed against neo (5'-ATTCGCCAATGACAAGAC-3') and NfX4I. The PCR products for
Nflwt and Nfl n 3 l are 230 bp and 350 bp, respectively. Homozygous embryos were generated
from heterozygous intercrosses. All animals described here are on a 129/sv x C57BL/6 mixed
Figure 2.1 Targeted disruption of the murine Nfl locus.
The relevant position of the Nfl gene involved in gene targeting is shown (top), with the open
box depicting the GAP-related domain (GRD), and the hatched boxes indicating the IRA-related
domains flanking the GRD. The pNflKO vector consists of a MCl-neo cassette in the opposite
transcriptional orientation to the Nfl gene, flanked by 5' and 3' Nfl homologous regions of 5.1
kb and 1.4 kb, respectively. A HSV-TK cassette transcribed in the opposite orientation to Nfl
precedes the Nfl sequences. Homologous recombination between the pNflKO vector and an
endogenous Nfl allele results in the insertion and partial replacement of intron 30 and exon 31
with the neo gene expression cassette. ES cells were screened by Southern blot analysis of
genomic DNA digested with PstI and hybridization with probe A. Relevant BamHI (B), HindIII
(H), MboI (M), Ncol (N), PstI (P) and EcoRV (R) recognition sites are shown.
Figure 2.1 Targeted disruption of the murine Nfl locus.
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genetic background, but we have observed similar results using animals on an inbred 129/sv
genetic background.
Nfl RNA Analysis.
Total cellular RNA was prepared from 12.5 dpc whole mouse embryos using the RNAzol B
RNA isolation kit (Biotecx). Northern blotting was performed essentially as described
(Shackleford and Varmus, 1987). Probes used were a 1.3 kb EcoRI fragment of mouse Nfl
cDNA located just upstream of the GAP-related domain (GRD) (The et al., 1993) and a 0.5 kb
Eagl-NcoI fragment from pMClneo (Stratagene).
Nfl cDNA Sequencing.
Embryonic fibroblast cultures were prepared according to the protocol of Robertson (1987) from
12.5 dpc embryos. Total RNA was isolated from cultures (Xie and Rothblum, 1991) and 3 mg
were reverse-transcribed using synthetic random hexamers (Ausubel et al., 1994). A fragment
extending from exon 30 to 32 was amplified using primers specific to each exon (NFX35'3': 5'-
CTATAATCTCCTGTGTGC-3' and NFX53'5': 5'-ACTCGACACCAATTTCAC-3'), and
subsequently cloned into pT7Blue Vector (Novagen). DNA mini-preps were made from
colonies containing correct fragment insertions and sequenced using Sequenase (USB) with
either the NFX35'3' or the NFX53'5' primer.
Immunoprecipitation Analysis.
Radiolabeling of cellular proteins and immunoprecipitation were performed essentially as
described (the et al., 1993). Cell lysates were made from embryonic fibroblast cultures
incubated for 16 h with 0.5 mCi of [3 5 S]-EXPRE 3 5 S3 5 S (DuPont NEN, specific activity
>1000Ci/mmol). Antibodies directed against specific synthetic C-terminal (serum 912) and
GRD peptides (serum 1034) were used separately to immunoprecipitate neurofibromin. Proteins
were resolved on a 6% SDS-polyacrylamide gel.
Histopathology.
Histological analysis of tumors and embryonic tissues were performed as described (Xu et al.,
1992). Tissue samples were fixed in either Bouin's solution or 10% neutral buffered formalin,
processed for histology, embedded in paraffin, sectioned at 6 m, and stained with hematoxylin
and eosin.
Southern Analysis of Tumor DNA.
Loss of heterozygosity analysis was performed on DNA isolated from fresh tumor samples
according to the method of Laird et al. (1991). The genotype of the tumor DNA was determined
by Southern blotting following Ncol/HindIII digestion and hybridization with a NcoI-PstI
fragment from intron 31 (Figure 2.1).
Results
Nfl gene targeting.
One allele of the Nfl gene was disrupted in the D3 murine ES cell line using the targeting vector
pNflKO shown in Figure 2.1. pNflKO was designed to create a mutant allele of Nfl
representative of certain human NF1 mutations. It carries a portion of mouse genomic Nfl DNA
surrounding exon 31, which is the site of several mutations in human patients with NF15, 2 7 ,2 8 .
The mutation introduces a neomycin resistance gene (neo) expression cassette in place of the first
42 codons of exon 31 and also replaces the exon 31 splice acceptor sequence and approximately
2 kilobases (kb) of intron 30. The direction of transcription of neo is opposite to that of Nfl. In
addition, pNflKO contains the herpes simplex virus thymidine kinase gene (HSV-TK) to provide
a means for negative selection according to the protocol of Mansour et al. (1988) (Figure 2.1).
However, previous experiments using a related targeting vector indicated that this fragment of
Nfl genomic DNA underwent homologous recombination at high frequency (data not shown).
Therefore, the HSV-TK negative selection protocol was not used in the experiment described
below.
The pNflKO targeting vector was introduced into D3 ES cells (strain 129/sv) (Gossler et al.,
1986) by electroporation, and, following drug selection for neo (with G418), ES cell clones were
screened by Southern blotting. As shown in Figure 2.1, homologous recombination between
pNflKO and endogenous Nfl creates a mutant allele that can be distinguished from the wild-type
gene following digestion of genomic DNA with several different restriction enzymes. DNA
samples isolated from ES cell clones were initially screened using PstI digestion and a probe
located 5' to the sequences present in pNflKO which recognizes 10.5 kb and 7 kb fragments from
the wild-type and mutant Nfl alleles, respectively (Figure 2.1). From approximately 150 G418-
resistant ES cell clones examined, two showed the mutant-specific band, indicating that they
were heterozygous for the targeted Nfl mutation (not shown). Therefore, the targeting efficiency
was approximately 1/75 G418 resistant clones. The structure of the targeted allele in these two
clones was confirmed using a probe located 3' to exon 31 (probe B in Figure 2.1; data not
shown). We have termed this mutant allele Nfl n3 1 to indicate the insertion of the neo gene into
exon 31.
Both heterozygous ES cell clones were independently injected into C57BL/6 blastocyst-stage
embryos in order to create chimeric animals. Each clone yielded chimeras with contribution of
the mutant cells to the germline, as evidenced by their ability to produce agouti-colored offspring
when bred to C57BL/6 animals. Tail DNA was isolated from these agouti offspring at weaning
and tested for the presence of the Nfl n 31 allele using the Southern blot strategy outlined in
Figure 2.1. As expected, approximately half of the agouti animals were heterozygous for the
Nfl n 3 1 mutation (data not shown). Germline chimeras were also crossed to 129/sv females in
order to establish the mutation on an inbred genetic background. Animals on the mixed (129/sv
x C57BL/6) and inbred 129/sv genetic background exhibited the same heterozygous and
homozygous mutant phenotypes as described below.
Molecular Effects of the Nfl n3 1 mutation.
In order to characterize the effects of the exon 31 neo insertion on the expression of Nfl mRNA
and neurofibromin protein, we analyzed tissues and cells isolated from heterozygous and
homozygous mutant and wild-type embryos (see below). Total RNA was isolated from
Nfl+/Nfl+, Nfl +/Nfln 3 1 , and Nfln3 1/Nfln 31 embryos at 12.5 days of gestation and examined
by northern blotting using probes derived from mouse Nfl cDNA. As shown in Figure 2.2a, the
Nfl probe detects a transcript of similar size and abundance in embryos of all three genotypes.
This result indicates that the Nfl n 3 1 allele is efficiently transcribed and processed and that the
resulting mRNA is stable. Based on the structure of the targeted mutation (Figure 2.1), we
thought that the mRNA produced from the mutant allele might contain sequences from the
noncoding strand of neo. Indeed, a double-stranded probe directed against neo detects an mRNA
Figure 2.2 Molecular effect of Nfl n 3 1 disruption.
a, Northern blot analysis of Nfl RNA expression in embryos at 12.5 days of gestation.
Approximately 30 plg of total RNA isolated from whole embryos was resolved by
electrophoresis, transferred to nylon membrane, and hybridized with an Nfl-specific probe (left
panel, see Methodology). An mRNA of approximately 13 kb was detected in samples from
wild-type (+/+), heterozygous (+/-) and homozygous (-/-) embryos. The slightly stronger signal
in the -/- sample results from more total RNA in this lane (not shown) rather than increased
expression. The double-stranded neo-specific probe (right) recognizes a 13 kb Nfl n 3 1 message
as well as the 1 kb message from the neo cassette. b, Diagram of splicing in the Nfl n 3 1
transcript. The pMC]neo cassette in the opposite orientation (as shown) creates both consensus
splice acceptor and donor sequences (intronic splicing sequences are shown in lower cases, with
highly conserved nucleotides doubly underlined). As revealed by sequences of a cDNA product
of the mutant mRNA, exon 30 splices into the neo cassette at position 1531 of the MCl-neo
sequence (Stratagene), and after 473 nucleotides, splicing occurs from a splice donor located in
neo at position 1059 of MC -neo (Stratagene) into exon 32. This novel sequence in the Nfl n 3 1
mRNA contains no stop codons and therefore replaces the entire exon 31 coding region with a
larger open reading frame derived from the non-coding strand of neo. Amino acid residues
adjacent to the splicing junctions are shown. P and A represent the promoter and poly-A
addition sequence of pMClneo. c, Immunoprecipitation of mouse neurofibromin. Cultured
fibroblasts isolated from wild-type (+/+), heterozygous (+/-) and two homozygous mutant
embryos (-/-) were radiolabeled, and lysates immunoprecipitated with serum 912, directed
against the extreme C-terminal 13 a.a. peptide (a-C-term) of human neurofibromin, or with
affinity purified serum 1034, directed against a synthetic 21 amino acid GRD peptide (a-GRD)
(The et al., 1993). A neuroblastoma cell line (90-5) (The et al.,1993) expressing high levels of
neurofibromin was used as a positive control (PC). Approximately 2 mg of total protein
(determined by the Bradford method (Biorad)) was used for each immunoprecipitation. The
position of full-length neurofibromin is indicated (nfn). Note the mutant cells do not produce
full-length neurofibromin or a protein of slightly higher mobility which could result from
translation of the Nfl n 3 1 mRNA. Also, the heterozygous cells contain approximately half as
much neurofibromin as the wild-type cells. The protein at approximately 200 kD detected by the
a-C-term antibody has been seen at variable levels in cells of all genotypes in different
experiments and differs substantially between the two -/- samples examined here.
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in the heterozygous and homozygous mutant samples that co-migrates with the Nfl message, as
well as the 1 kb transcript from the neo expression cassette (Figure 2.2a).
In order to better characterize the mRNA product of the Nfln 3 1 allele, we performed reverse
transcriptase PCR (RT-PCR) on mRNA isolated from homozygous mutant embryonic fibroblasts
using primers surrounding the site of the mutation. As diagrammed in Figure 2.2b, the sequence
of the RT-PCR product revealed that the mutant transcript contains a stretch of 473 nucleotides
derived from the non-coding strand of neo, located between Nfl sequences encoded by exons 30
and 32. This neo insertion and complete replacement of the Nfl exon 31 sequences results from
mRNA splicing from the exon 30 splice donor to a canonical splice acceptor sequence located in
neo followed by splicing from a donor sequence in neo to the splice acceptor of exon 32 (Fig.
2.2b). Quite unexpectedly, the insertion in the mutant mRNA maintains an open reading frame,
potentially allowing the translation of an altered Nfl protein product which would lack the 64
amino acids encoded by exon 31 and contain an additional 167 amino acids encoded by the non-
coding strand of neo. This mutant neurofibromin species would be predicted to be
approximately 10 kilodaltons (kD) larger than the wild-type protein.
To determine whether the altered neurofibromin species was stably produced, we performed
immunoprecipitation of radiolabeled lysates from fibroblasts isolated from embryos of the three
genotypes. Secondary fibroblast populations were labeled with 3 5 S-methionine and -cysteine in
vitro, and the lysates were precipitated with polyclonal sera raised against two human
neurofibromin peptides. Serum 1034 recognizes an epitope located in the GAP-related domain
(GRD), N-terminal to the targeted mutation, while serum 912 is directed against the extreme C-
terminus of the protein (The et al., 1993). As shown in Figure 2.2, both of these sera precipitate
a protein of approximately 250 kD from wild-type mouse fibroblasts which co-migrates with
human neurofibromin. Also, fibroblasts from heterozygous animals produced approximately
half that of the wild-type cells (Fig. 2.2c, data not shown). However, fibroblasts derived from
Nfln3 1/Nfl n 3 1 embryos lack full-length neurofibromin (Fig. 2.2c), and we also do not observe a
higher molecular weight species that might correspond to the slightly larger mutant
neurofibromin protein. These data suggest that the mutant protein product is unstable and does
not accumulate in cells. It is also possible that the 1 kb neo mRNA transcribed from the MCI
promoter might hybridize to the complementary neo sequences present in the mutant Nfl mRNA
and block its translation. These data indicate that the Nfln3 1 mutation eliminates the production
of stable neurofibromin and, therefore, should act as a null. It is also relevant that the mutation
causes skipping of exon 31 all together, since this exon is the site of several missense (Cawthon
et al., 1990) and nonsense (Ainsworth et al., 1993) mutations in human NF1 patients.
The heterozygous phenotype.
Animals heterozygous for the Nfl n 3 1 mutation are potential models for human NF1. Therefore,
we carefully screened heterozygotes for the common lesions associated with this disease, as well
as any other signs of pathology. From a total of more than 250 Nfl+/Nfln3 1 animals followed
for 7 months to over two years of age, none has developed obvious neurofibromas or
pigmentation defects resembling human cafe-au-lait spots. Also, we failed to detect Lisch
nodules or other pathology of the iris in more than 30 heterozygotes examined microscopically.
Therefore, with respect to these and most of the other cardinal features of human NFl, the
Nfl] +/Nfln3 1 mice do not represent an accurate animal model for this genetic disease.
Consistent with the putative role of Nfl as a tumor suppressor gene, however, heterozygosity for
the Nfl n 3 1 mutation does increase the rate of tumorigenesis in the mouse. As shown in Figure
2.3, in a closely monitored set of 40 Nfl +/Nfln3 1 animals, 30 (75%) succumbed to tumors over
a period of 27 months, as compared to 15% (8/52) in a comparable set of wild-type animals. In a
larger series of 62 heterozygous animals, we have observed a variety of tumor types, including
lymphoma (14 animals), lymphoid leukemia (2 animals), lung adenocarcinoma (9 animals),
hepatoma (4 animals), and fibrosarcoma (3 animals). This spectrum of tumors is similar to that
Figure 2.3 Survival curve of Nfl +/31
Viability of a population with 52 wild-type animals (filled squares) and 40 heterozygotes (open
triangles) was monitored for a total of 27 months. Points represent animals that had died or
required euthanasia due to ill health. Tumors were observed in 30 heterozygotes and 8 wild-type
animals in this population as revealed by necropsy. Tumors found in these heterozygous animals
included lymphomas (8), adrenal tumors (9), adenocarcinomas of the lung (8), fibrosarcomas (3),
hepatomas (3), leukemias (3), and one neurofibrosarcoma. In addition, two heterozygotes mice
not included in this data set also developed adrenal tumors.
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seen in older wild-type mice (Bronson, 1990), suggesting that the germline Nfl mutation may
accelerate the development of tumor types to which these animals are already susceptible. A
section through a typical lymphoma from a Nfl +/Nfln 3 1 is shown in Figure 2.4d.
The Nfl+/Nfln 31 mice also develop certain tumor types that are characteristic of human NFl. A
single heterozygous animal was found to have a neurofibrosarcoma at 21 months of age, and
twelve heterozygotes in the total study population developed adrenal tumors at 15 to 28 months
of age (Figure 2.3, data not shown). Nine of these adrenal tumors have been classified
histologically as pheochromocytoma, with one example of a composite tumor also showing
neuronal involvement. In addition, three of these animals developed bilateral
pheochromocytomas. Representative sections of these tumors are shown in Figure 4.4. Also,
seven heterozygotes ages 17.7 to 27 months developed myeloid leukemia, as evidenced by the
overabundance of myeloid cells in the blood and the spleen.
In approximately 10% of human NF1 patients, benign neurofibromas progress into malignant
neurofibrosarcomas (Riccardi, 1992). Phaeochromocytoma is diagnosed in approximately 1% of
NF1 patients (Riccardi, 1981), and composite pheochromocytomas with areas of ganglioneuroma
have been described (Chetty and Duhig, 1993). Pheochromocytoma occurs rarely in mice
(Bronson, 1990), and the relatively frequent occurrence of this tumor in the Nfl+/Nfln3 1
animals (8 of 43) is therefore striking. Indeed, it represents the strongest similarity between the
human and mouse phenotypes observed to date. It is also noteworthy that the transformed
chromaffin cells of the pheochromocytorna are of neural crest cell origin (Le Douarin, 1982).
Moreover, it has been documented that myeloid disorders develop at an abnormally high
frequency in children with NF1 (Shannon et al., 1994). Finally, the Nfl +/Nfln31 animals are not
apparently predisposed to optic glioma, another tumor type linked to NFl.
Figure 2.4 Histopathology of tumors from Nf heterozygous mice.
a, Ganglioneuroma associated with pheochromocytoma. The entire adrenal is replaced by a
dimorphic population of cells, including chromaffin medullary cells typical of
pheochromocytoma (P) and ganglionic neurons (arrows). b, Pheochromocytoma. Polygonal
cells (P) forming rounded nodules (arrows) are surrounded by a delicate fibrovascular stroma. c,
Neurofibrosarcoma found in neck of heterozygote. Note nodules of spindle cells arranged in
whorls (arrows), which infiltrate adipose tissue (a). d, Follicle center cell type lymphoma in
spleen. Sheets of large and small lymphocytes replace normal splenic architecture.
Magnifications: a, 50x, b, 100x, c, 25x, and d, 100x.
Figure 2.4
According to Knudson's "two-hit" model for tumor suppressor gene inactivation (Knudson,
1971), tumor development in the Nfl+/Nfln 3 1 animals should be accompanied by mutation of
the remaining wild-type Nfl allele. Therefore, we used Southern blotting to examine the state of
the wild-type allele in the DNA of several tumors isolated from heterozygous animals. This
assay detects gross mutational events such as large deletion, chromosomal nondisjunction and
mitotic recombination. Approximately half of the tumors tested, including all of the
pheochromocytomas and all of the myeloid leukemias, showed loss of the wild-type Nfl allele
(Figure 2.5, data not shown). In addition to the pheochromocytomas, the one lung
adenocarcinoma and one of nine lymphomas examined by this assay showed evidence of
reduction to homozygosity in the tumor DNA. These data support the view that elimination of
residual Nfl function can contribute to tumorigenesis. In our experiments, those tumors (such as
the one neurofibrosarcoma) that retained the fragment corresponding to the wild-type Nfl allele
(see Figure 2.5) may have incurred a subtle mutation that was not detectable by our assay.
Alternatively, in these tumors, the wild-type allele may have survived intact.
The homozygous phenotype.
To begin to investigate the developmental requirements for Nfl function, we intercrossed
heterozygous animals and determined the genotypes of the offspring at weaning. Of the first 131
offspring tested, we recorded 39 Nfl+/Nfl+, 92 Nfl +/Nfln 31 , and 0 Nfln3 1/Nfl n 3 1 animals.
This result establishes that Nfl function is essential for some aspect of mouse development. The
timing of the lethality associated with Nfln 31 homozygosity was then determined by recovering
and genotyping embryos from heterozygous intercrosses at progressively earlier times of
gestation. Through 11.5 days post-coitum (dpc), homozygous mutant embryos of normal
appearance were recovered at the expected Mendelian value of 25%. Beginning at 12.5 dpc,
homozygous mutant embryos were recognizable, being slightly edematous, although all but one
Figure 2.5 Loss-of-heterozygosity (LOH) analysis.
Southern blot analysis of nine representative tumor DNA samples. Note the absence or under-
representation of the wild-type allele (wt) in one lung adenocarcinoma (lane 4), two lymphomas
(lanes 5-6), and three pheochromocytomas (lanes 7-9). The lymphoma N207 (lane 6) showed
only a slight indication of LOH, possibly due to the contamination of surrounding normal cells in
the spleen. Tumors showing maintenance of the wild-type allele are a thymic lymphoma (lane
1), a lung adenocarcinoma (lane 2) and a neurofibrosarcoma (lane 3).
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of eleven Nfln 31 /Nfln 3 1 embryos recovered at this stage were alive. Approximately 23% (3/13)
of the homozygotes recovered at 13.5 dpc were dead upon isolation and the remainder were very
edematous and pale (Figure 2.6). No homozygous mutant embryos isolated after day 13.5 dpc
were viable. Thus, the lethality associated with homozygosity for the Nfl n 3 1 mutation occurs
between days 12.5 and 14 of gestation.
The appearance of the homozygous mutant embryos at day 13.5 of gestation (Figure 2.6) is
suggestive of a defect in red blood cell development or circulation. Therefore, we performed
gross dissection on several of these animals, concentrating on the liver (the main site of
erythropoiesis at this stage of development) and the heart. The livers of the Nfln31/Nfln31
embryos were apparently normal (not shown), but the hearts were obviously defective. As
shown in Figure 2.7, rather than the proper configuration of the great vessels, with the aorta
exiting the left ventricle and the pulmonary artery exiting the right, the hearts of the Nfl n 3 1/ 3 1
embryos had both great vessels emerging from the right ventricle, a condition known as double
outlet right ventricle (Figure 2.7c, d). We have observed this defect in all of the approximately
15 homozygous mutant embryos examined at 13.5 dpc. This is an unexpected finding, since
heart abnormalities are not a common feature of human NFl. However, it is known that cells
derived from the neural crest contribute to the formation of the outflow tracts of the heart (Kirby
et al., 1983). Also, Huynh et al. (1994) have recently reported high levels of neurofibromin
expression in the developing mouse heart coincident with the development of the abnormalities
observed here.
To further investigate this heart abnormality and to uncover any other pathology, we next
analyzed embryos histologically. Homozygous mutant embryos and littermate controls were
serially cross sectioned at 6 g, stained with hematoxylin-eosin, and examined by light
microscopy. Given the neuronal manifestations of NF1 and the restricted neuronal expression of
neurofibromin at later stages of gestation, we paid particular attention to the developing central
Figure 2.6 Appearance of Nfln 3 1/Nfln31 embryos at 13.5 days of gestation.
Two typical mutant embryos at 13.5 dpc (left and center) compared with a control Nfl+/Nfln 3 1
embryo (right). Note the generalized edema, particularly in the pericardial space and in various
regions below the epidermis (arrows). The two embryos on the right were derived from the
same litter; the photograph of the left embryo was taken at a higher magnification.
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and peripheral nervous system as well as other structures to which neural crest cells contribute
(e.g., thymus, thyroid, parathyroid, cranio-facial structures). However, with the exception of the
heart (see below), all organs and tissues of the Nfln 3 1/Nfln31 embryos were comparable to the
controls. A section showing the normal appearance of the spinal cord and a dorsal root ganglion
of a mutant embryo is included in Figure 2.7 (a, b).
Histological analysis of the mutant hearts confirmed the presence of double outlet right ventricle.
In particular, serial cross sections indicated that the truncus arteriosus (the single outflow vessel
that gives rise to the aorta and pulmonary artery) was septated into two outflow tracts both of
which connected through the right ventricle (Figure 2.7d,f). In addition, the cells lining the aorta
and pulmonary artery were decidedly more abundant in the hearts of Nfln 3 1/Nfln31 mutants
(Figure 2.7e,J). This increased cell density results in a partial occlusion of the great vessels and
could account for the reduced blood flow, edema, and ultimate death of the mutant embryos.
The pericardial sacs of the homozygous mutants were also distended (Figure 2.7), presumably
because of the increased fluid in the pericardial space. Finally, in most of the Nfln 3 1/Nfln31
embryos examined, the myocardium, particularly of the ventricles, was lacy in appearance and
thinner than normal (Figure 2.7g, h). This could be a primary consequence of the Nfl mutation
or secondary to the other defects in cardiac development.
In addition to noting the cardiac abnormalities, Brannan et al. (1993) have recently described
other developmental phenotypes in embryos homozygous for a similar targeted disruption of Nfl.
One such phenotype involved the hyperplasia of splanctic ganglia in 13.5 g.d. embryos. We did
not observe these defects in our Nfln 3 1/Nfln3 1 embryos, which could be due to subtle
differences in the mutant alleles, or the timing at which embryological and histological
examinations were performed.
Figure 2.7 Histopathology of Nfln 3 1/Nfln3 1 mutant embryos.
All heterozygous or wild-type control embryos (a, c, e, g) and homozygous mutant embryos (b,
d,f, h) were isolated at 13.5 dpc. a, b, Cross sections through the lumbar region show normal
development of the spinal cord (SC) and dorsal root ganglia (arrows). c, d, Intact hearts isolated
from embryos fixed in Bouin's solution. c, The normal heart shows the pulmonary artery (P) and
aorta (A) exiting the right (RV) and left (LV) ventricles, respectively. d, In contrast, the mutant
heart has a single, large vessel exiting the right ventricle. Histological analysis reveals that this
vessel is septated into the aorta and pulmonary artery. e,f, Cross sections through the outflow
tracts. Note the large, well-structured lumen of the aorta (A) (filled with blood) and pulmonary
artery (P) of the control heart, e, as compared to the restricted lumenal space in the mutant, f
Arrows point to the overabundant cells lining the outflow tracts in the mutant heart. g, h, Cross
sections through the ventricles of the hearts. Left (LV) and right (RV) ventricles are shown.
Note the thinner myocardium in the mutant heart (arrows).
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Discussion
Although predisposed to malignancy, mice heterozygous for the Nfln 3 1 mutation do not develop
the hallmark features of human NFl, including neurofibromas, Lisch nodules, or pigmentation
defects. Therefore, as with mice mutant for Rb (Xu et al., 1992; Jacks et al., 1992; Lee et al.,
1992) or HPRT (Clarke et al., 1992; Hooper et al., 1987) genes, the Nfl-mutant animals do not
serve as an accurate model of the cognate human genetic disease. Several factors could account
for this difference in phenotype. For example, the various symptoms of human NF1 may all
require the somatic inactivation of the wild-type NF1 allele. Perhaps due to the reduced number
of target cells in the mouse, their more rapid development, or an intrinsically lower mutation rate,
the wild-type Nfl allele is not inactivated at a sufficiently high rate in the relevant cells of the
Nfl +/Nfln 3 1 animals. Alternatively, the regulatory mechanisms controlling the growth and
differentiation of these cells in the mouse may be coordinated differently than in the
corresponding cells in humans.
The phenotypic expression of NF1 mutations in humans is highly variable, such that the same
mutation can cause a distinct array of symptoms in different individuals. Pedigree analysis by
Easton et al. (1993) has indicated that the NF1 phenotype is strongly affected by unlinked
modifier genes. Therefore, it will be important to cross the Nfln 31 mutation onto several
different genetic backgrounds. In addition, Jay and co-workers (Easton et al., 1993; Hinrichs et
al., 1987) have previously described a transgenic mouse line expressing the HTLV-1 tat gene
that develops various lesions reminiscent of human NFl. Intercrossing this transgenic line with
the Nfl mutation described here could potentially accentuate this phenotype.
Based on our failure to detect mutant neurofibromin using antisera which recognize two different
epitopes on the protein, we believe that the targeted mutation results in destabilization of the
protein, and therefore, acts as a null. The instability of the protein could result from the deletion
of exon 31 encoded sequences, insertion of amino acids encoded by the non-coding strand of
neo, or both. It is also noteworthy that the splice acceptor and donor sites located on the
noncoding strand of neo used in the production of the Nfl n 3 1 mRNA species closely match the
different consensus sequences and are used in this context quite efficiently. This, coupled with
the fact that the neo sequences located between these sites constitutes an open reading frame,
should be considered by others using this general strategy for making mutations by gene
targeting.
The acceleration of tumorigenesis in the Nfl +/Nfln3 l animals reported here, along with the high
frequency of mutation of the wild-type Nfl allele, is perhaps the best evidence to date that this
gene functions in negative growth regulation and tumor suppression. Since the heterozygous
animals develop a wide range of tumors, it appears that the elimination of neurofibromin
function can promote transformation of a variety of cell types, perhaps through changes in ras
signaling. Mutations in the human NF1 gene have also been found in a variety of tumor types,
including neurofibrosarcoma, astrocytoma, neuroblastoma, melanoma, and colon carcinoma
(Legius et al., 1993; Li et al., 1992; Andersen et al., 1993; Johnson et al., 1993).
The most striking aspect of the heterozygous phenotype in the mouse is the relatively high
incidence of pheochromocytoma, a tumor of the adrenal medulla consisting of cells of neural
crest origin, in mixed background animals (C57BL/6 x 129sv). Indeed, predispositions to
pheochromocytoma (mixed background animals) and myeloid leukemia (seen only in 129sv
inbred strains) are the closest phenotypic similarity between the Nfl +/Nfln3 1 mice and human
NF1 patients. In addition, from a total of eight pheochromocytomas and seven myeloid
leukemias examined from these animals, we have observed the absence of the wild-type Nfl
allele in the tumor DNA in each case. Pheochromocytomas from human NF1 patients also show
loss of heterozygosity on chromosome 17 (Green et al., 1992), and in the three informative cases
in this study the markers from the chromosome 17 carrying the presumed wild-type allele of NF1
were lost during tumorigenesis. Furthermore, children with NF1 also develop malignant myeloid
disorders at an increased frequency, and approximately half of these show loss of heterozygosity
for markers in and around the NF1 locus (Riccardi, 1981).
The strain-specific tumor spectrum in the Nfl mouse model suggest the presence of modifier
genes which influence the development of particular tumor types in mice. Myeloid leukemia
were found exclusively in the 129sv inbred mouse strain, while pheochromocytomas were seen
only in mixed background mice. Given the carefully-controlled environmental conditions under
which our study population was kept, it is likely that genetic (rather than environmental)
variability contributed toward the disparity in phenotype. Modifier genes have been proposed to
modulate tumor phenotype in a variety of tumors, and cloning of such genes have been
demonstrated in the case of Mom-1, a modifier of the Min (multiple intestinal neoplasia) gene
(Dietrich et al., 1993) in mice. More recently, the phospholipase A2 gene was suggested as the
actual modifier gene residing in the Mom-i locus (MacPhee et al., 1995). Modifier genes present
in various human genetic backgrounds may indeed explain the variable expressivity across the
human NF1 population.
Homozygosity for the Nfln3 1 mutation leads to mid-gestational embryonic lethality with
associated defects in cardiac development. Neural crest cell lineage mapping using chick/quail
chimeras has shown that cardiac neural crest cells contribute to the formation of the outflow
tracts of the heart (Kirby et al., 1983). Laser ablation of this population of neural crest cells in
the chick leads to cardiac abnormalities very similar to those described here (Kirby and Waldo,
1990). In addition, homozygosity for the Splotch mutation in the Pax-3 gene (Epstein et al.,
1991) leads to defects in several neural crest cell-derived structures, including the septation of
the truncus arteriosus (Franz, 1989). Thus, it is likely that the abnormal cardiac development
caused by homozygous mutation of the Nfl gene results from either a failure of the cardiac
neural crest cells to properly migrate to the heart or to function normally once there.
Interestingly, one of the two known alternatively spliced forms of NF1 mRNA is restricted to
skeletal and cardiac muscle (Gutmann et al., 1993), and there is a dramatic rise in neurofibromin
expression in the heart on day 12 of mouse development (Huynh et al., 1994). In addition, a
variant form of NF1 known as Watson's syndrome includes the cardiac defect pulmonary
valvular stenosis (Tassabehji et al., 1993). The connection between the homozygous mutant
phenotype described here and this rare manifestation of NF1 is unclear at present, but it is
interesting that a recently described allele of NF1 from a patient with Watson's syndrome showed
an in-frame duplication in exon 28 (Tassabehji et al., 1993). It is possible that this mutant
protein could act in a dominant negative fashion leading to partial functional inactivation of
wild-type neurofibromin in the developing heart.
We have also noted an overabundance of cells lining the outflow tracts of the homozygous
mutant embryos. Given the other associations between neurofibromin function and
proliferation/differentiation of neural crest cells, it is tempting to speculate that Nfl-deficient
cardiac neural crest cells do migrate to the heart but fail to differentiate properly and continue to
proliferate. In this way, the growth properties of these cells may provide a model for the various
pathological effects in the human disease. We expect that the study of this phenotype as well as
the tumor development in heterozygous mice will provide important insights into the
pathogenesis of human NF1.
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Chapter 3
Nfl Double Knock-out Chimeras:
Characterization of a Murine Neurofibroma Model
Introduction
The hallmark lesions associated with the human NF1 condition includes the development of benign
neurofibromas, Lisch nodules and cafe-au-lait spots. In fact, the presentation of a certain
combination of such lesions is usually considered diagnostic of the NF1 disease. The cell types
involved in all these lesions have a common, neural crest origin, namely the peripheral nerve
sheath, iris and skin melanocytes (Bolande, 1974). Of these lesions, the neurofibroma poses the
biggest threat to the patient, since it is precisely the progression of these benign growths (into
neurofibrosarcomas, or more recently categorized as a type of malignant peripheral nerve sheath
tumors, MPNSTs (reviewed in Fletcher CDM, 1995)) that results in nerve compression, pain, and
even death. In fact, treatments for NF often focus on the removal or shrinkage of neurofibromas
and their malignant outgrowths.
Neurofibromas arise under the skin (subcutaneous) or in the deep plexus of the peripheral nerve
trunks (plexiform). It is also widely accepted that neurofibromas are composed predominantly of
neurons, Schwann cells, perineurial cells and fibroblasts. A subset of the tumors also include mast
cells, although the role such cells play in the formation of neurofibromas is still unknown (Lascano
EF, 1958; Johnson et al, 1989).
Unfortunately, the etiology of these neurofibromas has also remained elusive to researchers. There
have been long-standing disagreements among pathologists as to the cell types involved, and the
role in which each one plays in tumor formation. For example, a survey of the literature describing
the composition of plexiform neurofibromas show a wide range of findings, from predominantly
Schwannian (as shown by the positive staining with S-100, MBP or PO antibodies) to
predominantly perineurial/fibroblastic (staining positive for EMA and/or negative with S-100)
(reviewed in Riccardi, 1992). Some argue that the lack of S-100 protein expression in
neurofibromas resulted from the inability of proliferating Schwann cells to produce such cell-
specific markers. Others suggest that Schwann cells, perineurial cells as well as fibroblasts
represent distinct differentiation states from a common precursor, and that the hyperplastic cell type
in neurofibromas represents an intermediary differentiation state (Hirose et al, 1986). Electron
microscopy has been used in an attempt to address this question, but has done little to resolve these
issues.
Consistent with the tumor suppressor hypothesis, loss-of-heterozygosity (LOH) at the NFI locus
has been documented in various hyperplastic/tumor tissues from human patients. However,
whereas the malignant growths show a high incidence of NF1 LOH, benign neurofibromas have
rarely shown deficiency in NF1 function (either by mutational analysis or protein detection)
(Huson, 1994). A popular hypothesis to explain this discrepancy assumes that a single cell type in
a peripheral nerve trunk initially incurs LOH at the NF1 locus, and begins to proliferate.
Alternatively, this NFl-deficient cell could start to secrete some factor to induce other cells to
grow, be it in an autocrine (same cell type) or paracrine (other cell types) fashion. Unless the
growth is clonal from the NF1 -/- cell, it would be very difficult to detect the LOH in a small subset
of mutant cells using PCR or Southern blot analysis.
Given the prevalence of NF1 (one in 3,500 (Stumpf, 1987)) and the unanswered questions on
tumor etiology, we decided to address these issues by expanding upon the mouse model of Nfl
generated in our lab (Jacks et al., 1994). The previous Nfl mouse model proved to be an
insufficient model due to the early embryonic lethality resulting from Nfl deficiency and prolonged
tumor latency in the heterozygous cases (Jacks et al., 1994). Instead, we wished to generate a
model to study the effect of Nfl-deficiency in the context of adult animals. The particular approach
that would allow us to artificially create such a model is to generate double knock-out (DKO)
chimeras, where Nfl -/- embryonic stem (ES) cells are injected into normal blastocysts. The
resulting chimeric animals would be partially composed of Nfl +/+ and mutant cells (Figure 3.1c).
First, the DKO chimera generation approach has allowed researchers to bypass the embryonic
lethality phenotype by limiting the contribution of the mutant ES cells to certain tissue types, as in
the case of the retinoblastoma (Rb) gene (Maandag et al., 1994; Williams et al., 1994). Second, if
the Nfl -/- ES cells differentiate into cell types critical to the formation of neurofibromas (or other
diagnostic NF1 lesions), we would be able to (1) suggest a role of Nfl-deficiency in the formation
of these lesions and (2) identify the cell types that are Nfl-deficient in these benign growths. The
latter question could be addressed by engineering appropriate molecular markers into the injected
mutant ES cells.
One such marker is the neo gene inserted as a part of the Nfl mutant allele construct. This single
copy transgene can be specifically amplified by in situ PCR . Alternatively, a radio-labeled
riboprobe against neo can be used to detect the mRNA produced by the Nfl-neo mutant allele,
which contains a stretch of the neo gene sequence (Jacks et al., 1994). Another ES cell marker is
the reverse orientation splice acceptor (ROSA) transgene developed by Friedrich and Soriano
(1991) as a part of a screen to identify developmentally-regulated genes in mouse embryos.
Strains of ROSA mice were generated by electroporation of promoterless reporter constructs
consisting of fusion 3-gal and neo genes (P-geo) into ES cells. Such strains can be categorized
into two groups: some strains express the 0-geo gene product in a spatially- and temporally-
regulated fashion, while others show ubiquitous expression throughout development. For our
purposes, we used the used the ROSA-26 strain, which was shown to express strongly and
ubiquitously the transgene (Friedrich and Soriano, 1991). Equally important was the observation
that mice homozygous for this single-copy insertion showed no phenotypic effect. By introducing
the ROSA-26 transgene into Nfl DKO ES cells, we were hoping to provide a specific marker for
cells derived from these injected clones, regardless of tissue type. The presence of the 0-geo
transgene can be easily detected by staining the tissues of interest with X-gal. Chimeric tissue
sections were stained with X-gal in order to further analyze, at the cellular level, the contribution
of Nfl-/- ES cells to various tissues and organs. Previous studies have reported the X-gal staining
patterns for various tissues from ROSA-26 animals (Friedrich and Soriano, 1991; Williams
dissertation, 1996). It was found that even though the 0-geo expression was found in almost all
cell types examined, the subcellular localization of the -galactosidase protein varied widely among
cell types. The X-gal staining patterns also differed depending on the type of tissue preparation
and staining protocols used. Given the likely localization of Nfl-associated lesions to the
peripheral nervous system, we focused our efforts on optimizing the staining pattern analysis for
various neuronal tissue sections.
About twenty Nfl DKO chimeras were generated using both ROSA-26 and non-ROSA-tagged ES
cells. Pathology was performed on animals showing signs of wasting or other phenotypes. A
subset of animals with moderate contribution from the Nfl-deficient ES cells grew increasingly
weak with neuro-motor defects. It was within this population of animals where we found the
presence of lesions reminiscent of human neurofibromas as well as myeloid dysplasia. The murine
neurofibromas were characterized using immunohistochemistry, electron microscopy and, where
available, X-gal staining.
Methods
Generation of Nfl-DKO ES Cells
Re-targeting of wild-type allele in heterozygous cells
ES cells heterozygous for the Nfl mutation (Jacks et al., 1994) were electroporated with an Nfl-
targeting vector containing a hygromycin resistance gene (hygro) in place of the neomycin
resistance gene (neo) of the original construct, as described in Jacks et al., 1994. The hygro gene
is driven by the PGK promoter and polyadenylation sequences. Conditions for the hygro vector
electroporation were identical to the first round of neo targeting steps (Jacks et al., 1994).
Following electroporation, the cells were plated either in the absence of feeders or in the presence
of G418-resistant feeder cells (courtesy of R. Jaenisch), and subsequently selected with 300 pgg/ml
G418, 125 pgg/ml hygromycin and 2 mM gancyclovir (Figure 3.1a). Colonies were picked and
expanded for DNA analysis. Confirmed Nfl DKO (-/-) ES cell lines were chosen for blastocyst
injection.
Increasing drug selective pressure
An alternative protocol for obtaining Nfl -/- ES cells was also used (Mortensen, 1992). Nfl +/-
ES cells were incubated in selection media containing higher levels of G418 (300 gg/ml, 700
gg/ml, 800 gg/ml, 900 gg/ml, 1.1 mg/ml and 1.3 mg/ml). Ten thousand ES cells were used for
each ten centimeter plate, and three plates were used per condition. The cells were selected at the
lowest selection concentration for one day (300 mg/ml of G418). All plates were pretreated with
gelatin and layered with drug-resistant feeder cells. Selection began on the second day and fresh
media was added daily. The increased selective pressure may potentially lead to the duplication of
the drug resistance gene, be it from nondisjunction, non-reciprocal recombination or chromosomal
loss events. Colonies were picked from plates where significant selection has occurred (judged by
significantly reduced number of colonies in the plate).
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Generation of ROSA-26 DKO ES Cells
Genotyping of ROSA-26 animals
ROSA-26 animals were genotyped by colorimetric and PCR methods. Small sections of the ear
were removed with an ear punch and placed in a staining solution at 37C for 2-8 hours. The
solution reacts with the -galactosidase enzyme (present in most tissues of ROSA-26 animals) to
turn the ear tissue blue, identifying the animal as ROSA-26 (Friedrich & Soriano, 1991). The
PCR assay was performed on precipitated tail DNA as described previously using the following
primers (ROSA-F=5'-TTTCCACAGCTCGCGGTTG-3' and ROSA-R=5'-
GATCCGCCATGTCACAGA-3'). The conditions for the PCR reaction are as follows: 94C for
3 minutes, followed by 30 cycles of 94C for 1 minute, 62'C for 2 minutes and 72C for 2
minutes. It must be noted that the two assays described here only detects the presence of the
ROSA-26 single-copy transgene, but do not elucidate whether the animal carries one or two copies
of the gene (heterozygous and homozygous for ROSA-26, respectively).
Ovariectomization and delayed blastocyst harvest
Timed matings were performed between a 129SV inbred Nfl +/- animal and an Fl hybrid (129SV
x C57BL/6) Nfl +/- animal. At least one of the parents was previously identified as a carrier for
the ROSA-26 transgene. The ovariectomy procedure was performed on the female 2.5 days after
the detection of a vaginal plug (equated to day 0.5). In addition, the female is injected with 0.1 ml
of 10 mg/ml Depa-Provera subcutaneously in order to inhibit the implantation of the blastocyst into
the uterine wall, creating "delayed blastocysts" (Bradley, 1987). At 6.5 days after the vaginal
plug, the females are sacrificed and the uterine horns flushed with blastocyst media. Delayed
blastocysts (having lost the zona pellucida) are then collected and individually placed over feeder
layers in 24-well wells (previously coated with 0.1% gelatin) and fed with ES cell media. The
feeder layer is plated 1-2 days prior at the density of 1x106 cells per well. The feeder layers are
derived from murine embryonic fibroblast cell lines and irradiated with 6 Grays (Gy) of ionizing
radiation to stop cell proliferation. After 3-4 days in culture (or until the delayed blastocysts have
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attached to the feeder layer and flattened into a colony of cells grown out from the inner cell mass
(ICM)), the well is washed with sterile PBS and the colony is picked using a sterile plastic pipette
tip. The cells are then placed into approximately 50 ml of ES-grade trypsin (Robertson, 1987) for
5-10 minutes at 37°C, after which the cells are gently disaggregated into single cell suspension by
pipetting action. The suspension is then placed in gelatinized 24-well wells plated with ES feeder
1-2 days earlier. Over the next 5-10 days, the wells are monitored for the appearance of ES cell
colonies. Once the ES colonies have grown to the appropriate size and morphology, they are
removed, disaggregated (as described above) and expanded over ES feeders and gelatin. The ES
cells over feeder are kept undifferentiated and are subsequently frozen back in ES freezing media
(Robertson, 1987) and stored at -80'C or in a liquid nitrogen freezer. DNA is made from ES cells
grown on gelatin-only plates in order to determine the genotype of the ES cells.
Identification of appropriate clones
ES cell lines are genotyped for Nfl status by Southern analysis as described in previous chapters.
In addition, the presence of the Y chromosome-specific Zfy gene was determined using a PCR-
based assay (Page et al., 1987). The cell line is determined to be male by the presence of a Zfy-
specific band, while the absence of such a band suggested that the cell line was female. ES cell
lines that are Nfl-heterozygous, ROSA-26 and Zfy positive are then re-targeted with the Nfl-
hygro vector to disrupt the wild-type allele of Nfl (as described above).
Preparation of ES cells for blastocyst injection
Nfl DKO ES cell clones were thawed onto 6-well plates coated with either gelatin or layered with
ES feeders 1-4 days prior to the scheduled injection date. On the day of injection, the ES cells
were disaggregated into single-cell suspension using trypsin, spun into a pellet at 1000 rpm, and
resuspended in blastocyst media (Robertson, 1987) at a concentration of approximately 60,000
cells per ml.
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Generation of Nfl-DKO mice
Murine chimera generation techniques were used as described in Robertson, 1987 and Bradley,
1987.
Blastocyst isolation
Female mice were prepared in one of two ways for blastocyst isolation. One, C57BL/6 females
over 7 weeks of age were mated to males of identical strain. Pregnant females (identified by the
detection of vaginal plugs) were sacrificed three days after mating and blastocysts were then
harvested by flushing the uterus with blastocyst media. The second method involved
superovulating C57BL/6 females over 3 weeks of age (but less than 5 weeks old): First, the
females received 5 IU of pregnant mare serum (PMS) intraperitoneally (IP), followed forty-eight
hours later by IP injection of human chorionic gonadotrophin (HCG) and subsequent housing with
C57BL/6 males. Blastocyst harvest procedures were identical to the above for females in which
vaginal plugs were detected on the following day (Figure 3.1c).
For Nfl +/- blastocyst harvest, Nfl +/- C57BL/6 males were mated naturally to wild-type females
of the same strain. Blastocyst collection procedur5 above.
Blastocyst injection and Implantation
The injection and implantation procedures were described by Bradley, 1987. Each blastocyst was
injected with between 2-5 ES cells. Typically, between 5-10 blastocysts were implanted into each
uterine horn of pseudopregnant Swiss Webster female mice (Taconic Farms).
Assaying for ES cell contribution
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Nfl -I- ES cell contribution was assayed in two ways: First, agouti coat color chimerism was
estimated by observation. Second, glucose phosphate isomerase enzymatic isoform analysis was
performed on various tissues from the chimeric mice (Robertson, 1987).
Analysis of chimeras generated from heterozygous blastocysts
Tail DNA from potential Nfl DKO chimeras was prepared with proteinase K digestion and
subsequently purified using phenol-chloroform extraction. 15 gg of DNA was digested with
NcoI and HindlII for Southern Blot analysis. The probe used was an NaeI-PstI (449 basepair)
fragment of the NEO gene from the pMCI-neo vector. This NEO fragment was first cloned into
the pBS-KS vector (Stratagene). The probe was isolated for radio-labeling by digesting the pBS-
KS vector with PstI and XhoI.
Histology and 3-gal staining
Embryonic and neonatal: Embryos prior to mid-gestation (13.5 g.d.) were extracted from
euthanized females, washed once in pH 7.3 buffer and fixed with 10% NBF, Bouins fixative or
4% paraformaldehyde for 30 minutes up to one hour (depending on size). Larger embryos and
neonates required exposure of the cranium and abdomen prior to fixation to ensure penetration of
the fixative. The animals were then washed in the buffer for three times (15 minutes each) and
then placed into 3-gal staining solution (described above) for overnight to a maximum of a week at
room temperature (changing to fresh solution once every two days). The embryos were then
photographed under dissecting microscopes for staining patterns.
Adult: The animals were euthanized using C02 asphyxiation. The mice were fixed by either
intracardial perfusion (Bronson & Lipman, 1991) or whole-mount fixation after the tissues were
dissected. The tissues were carried through the 3-gal staining protocol identical to that for
embryos and neonates. The tissues were sliced as thinly as possible to assure stain penetration,
either with a sharp razor blade or with vibratome.
Frozen Section n-gal staining: Adult chimeras were dissected and desired tissues were isolated in
sections no larger than 1 cm 3 . These tissues were then fixed in 4% paraformaldehyde at 4°C for
30 minutes. The sections were then washed in cold PBS (4°C) for 30-45 minutes using three
changes of fresh PBS. After the washes, the sections were placed in 30% (weight/volume)
sucrose in PBS for 18 hours or until the tissues have equilibrated and no longer float in the sucrose
solution (this equilibration step was performed unless otherwise noted). The sections were then
immersed in OCT (Tissue-Tek) media and quickly frozen by dipping into a beaker of isopentane
cooled by liquid nitrogen. Frozen sections between 5-10 microns were then cut using a cryostat
and stored in -80'C. Immediately prior to staining, the sections were thawed and post-fixed briefly
with 4% paraformaldehyde (in PBS), followed by two washes of PBS for 5 minutes each.
Sections were then incubated in X-gal staining solution between overnight to a week (depending
on the time required for the X-gal crystals to form) in a light-protected humidified chamber. X-gal
stain contained the following: (PBS with 1 mg/ml 4-chloro-5-bromo-3-indolyl-p-galactoside (X-
gal), 4 mM potassium ferrocyaniade, 4 mM potassium ferricyanide, and 2 mM magnesium
chloride).
Blood smears
A drop of blood from the mouse was placed on a glass histological slide. An edge from a clean
glass slide was used to apply even pressure in spreading the blood into a mono-layer. After drying
for at least thirty minutes, the slide was covered with Wright stain (Sigma Diagnostics) for 3
minutes and then Giemsa stain (Sigma Diagnostics, diluted 1:1 with ddH20) for 8 minutes. The
slide was subsequently washed with ddH20, let dry and cover-slipped with permount. The
number and type of blood cells are then counted by taking the average number of cells of 40X
magnification
Immunohistochemistry
105
Immunohistochemistry protocols were essentially as described in Williams et al., 1994.
Incubation buffer comprise of 10% normal goat serum (Sigma), 0.05% Tween 20 and 0.02%
sodium azide. Antibodies against Neurofilament 200 (Dako, 1:200 dilution in buffer), S-100
(Dako, 1:200), vimentin (courtesy of R. Hynes, 1; 100), myelin basic protein (MBP) (Dako,
1:200), epithelial membrane antigen (EMA) (ICN, 1:75 and Dako, 1:200), human milk fat globulin
protein (Novocastra, 1:50) and anti-coagulation factor XIIIA (Calbiochem, 1:500) were used.
Appropriate secondary antibodies were used against the primary antibodies, including biotinylated
anti-mouse (Jackson ImmunoResearch Labs, 1:200), FITC goat anti-rabbit (Vector, 1:100) and
biotinylated goat anti-rabbit (Jackson, 1:200). Mast cells were visualized in paraffin sections by
staining with 0.5% toluidine blue for up to 10 minutes.
Antigen retrieval/exposure techniques included microwave heating as described by Tischler, 1995
or 15-30 minute digestion with diluted trypsin (0.05%, Sigma type II) in 0.05% calcium chloride
at pH 7.8.
Transmission Electron Microscopy
Tissues were prepared for EM in one of two ways. Freshly-dissected tissues were fixed in 4%
paraformaldehyde and 2% EM-grade glutaraldehyde (Ted Pella, Inc.) for one hour or longer
(depending on the size of the tissue). For tissues that were already paraffin-embedded, the paraffin
block was first melted, the tissue re-hydrated to PBS, followed by at least one hour of fixation
with 4% paraformaldehyde and 2% glutaraldehyde. If decalcification of bone is required, tissues
are then placed into 0.5 M EDTA at 4°C for two weeks prior to sectioning. After proper fixation
and necessary decalcification, the tissues are washed thoroughly with three changes of 0.1 M
cacodylate buffer (Hayat, 1970), and can be subsequently stored in the 0.1 M cacodylate buffer at
4°C until the next step. This is followed by perfusing the tissues with osmium tetroxide (OsO4, in
0.1 M cacodylate buffer) for 1 hour on ice, then incubated overnight in cold 0.1 M cacodylate
buffer). The sections are then taken through a series of dehydration and staining steps including
50% ethanol for 10 minutes, 2% aqueous uranyl acetate in 70% ethanol for one hour (4°C in the
dark), 90% ethanol for 10 minutes, followed by 100% ethanol for three changes of 10 minutes
each. The sections were then washed with propylene oxide for 20 minutes (change of fresh
solution after the first 10 minutes). The embedding medium used for all EM work was Spurr
resin: First, the tissues were placed in a small glass jar with 1:1 resin:propylene oxide and rotated
overnight at room temperature. Second, the tissues were transferred to freshly-made resin in
embedding capsules and allowed to polymerize at 70'C for 24 hours. Semi-thin sections were cut
and stained (1% methylene blue and 1% azure II in 1% borate) to identify the histological regions
of interest. Ultrathin sections were then cut on Leica Ultracut S at 60 to 90 nm, embedded in 200
mesh copper EM grids, and stained with 4% uranyl acetate and Reynold's lead citrate. EM images
were captured on Kodak EM Film 4489 using a JEOL 1200 EX electron microscope set at 80.0
KV.
In situ PCR
Histologically slides were deparaffinized and hydrated as described for immunohistochemistry,
followed by 5 minute washes with 0.1 M Tris (pH 7.4) and then 0.3% Tween20 and 0.5% NP40
in 0.1 M Tris pH 7.4. The sections were then permeabilized with trypsin (2 mg/ml) for one hour
at room temperature, followed by 2 washes with 0.1 M Tris 7.4 for 5 minutes each. The slides
were then incubated in the appropriate PCR buffer, cover-slipped and sealed with nail polish (PCR
buffer consist of 10 mM Tris pH 8.4, 50 mM KC1, 4 mM MgCl2, 0.01% gelatin, 0.05% Tween-
20, 0.05% NP40, 100 pmol of each of the Nfl mutant allele PCR primers NfX4I and neo (Jacks
et al., 1994), 62.5 mM of dATP, dCTP, dGTP, and dTTP-biotin and 5 units of AmpliTaq). The
slides were then placed inside a HybAid OmniSlide thermocycler pre-heated to 80"C (hot-start).
The PCR cycling times are: 92°C for 3 minutes, followed by 40 cycles of 92°C for 1 minute, 55°C
for 2 minutes and 75°C for 2 minutes. Sections incubated in PCR buffer without primers served
as negative controls for these experiments. Incorporated biotin-conjugated dTTP was visualized
with an avidin and biotinylated horseradish peroxidase complex (Vectastain ABC kit). Finally, the
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sections were counter-stained with either methyl green or nuclear fast red prior to observations
using the microscope.
In situ hybridization
A PstI-PstI 200 bp fragment of the NEO gene from pMC1-neo (Stratagene) was cloned into pBS-
SK. The sense in situ riboprobe against neo was made using the T3 promoter after linearization of
the vector with HindII, while the anti-sense probe was made using the T7 promoter after
linearizing with BamH1. The in situ protocol is essentially as described in McClatchey et al.,
1997.
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Results
Generation of Nfl DKO chimeras
ES cell clones heterozygous for the Nfl mutation (Jacks et al., 1994) were re-targeted with the
Nfl-hygro vector (Figure 3.1a). Electroporated clones were genotyped by Southern blot analysis.
ES cell lines that included both the Nfl-neo and Nfl-hygro mutant alleles were selected for
blastocyst injection. Two of the 63 ES cell lines established were shown to be Nfl -/- (Nfdko6
and Nfdko48). Figure 3. 1c graphically depicts the process of generating the DKO ES cells and the
subsequent Nfl DKO chimeras.
Initially, 5-7 ES cells were injected into each blastocyst. It proved exceedingly difficult to generate
adult chimeras, and the yield of pups born per recipient female (versus the number of blastocysts
implanted) was consistently low. This suggested that the contribution of Nfl -/- ES cells to certain
developing tissues resulted in reduced fitness of these embryos in utero. To address this question,
embryos were taken at various stages of gestation and the level of ES cell contribution was
determined using GPI analysis (Figure 3.2). Table 3.1 summarizes the results of that set of
experiments.
Table 3.1 Developmental bottlenecks associated with Nfl deficiency as seen by high mid-
gestational and embryonic lethality in the Nfl-DKO chimeric population.
Age Total Chimeric % Chimeric
13.5 g.d. 18 11 61%
15.5 g.d. 22 4 18%
neonates (d)* 42 10 24%
*Dead neonates recovered from litters within 2 days after birth
The results suggested that a percentage of chimeric embryos were not progressing beyond the 13.5
g.d. mid-gestational stage. We speculated that these embryos were dying from the same cardiac
defects as the Nfl-mutant embryos (Jacks et al., 1994). By examining the developing hearts of
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Figure 3.1. Schematic and Southern blot analysis for DKO ES cell generation
a. Two round targeting protocol to inactivate both Nfl alleles in ES cells. The neo and hygro
selectable markers were used for each targeting construct. The Southern probe used is indicated by
(Pr). b. Southern analysis showing the loss of the wild-type Nfl allele in NfDKO6, NR30 and
NR47. c. Schematic diagram describing the sequence of events resulting in the generation of
DKO chimeras.
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Figure 3.2. GPI analysis for ES cell contribution in chimeric animals.
GPI isoforms were separated on a TLC plate electrophoretically. The C57BL/6 isoform (b)
migrates faster than the 129sv isoform (a). Chimeras show varying levels of isoform band
intensities, from which relative contribution can be determined. In this animal (NfDKO#1), the
thyroid gland and kidney received low levels of contribution, while the liver and diaphragm were
basically nonchimeric. Muscle tissues exhibit an intermediate band due to the fusion of ES-derived
and wild-type muscle cells (syncitium), leading to the heterodimerization of the two different
isoforms.
112
(JQ
0I -4
ro
w
 
to
c
o
 <
B6
 c
tr
l
12
9 
ct
rl
th
yr
oi
d
ep
id
er
m
is
in
te
sti
ne
S 
n
o
se
-
ki
dn
ey
te
st
ic
le
liv
er
di
ap
hr
ag
m
m
u
sc
le
es
o
ph
ag
us
lu
ng
some of these chimeric embryos under the dissecting scope, we found a number of the hearts (3/5)
exhibited either delayed development or dorsal outlet right ventricle (DORV) at 13.5 g.d.
Furthermore, a number of chimeric neonates were unable to survive past 1-2 days after birth. A
few of these deceased neonates were salvaged before cannibalization by the female, and thorough
pathology was performed. We found a particular adrenal medullary defect in two of the four dead
neonates. This lesion was best described as a "streaming" of cells resembling the adrenal
medullary differentiation from the developing adrenal gland (Figure 3.3a). A quick examination on
some nonchimeric neonates revealed that the normal neonatal adrenal glands were fully enclosed
(medulla within the adrenal cortical layer, Figure 3.3b). Therefore, we hypothesized that the
adrenal medullary abnormality was either a result of incomplete migration of neural crest
precursors into the developing adrenal primordium, or a hyperplastic outgrowth of these same
cells. In either case, such a lesion could cause severe imbalance in the blood epinephrine and
norepinephrine levels, resulting in the animals' failure to thrive after birth.
It was hypothesized that the some of the steps involved with re-targeting single knock-out (SKO)
ES cells with the Nfl-hygro allele (re-electroporation, selection with hygromycin, etc.) might have
rendered the resulting Nfl -/- cells less effective in generating adult chimeras. To bypass
potentially damaging steps, we utilized an alternative protocol in which Nfl SKO ES cells were
subjected to high G418 selection. The increased selection pressure would select for ES cell clones
in which a non-reciprocal recombination has taken place, resulting in the duplication of the Nfl-
neo mutant allele. These DKO ES cells should be able to tolerate higher G418 selection than cells
with only one copy of the neo-resistance gene (Mortensen, 1992).
An Nfl SKO ES cell line (Nfskol55) was placed in five concentrations of G418 (300 mg/ml, 700
mg/ml, 800 mg/ml, 900 mg/ml, 1.1 mg/ml and 1.3 mg/ml) for ten to 14 days. Starting at 900
mg/ml, a dramatic reduction in colony numbers was seen relative to 300 mg/ml, which was the
Figure 3.3 Pathological and histological features of Nfl DKO chimeras.
(a) Adrenal medullary abnormality as observed by the outgrowth of the medullary tissue (arrow)
from within the adrenal cortex (white arrow). (b) A normal neonatal adrenal gland, with the
medulla (arrow) fully enclosed (white arrow). (c) Myeloid dysplasia from peripheral blood
smears. The ring-shaped nuclei are indicative of terminally-differentiated myeloid cells, or
neutrophils. (d) wholemount observation of a neurofibroma on the left 5th cranial (trigeminal)
nerve (white arrow). The normal-sized right trigeminal is also present. (e) Sagittal section through
the tongue showing the neurofibromas as white, round masses. (f) Neurofibroma found arising
from the sciatic nerve (H&E, 100x). Note the diffuse and disorganized pattern of the tumor
compared to the normal sciatic nerve above. (g) Multiple neurofibromas growing within muscle
(H&E, 40x). Note that the hyperplastic cells surround normal nerves, which is indicative of the
nerve sheath origin. (h) Neurofibromas arising from smaller peripheral nerves (H&E, 400x).
Note the whorl patterns of the diffuse cells.
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Figure 3.3
normal drug concentration for one copy of the neo resistance gene. One hundred and sixty
colonies were picked (16 from 1.3 mg/ml, 37 from 1.1 mg/ml, 43 from 900 gg/ml and 64 from
700 gg/ml). Eighty-eight of these clones remained undifferentiated after expansion and were
genotyped by PCR and Southern analysis. None of the picked colonies showed the expected LOH
at the Nfl locus. These colonies might have developed increased drug resistance due to
hyperactive mutations in the neo promoter or within the gene itself.
In the meantime, we continued to use the two characterized DKO ES clones (Nfdko6 and
Nfdko47) in chimera generation. Two changes were made in the standard injection protocol:
First, the number of ES cells injected per blastocyst was lowered to 2-4 in an attempt to reduce the
overall contribution to the chimeric animals (and more specifically, to lower the likelihood of these
Nfl -/- cells from contributing to the developing heart and adrenal medulla). Second, the ES cells
were plated on irradiated feeder cells rather than on gelatin only. This treatment has been
suggested to maintain the undifferentiated state of the ES cells and therefore facilitate chimera
generation (A. McClatchey, personal communication). As a result of these two changes, a total of
eighteen chimeras were generated in a year.
Adult chimera phenotype
Table 3.2 below summarizes the relevant results on the eighteen chimeras. As expected, a slight
male predominance was seen because the ES cells used contain the XY (male) chromosomes.
Animals generated from both ES cells clones exhibited the same sets of phenotype, showing that
the lesions were not due to mutations specific to any one clone.
The chimeric phenotype can be divided up into three groups, depending on the level of contribution
by the Nfl-deficient ES cells. First, the high contributors (usually over 80% coat color chimerism)
survive less than one month. Upon necropsy, the only clear observation was a bloating of the
intestines, which may be associated with death. No neurofibromas, Lisch nodules or adrenal
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Table 3.2 Summary of adult DKO chimera phenotype
Chimerism I Sex Age2 NF? 3  Location 4  Lisch 5  Myeloid 6 clone Other lesions
85% M <1 -- -- -- -- 6
80% M < 1 No -- No No 47
80% M < 1 No -- No Slight 47
65% M < 1 No -- No -- 47
75% F 5.1 Yes DRG, ovary No Yes 6
70% M 2.3 Yes DRG, subQ No Yes 47
60% M 4.5 Yes DRG No Yes 47
45% M 2.4 Yes DRG No No 47
40% M 3.3 Yes muscle No Slight 6
40% F 3.7 Yes DRG, rectal No Yes 47 Meningioma
35% F 4.0 Yes DRG -- -- 47
30% M 6.9 Yes DRG No Slight 6
25% F 7.0 Yes TR, DRG No Slight 6
25% M 11.0 Yes DRG, lung No No 47 Ganglioneurom
a
20% F 11.0 Yes TR, DRG, No No 6
tongue
20% M 26.4 Yes rectal No Slight 6
15% M 15.0 No -- No No 6
10% M 17.6 - -- No No 6
IChimerism is determined by approximating the agouti coat color contribution
2Age in months
3Detection of neurofibromas
4Location of neurofibromas: DRG=dorsal root ganglia, subQ=subcutaneous, TR=trigeminal
5Irises of chimeras were examined under a dissecting scope while directing a iightsource at the eyeball.6Presence of myeloid hyperplasia as determined by counting the number of cells in the myeloid lineage
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medullary hyperplasia were found (Figure 3.3c), possibly due to the lack of time for significant
growth. One of these animals developed a slight myeloid dysplasia, a condition found with
increased frequency in the human NF1 population. Another animal only had 65% coat color
contribution, yet survived less than one month. This may be caused by lesions resulting from the
contribution of ES cells to certain critical -- yet unknown -- tissues. A second category was the
low contributors (15% or less by coat color). These animals survived for over a year without
obvious phenotype.
The third, and most revealing category, involved the mid-range contributors (between 20-75%).
These animals developed steadily worsening neuro-motor defects that included tremors, grasping
of the hind legs and general wasting. The onset of these symptoms and the age of death generally
correlated with the extent of chimerism. None of these animals developed Lisch nodules, yet 2/3
of the animals exhibited various extents of myeloid hyperproliferation in peripheral blood smears.
The myeloid disorders were characteristically benign, since most of the cells found were
neutrophils (Figure 3.3c), which constitute terminally-differentiated myeloid cells (as opposed to
the more undifferentiated, blastic cells).
Furthermore, all of these animals developed peripheral nerve lesions reminiscent of human
plexiform neurofibromas. Some of these lesions were large enough to be found using a
microscope, including the trigeminal (Figure 3.3d) and tongue (Figure 3.3e). Histologically, these
lesions appear diffuse and fairly acellular (predominantly composed of collagen), with distinctive
whorl patterns similar to human neurofibromas (Figures 3.3f-h). Normal nerve bundles are often
found in the center of these whorls (Figure 3.3g and 3.3h), suggesting that the hyperproliferative
cells originated from the nerve sheath.
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Characterization of nerve sheath lesions
It was necessary to determine whether the cell types present in these murine lesions correspond to
those in their human counterparts. These peripheral nerve lesions were characterized by antibody
staining against specific antigens, chemical stains and ultrastructurally.
Twenty-two lesions from eight chimeras were stained with antibodies against neurons
(neurofilament-200, NF200), Schwann cells (S-100), fibroblasts and perineurial cells (vimentin).
Results are shown in Figure 3.4. All the lesions studied show localized NF200 and S-100 staining
in the normal nerve bundles. In the hyperplastic regions of the neurofibromas, however, only
spotty NF200 and S-100 staining are seen, suggesting that some neurons and Schwann cells have
been displaced by infiltrating tumor growths. The hyperplastic areas stained strongly for vimentin,
an intermediate filament protein present on fibroblasts, perineurial cells and Schwann cells. These
staining patterns suggest that the abnormally proliferating cell types in these lesions are fibroblastic
in nature or perineurial cells. While antibodies such as epithelial membrane antigen (EMA,
Coagulation Factor XIIIA and human milk globule protein (HMGP)) have been widely used to
detect the presence of perineurial cells in tumors, we have been unsuccessful in showing specific
staining with these antibodies despite trying a variety of conditions and treatments.
To further characterize the cell types involved, three of these lesions from two chimeras were
studied ultrastructurally. One of these sections had to be removed from paraffin wax and
reprocessed for EM analysis. Figure 3.5 shows some of the common features of these lesions.
Normal myelinated nerve bundles were frequently found in close proximity (Figure 3.5a),
suggesting the relative preservation of normal nerve bundles. The tumor cells exhibit long
processes that are often found to run in parallel, covered in continuous basal lamina (Figure 3.5b),
and laced with numerous pinocytotic vesicles (caveolae, Figure 3.5b and 3.5c). The tumors cells
are also collagen-producing, as shown by the presence of collagen packets (Figure 3.5d). Lastly,
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mast cells have been found within the lesions by EM (Figure 3.5e) and by toluidine blue staining
(data not shown).
These EM results provided some answers: First, the hyperplastic cells are not fibroblastic, since
the cells in question produce either a continuous or disrupted basal lamina, which fibroblasts do
not. Beyond this, however, the cellular identify becomes less clear: Some of the features found
using EM suggest that the hyperplastic cells exhibit features common to both Schwann cells and
perineurial cells, while others show characteristics exclusive to one or the other (see Table 3.3). It
is possible that the hyperplastic cells represent proliferating Schwann cells that have lost S-100
expression. It is equally likely that the abnormal cells are dividing perineurial cells that are
producing continuous basal lamina (as opposed to a normally discontinuous layer). Lastly, these
cells could be an intermediate differentiation cell type between Schwann cells and perineurial cells,
since some have argued that both cell types originated from a common precursor (Bolande, 1974).
Table 3.3 Ultrastructural comparison between Schwann cells and perineurial cell
Schwann Cell Features Perineurial Cell Features
interdigitating processes, sometimes long long, parallel processes
continuous basal lamina discontinuous basal lamina
pinocytotic vesicles pinocytotic vesicles (caveolae)
normally found ensheathing neurons normally form barrier layer surrounding nerve bundles
Identification of ES-derived cells
As mentioned previously, one of the unanswered question in neurofibromatosis research is the
identity of the cell type responsible for initiating the development of a neurofibroma. In these
chimeric models of neurofibromatosis, we have an unique opportunity to answer this question by
attempting to identify the Nfl-deficient cells in the murine peripheral nerve sheath tumors. To this
end, we have attempted to (1) amplify the mutant allele by performing in situ PCR on the
histological slides and (2) detect the mutant Nfl transcript and/or the neo mRNA, which should be
specific to only the ES-derived cells.
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Figure 3.4 Immunohistochemical analysis of murine neurofibromas.
A neurofibroma was found in between normal ganglia (to the right) and a nerve bundle (to the left).
Neurofilament (b) and S-100 (c) staining were only sporadic and confined to the nerve from which
the lesion arose. However, the entire lesion stains positive with vimentin (d), which suggest the
fibroblastic or perineurial nature of the hyperplastic cells. All images were taken at 100x
magnification.
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Figure 3.5 EM analysis of murine neurofibromas.
(a) Localized areas of normal neurons ensheathed by myelinating Schwann cells (arrows)
(2,500x). (b) Long, parallel processes with continuous (and sometimes interrupted) basal lamina
(arrow). Several caveolae can be seen along these processes (small arrowheads) (25,000x). (c)
Hyperplastic cells containing caveolae (small arrowheads) and collagen packets (to the lower
right). Note the basal lamina covering the cells (25,000x). (d) Enclosed collagen packet (collagen
bundles circumscribed by plasma membrane within the cell) showing that the hyperplastic cells
produce collagen (15,000x) (e) Mast cell, with the electron-dense granules (12,000x).
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The primers used in the in situ PCR protocol were described in the Nfl mouse knock-out
manuscript (Jacks et al., 1994). Instead of dTTP, a biotinylated dTTP was used in the reaction
solution. The biotin was subsequently detected using the DAB protocol (see Methods). Despite
the many trials using various thermocyclers, cycle times/temperature, and reagent concentrations,
we could not specifically amplify the nuclear signal in mutant cells (in either positive control
sections or neurofibromas). One possible explanation for the failure of the technique is the damage
or fragmentation of genomic DNA during the fixation and/or tissue processing steps.
Alternatively, in situ hybridization was used. Radiolabeled nucleotides were incorporated into the
riboprobes prior to the hybridization step. The advantages of in situ hybridization include the
presence of multiple copies of the target mRNA available for binding (signal enhancement). We
used antisense probes against the neo gene as well as the nonsense neo sequences present in the
mutant Nfl-neo mRNA (Jacks et al., 1994). However, these attempts yielded nothing more than
high background hybridization. It is possible that the 200 bp neo probe used was particularly
sticky (e.g. have sequence similarity to other mammalian genes).
Generation of ROSA-26 Nfl DKO chimeras
Data from the DKO chimera experiments suggest that the contribution of Nfl-deficient cells to the
adult mouse is able to induce the formation of neurofibromas. However, attempts at identifying
tumor cells derived from the ES cells have fallen short of a conclusive answer. Therefore, we
decided to generate Nfl DKO ES cells with a 3-gal marker, using the ROSA-26 transgene (which
has been reported to express ubiquitously in mice). Two such Nfl-deficient/ROSA-26 positive
clones were generated using the delayed blastocyst protocol (see Methods). To date, seven
chimeras were generated and three have been sacrificed and analyzed histologically. The ROSA-26
chimeras exhibited a slightly different spectrum of lesions associated, which may be attributable to
126
the ES cell strain differences (129sv x C57BL/6 mixed background for the ROSA-26 chimeras as
opposed to the 129sv inbred ES cells for the non-ROSA-26 experiment).
Generation of ES cells
Thirty-seven females were ovariectomized and 145 delayed blastocysts were collected. From these
blastocysts, 38 independent ES cell lines were established. After selection and expansion, 14
undifferentiated ES cell lines were chosen for genotyping. Of these 14 lines, ten were
heterozygous for the Nfl mutation, while the other four were wild-type. In addition, 9 lines were
found to be male (by Zfy PCR) and 7 lines were ROSA-26 positive. We decided to re-target one
of the mixed background Nfl +/- cell lines (NR3, which was also Zfy and ROSA-26 positive)
with the Nfl-hygro mutant allele in order to generate ROSA-26 DKO cells (see Methods). Zfy-
positive ES cells were used because, for reasons that are still unknown, male ES cells tended to be
better in terms of giving rise to chimeras (Robertson, 1987).
Fifty-nine colonies were picked from electroporated ES cells selected with hygromycin. Of these,
two clones (NRdko30 and NRdko48) were found to be Nfl-deficient using Southern analysis
(Figure 3.1b) and subsequently used for the creation of chimeric animals. During initial chimera
generation, the NRdko30 ES clone was found to give moderate to high contribution chimeras at an
increased frequency. Subsequent analysis of the clone found the presence of heterozygous ES
cells intermixed with the DKO cells. Single-colony re-derivation was performed on this ES cell
line. Of the 48 colonies picked, 21 undifferentiated colonies were analyzed, and one was found to
be Nfl -/- by PCR and then confirmed by Southern analysis.
Generation of ROSA-26 chimeras
To date, seven adult chimeras have generated using these ES cells from the NRdko48 clone. Only
three have been sacrificed and examined histologically (at 5.6, 3.4 and 5.3 months, respectively).
All three of these animals developed bilateral pheochromocytomas (Figure 3.6a), but none showed
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Figure 3.6 Phenotype and X-gal staining patterns of ROSA-26 chimeras.
(a) Pheochromocytoma (H&E, 40x). Note the compressed adrenal cortical layer (arrows). The
tumor exhibits extensive pleomorphism. (b) A normal trigeminal nerve with very low ES cell
contribution, as seen by the single blue cell (cytoplasmic staining) (Eosin only, 400x). (c)
Neurofibroma arising from the DRG (H&E, 400x), with (d) stained only with eosin to highlight
the X-gal staining. (e) Normal nerve with high levels of X-gal staining (400x). (e) Blood vessel
wall showing X-gal staining (100x).
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any signs of Lisch nodules or myeloid hyperplasia. Multiple nerve sheath lesions were found in
one of the animals (Figure 3.6c-d). The location (DRG, sciatic nerve) and histological appearance
of these tumors resembled those of the neurofibromas found in the non-ROSA-26 DKO chimeras
(Figure 3.3). In the same animal, some normal-looking peripheral nerve sections received very
limited ES cell contribution (Figure 3.6b). At the same time, other nerves showed high level
contribution (as determined by P-gal staining) yet still appeared normal (Figure 3.6e).
Chimera ES cell contribution assays
Initially, we needed to develop a consistent X-gal staining protocol for the various murine tissues.
Previous studies have found differences in the intensity and subcellular localization patterns of the
n-gal protein expression, depending on the cell type studied (Friedrich and Soriano, 1991; B.
Williams, personal communication). Because we were looking for NFl-related lesions, we
decided to focus on the neural crest derivative tissues -- specifically tissues of the peripheral
nervous system. Two X-gal staining protocols were used and the results compared: Wholemount
sectioning (with razor blades or vibratome) and frozen (cryostat) sectioning. It was determined
that wholemount sectioning produced good staining at the surface of most tissues, but the X-gal
staining solution was only able to penetrate 3-5 cell layers deep into the section. Frozen section
staining showed intense, uniform staining in only some tissues (B. Williams, personal
communication and dissertation). However, frozen section staining patterns tended to be punctate
(Figure 3.7c-d) rather than uniform, as in wholemount sections (Figure 3.7a-b).
Cellular components of the nervous system showed a distinct set of X-gal subcellular localization:
The blue X-gal crystals are found predominantly in the cell body of neurons and sheath cells, while
the axons and cellular processes for Schwann and perineurial cells had only diffuse X-gal staining
(Figure 3.7b). Given the relatively long processes of neurons, Schwann cells and perineurium,
the majority of the cellular structures seen at any plane of section would be processes rather than
cell bodies. The low level/diffuse staining in the cellular processes could potentially make the
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Figure 3.7 Comparison of X-gal staining assays.
(a-b) Whole mount staining followed by paraffin sectioning. (a) Trigeminal nerve stained with
eosin only (400x). (b) Nerve root with no staining. Note the blue haze in the axons and the
intense blue staining in the ganglia (40x). (c-d) Frozen section staining. (c) Trigeminal nerve
staining counterstained with nuclear fast red. Note the large, punctuate staining as compared to the
relatively uniform staining for (a) (400x). (d) Axons showing hazy X-gal staining (400x).
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identification of the Nfl-mutant extremely difficult. Preliminary data on the X-gal staining patterns
of neurofibromas from the sciatic nerve and DRG (wholemount staining protocol only) show that
most of the cells in the hyperplastic regions exhibit light, punctate staining (Figure 3.6c-d).
133
Discussion
In this chapter, we reported the generation and characterization of a mouse model for NFl. The
phenotype observed is consistent with human neurocristopathy, which includes neurofibromas,
pheochromocytomas and myeloid leukemia. Furthermore, this model represents the first genetic
animal model for type 1 Neurofibromatosis, and the population of chimeric mice has allowed us a
glimpse into the role of Nfl-deficiency in the etiology of the most common NFl-related lesion, the
benign neurofibroma.
Mouse model of neurocristopathy
The characterization of the murine neurofibromas has revealed several similarities -- as well as
differences -- compared to human plexiform neurofibromas (Figures 3.3 and 3.6). While the
involvement of nerve sheath cells (including Schwann cells, perineurium and fibroblast) is
indisputable, the hyperplastic cells consistently exhibit features indicative of perineurial
differentiation (lack of S-100 staining (Figure 3.4), collagen packets, long, parallel processes,
pinocytotic vesicles (Figure 3.5) and basal lamina). However, the presence of continuous basal
lamina covering some of these cell surfaces seems to indicate a Schwannian differentiation. The
presence of features from seemingly diverging cellular lineages on the same cell type may either (1)
result from the uncontrolled growth properties of a tumor, or (2) call into question the precise
origin of these cells. In fact, it has been reported that a type of Schwann-perineurial "transitional"
cells is often found in human neurofibromas, sharing ultrastructural and antigenic features of both
cell types (Hirose et al, 1986). Even in the medical literature, there is evidence showing differing
extents of Schwannian and perineurial contribution toward plexiform neurofibromas (reviewed in
Erlandson, 1991). Regardless, we cannot conclusively determine the cell type identity in this
report without performing additional analyses.
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To address the ambiguity of the cell types involved in these murine neurofibromas, we are
pursuing two independent lines of investigation. First, we are attempting to optimize the
perineurial-specific staining using various antibodies against the EMA epitope. Along the same
line, we plan to stain the tumors with antibodies against markers expressed only in
developing/immature Schwann cells (N-CAM, L1, p75 low affinity NGF receptor or
galactocerebroside; reviewed in Jessen and Mirsky, 1992), in addition to the terminally-
differentiated Schwann cell antigens (MBP or myelin protein PO). The use of immature Schwann
cell markers poses a problem because it has not been documented whether tumor cells will again
turn on the expression of these developmentally-regulated markers. To draw upon additional
experience, we are in the process of consulting with medical experts in the areas of human soft
tissue and neurogenic sarcomas, including Dr. Christopher Fletcher at the Brigham & Women's
Hospital in Boston as well as Dr. David Wolfe at the Mount Sinai Hospital in New York City. It is
our hope that their expertise in the EM and immunohistochemical identification of peripheral nerve
sheath tumors will help us in identifying the cell types involved.
Perineurial cells
Perineurial cells are normally found as concentric rings surrounding each nerve fascicle
(Bennington, 1978). There have been many studies supporting the normal function of the
perineurium as a diffusion barrier to most macromolecules (Olsson and Kristensson, 1973;
Thomas and Olsson, 1984), with tight junctions providing the seal between two cells. Transport
across the perineurium apparently occurs via the abundant pinocytotic vesicles found along the
cellular processes (Peters et al, 1991). It has been previously reported that only fibroblasts have
the ability to differentiate into perineurium in an in vitro differentiation study (Bunge et al, 1989).
However, other studies suggest that perineurium may have originated from other cell types,
including Schwann cells, arachnoid cap cells of the CNS (reviewed in Erlandson, 1991) and neural
crest cells (Bolande, 1974). Rosenbaum et al (1995) reports that Nfl-deficient fibroblasts acquired
a slight growth advantage in vitro and were unable to form normal perineurium in co-culture
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experiments with wild-type neurons and Schwann cells. This line of evidence, combined with our
data, points to a model in which Nfl -/- perineurial cells are sufficient to hyperproliferate into
entities known as benign neurofibromas, resulting in the breakdown of normal barriers shielding
nerve fascicles from exogenous growth factors. The exposure to altered levels of growth signals
may open the door to additional proliferation and novel mutation by other cell types, such as
Schwann cells and neurons, to eventually form malignant neurofibrosarcomas.
Schwann cells
Our data do not suggest a major role of proliferating Schwann cells in murine neurofibroma
formation. However, many researchers believe that there is an intrinsic role of Schwann cells in
the formation of such tumors because studies have estimated that 40-85% of cells in neurofibromas
are of the Schwann cell lineage, and that many of these Schwann cells no longer associate with
nerves (reviewed in Erlandson 1991; Riccardi, 1992). Moreover, researchers have hypothesized
that neurofibrosarcomas are derived from Schwann cells (Riccardi, 1992). In order to further
study the role of neurofibromin in Schwann cells, Kim et al (1995) have developed an in vitro
system where mouse embryonic Schwann cells can be grown and co-cultured with other cell types
of interest. They found that mutant Schwann cells become invasive, promote angiogenesis, and
become hyperproliferative when exposed to increased levels of cAMP (Kim et al, 1997).
However, the same study also noted that exposure to nerve growth factors such as glial growth
factor lead to growth arrest in Nfl -/- Schwann cells, and that growth is restored only after serum
removal (Kim et al, 1995). This indicates that simple Nfl-deficiency is not enough to trigger
Schwann cell growth, and that additional events may be required -- be it epigenetic (cAMP level
increase) or mutational (v-ras cooperates in transformation (Kim et al, 1995)). Since our model
only provides for mutations in the Nfl gene, it was not surprising to find the lack of a Schwann
cell component in the murine neurofibromas.
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Neurons
Several reports have suggested that Nfl-deficiency can alter the behavior of neurons. First,
Brannan et al (1994) found enlarged splanctic ganglia in about half of the 13.5 g.d. Nfl -/- mouse
embryos examined histologically. Furthermore, Nfl -/-sympathetic and sensory-derived neurons
were able to survive and extend neurites without the presence of neurotrophins, whereas wild-type
neurons did not (Vogel et al, 1995). This is consistent with the role of neurofibromin in negatively
regulating the neurotrophin/p2lras signaling pathway (Martin et al, 1990). It is possible that
neurons lacking Nfl secrete factors to cause the growth of nerve sheath cells (paracrine signaling),
resulting in the formation of neurofibromas. However, the inability to identify Nfl -/- cells
effectively in the context of the mouse neurofibroma does not allow us to answer this question.
Mast cells
It was found through chemical staining and EM analysis that mast cells are commonplace in the
murine neurofibromas. Mast cell infiltration has been found in a majority of human neurofibromas
(Lascano EF, 1958; Johnson et al, 1989). These cells are responsible for the secretion of
histamines, heparin and other mucopolysaccharides in areas of wound, inflammation or injury. It
has been hypothesized that mast cells were recruited to the site of traumatic injury in NF1 patients,
and has a role in promoting the growth of neurofibromas (Riccardi, 1992). However, it must be
noted that while mast cells are seldom found in normal human nerves, they are usually abundantly
present in healthy murine nerves (Gamble HJ and Goldby S, 1961). Given that the role of mast
cells is poorly defined in normal as well as neoplastic nerves, their presence in the murine lesions
may represent -- or cause -- inherent etiological discrepancies between human and mouse
neurofibromas.
Myeloid cells and Adrenal medullary cells
The role of Nfl gene mutations in human and murine lesions involving these two cell types have
been discussed in Chapter 2.
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Modifier Genes
Given the limited number of ROSA-26 chimeras analyzed, we nonetheless believe that there may
be phenotypic variations caused by genetic differences in the ES cell strain. For example,
pheochromocytomas were observed only in chimeric animals made from ES cells which were
derived from heterogeneous parental strains (ROSA-26 ES lines), while none of the 129sv inbred
ES cell lines gave rise to such tumors. Conversely, myeloid leukemia only developed in inbred ES
chimeras. This data corroborates our previous report on the phenotypic differences between inbred
and mixed strains of Nfl heterozygous mice (see Chapter 2). One study in human NF1 patients
have found that identical twins afflicted with the condition tend to develop more similar patterns of
NF1 lesions than either fraternal twins or the general NF1 population (Easton et al, 1993). Such
epidemiological findings in human and mice suggest the existence of modifier genes that determine
the extent, severity or expressivity of various NF1 phenotypes.
Genetic pathway for neurofibroma formation
What we have presented in this chapter represents the first genetic model of neurocristopathy
(tumors of neural crest-derived tissues) focusing solely on the role of the Nfl tumor suppressor
gene. Previous animal models of similar neurocristopathies have been established in several ways,
including mutagenesis, naturally-occurring, or by the introduction of viral proteins (reviewed in
Riccardi et al, 1994). A summary of the mouse models, strain used, and phenotypes are listed in
Table 3.4.
Even though a few of these models were able to demonstrate the development of neurofibromas as
well as other lesions arising from neural crest-derived tissues, the usefulness of these models are
often limited by (1) the inability to identify specific gene mutations or (2) the introduction of viral
gene products, which are known to be multi-functional: Viral proteins such as SV40 Large T
antigen and HTLV-1 tax are able to transactivate a variety of cellular genes, including those
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encoding growth factors (Green, 1991), oncogenes (Duyao et al, 1992; Ejima et al, 1993), and can
also sequester/downregulate tumor suppressor gene products, such as the retinoblastoma (RB)
susceptibility gene, p53 (reviewed in Van Dyke, TA 1994) and NF1 (Feigenbaum et al, 1996).
However, none of these models were able to address the early sequence of events necessary for the
development of neurofibromas.
Table 3.4 Summary of existing transgenic models of Nf 1
Group Description of vector and strain Phenotype
Mazaraki, NGF-driven SV40 T into C57BL 10 x neurofibromas
1996 CBA F1 (Schwannian component)
Messing, PO-driven SV40 T into C57BL/6J x Schwannomas, hypomyelination
1994 SJL F1
Jensen, MBP-driven SV40 T into C57BL/6J x Schwannomas, osteosarcomas
1993 DBA F1
Corallini, systemic HIV-1 tat into BDF1 (C57BL/6 leiomyosarcoma, carcinoma,
1993 x DBA/2 ) lymphoma
Green, HTLV-1 tax into CD-i (C57BL/6 x neurofibromas, iris & adrenal
1992 DBA/2) lesions
Nerenberg HTLV-1 tax into CD-1 F1 males spindle cell tumors
, 1987 (mesenchymal)
Hinrichs, HTLV-1 tax (tat) CD-1 neurofibromas (perineurial)
1987
We postulated that Nfl-deficiency is necessary -- and in the mouse, sufficient -- for the formation
of a benign neurofibromas for two reasons: First, given the early onset of these lesions (between 3
to 7 months of age), it was unlikely that other spontaneous mutations played a significant role in
the promotion of the neurofibromas. Second, other lines of tumor suppressor knock-out mice
created in our lab never developed similar neurocristopathies, while the phenotype was consistent
across the two independently-derived lines of Nfl DKO ES cells. This implied that the nerve
sheath lesions did not result from unexpected mutations present in the ES cell clones, and was
specific to the mutations in the Nfl alleles. Lastly, because (1) the number of lesions found per
animal and (2) the timecourse for the onset of tumor-induced neurological phenotype both seemed
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dependent on the extent of ES cell contribution, we further hypothesized that the neurofibromas
were congenital and grew slowly over time. This would indicate that a simple Nfl-deficiency
(without other genetic events that the animal might have incurred early in life) was the first step
toward the formation of neurofibromas, providing an environment that was conducive for
hyperproliferative nerve sheath cells.
Making a clear connection between NF1 mutations and neurofibroma formation has been
controversial because many studies have failed to find mutations in both NF1 alleles in benign
human neurofibromas. While it is possible that heterozygosity for the NF1 gene confers some sort
of growth advantage to nerve sheath cells (due, for example, to haploinsufficiency), a second
hypothesis must be considered: It is possible that the current diagnostic protocols for gene
mutations were not be able to pick up LOH in a mixed cell population (where only a some of the
cells were deficient for a particular tumor suppressor gene). In fact, only a few reports have been
able to document NF1 LOH in benign neurofibromas (Skuse et al, 1991; Colman et al, 1995;
Sawada et al, 1996; Serra et al, 1997). However, such studies were not able to demonstrate a
clean, causal relationship between the NFI deficiency and tumor formation, nor were they able to
identify the critical cell types that have incurred the LOH.
Future experiments
Given the similarities and discrepancies between the human and mouse neurofibromas discussed
above, two sets of experiments may help to address some of the underlying mechanisms and
differences between the two models.
Nfl +/- blastocysts
Given that every human NF I patient is constitutionally heterozygous for the NF1 mutation
(Huson, 1994), it is reasonable to imagine that once a critical cell type loses heterozygosity for the
NF1 function, it is able then to stimulate the surrounding Nfl +/- cell type(s) to proliferate and/or
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to secrete factors that eventually cause the formation of neurofibromas. The assumption here is
that, given the same level of growth signals, Nfl +/- cells have a lower threshold for
hyperproliferation. In fact, there are in vitro studies suggesting that Nfl heterozygosity in
Schwann cells (Kim et al, 1995) and fibroblasts (Rosenbaum et al, 1995) causes an intermediate
phenotype/growth property as compared to the Nfl -/- cells. Therein lies a major genetic
difference between our murine model and the human disease: in the current DKO chimera scheme,
cells that become Nfl-deficient are surrounded by wild-type cells (instead of Nfl+/- cells, as in the
human case). Using Nfl +/- blastocysts for chimera generation will allow us to more closely
recapitulate the human condition. Such studies are in the preliminary stages.
Generation of tissue-specific knockouts
Another way to identify the critical cell type for the formation of neurofibromas in vivo is to
generate animals in which the Nfl function is ablated in a tissue-specific manner. Several reports
have shown that such conditional knock-out mouse strains can be made using the cre-lox
technique, including the first manuscript by Gu et al (1994) describing experiments in which a
fragment of the DNA polymerase 3 gene was selectively deleted in mouse T cells. In order to
inactivate genes, animals are generated where selected regions of DNA are flanked by a 34 bp
bacteriophage P1 site called loxP (locus of crossing-over). By driving the expression of Cre
(causes recombination), an enzyme that causes two loxP sequences to recombine, with promoters
active only in defined cell types, the gene in question will be inactivated in those cell types.
Depending on the promoter used, this approach allows for temporal as well as tissue-specific gene
inactivation. By creating a strain of mice containing the loxP sequences surrounding crucial Nfl
coding regions, we will be able to mutate the gene only in Schwann cells, neurons, or other cell
types by breeding the animals to pre-established cre-expressing mouse lines (databases for existing
mouse cre lines are available). The development of neurocristopathy using a particular cre line will
help us to identify the cell type responsible for causing the lesions.
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Chapter 4
The effect of the murine Nfl mutation
on a p53 mutant background
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Introduction
Neurofibromatosis Type I (NFl) is one of the most common hereditary disorders in humans,
affecting one in 3,500 individuals (Stumpf et al., 1987). The gene associated with the NF1
disease was identified in 1990 (Cawthon et al., 1990; Viskochil et al., 1990; Wallace et al., 1990).
The normal gene product encoded by this locus, called neurofibromin, contains a region showing
close homology to the GTPase Activating Protein (GAP) for the p21 ras oncogene (Xu et al.,
1990) as well as the yeast IRAl and IRA genes (Xu et al., 1990, Ballester et al., 1990).
Neurofibromin was subsequently shown to downregulate the ras oncogene signaling function in
both in vitro and in vivo systems (Martin et al., 1990; Xu et al., 1990; DeClue et al., 1992).
Other studies on neurofibromin have suggested additional roles as a tubulin-binding protein
(Gregory et al., 1993) and a modulator of the cAMP pathway (Guo et al., 1997).
Human patients who inherit a defective allele of NF1 develop characteristic lesions such as cafe-au-
lait spots, Lisch nodules and neurofibromas. At a certain frequency (10%), neurofibromas can
progress to become malignant neurofibrosarcomas (Riccardi, 1992). This transformation leads to
poor prognosis for many NF1 patients. In addition, mutations in NF1 have been linked to a
variety of human tumors, including malignant peripheral nerve sheath tumors (MPNST),
neuroblastomas, sarcomas, myeloid leukemia and pheochromocytomas (Xu et al., 1992;
Seizinger, 1993; The et al., 1993; Shannon et al., 1994). We and other have created mouse strains
harboring the Nfl mutation in order to assess the in vivo function of the protein (Brannan et al.,
1994; Jacks et al., 1994). The Nfl mutation predispose mice to cancer, in particular
pheochromocytomas and myeloid leukemia (Jacks et al., 1994).
The multistep nature of human carcinogenesis has been demonstrated in many tumors. Perhaps the
best demonstration of this is the ordered nature of mutations which occur during colorectal
carcinogenesis (Fearon, 1992). One of the genetic alterations during this progression is the
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inactivation of the p53 tumor suppressor gene. In fact, p53 mutations have been shown to occur
in approximately 50% of all human tumors (Harris & Hollstein, 1993; Malkin, 1993; Greenblatt et
al., 1994). The creation by several groups of p53 deficient murine strains has enabled the
examination of how the gene functions in tumor suppression (see below for examples; Armstrong
et al., 1995; Donehower et al., 1992; Greenblatt et al., 1994; Harvey et al., 1993; Jacks et al.,
1994; Purdie et al., 1994; Tsukada et al., 1994). To date, the p53 gene product has been
implicated primarily to function in the apoptosis pathway (Clarke et al., 1993; Lowe et al., 1993;
Merritt et al., 1994; Ziegler et al., 1994), as a checkpoint for genomic stability (Kastan et al., 1991;
Kastan et al., 1992), and in the Gi cell cycle arrest pathway (Kastan et al., 1992).
Many groups have reported cases citing cooperativity between a tumor suppressor genes and
another tumor suppressor gene or an oncogene. The p53 gene has been most widely studied with
respect to its ability to cooperate with other genes in tumor progression. In NF1 patients, studies
found the concomitant loss of p53 function or mutations in p53 in most cases where benign
neurofibromas progressed into malignant neurofibrosarcomas (Menon et al., 1990; Greenblatt et
al., 1994). This suggests a role for P53 in tumor transformation. In mice, several important
studies have supported the role of the mouse p53 homologue in collaboration with other tumor
suppressor genes or oncogenes in tumor progression (Kindblom et al., 1995; Luongo & Dove,
1996). In one of the first studies on tumor suppressor cooperativity, Williams et al. (1994)
demonstrated that p53 and the retinoblatsoma susceptibility gene (Rb) cooperated to decrease tumor
latency and caused the development of new pathology in mice. Another group found an increase in
genomic instability and changes in mammary tumor histopathology when the Wnt-1 transgene was
crossed onto a p53 mutant background (Donehower et al., 1995). Kemp et al. (1993) found
dramatic changes in tumor progression and malignancy, but not initiation, when the p53 mutation
was combined with an activated H-ras gene. Moreover, the combination of severe combined
immune deficient (scid) and p53 mutations accelerated the development of thymic lymphomas in
mice (Bogue et al., 1996; Nacht et al., 1996).
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Because of synergistic effect of p53 with other genes, we decided to test the cooperativity between
the Nfl and p53 genes. It is hoped that the combination of these two mutations would exaggerate
tumor promotion and/or progression, and reveal novel tumor types previously masked by genetic
rate-limiting steps. There is additional difficulty in generating mice with the desired combination of
mutations, because the Nfl and p53 genes are very closely linked on the distal arm of mouse
chromosome 11. This was done by generating recombinants through breeding (see below).
Mice inheriting different combinations of Nfl and p53 mutations show reduced viability as well as
increased susceptibility to tumor formation. A novel mouse phenotype reminiscent of an human
NFl-associated lesion was found in two groups of these animals.
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Methods
Genotyping of animals.
Animals were genotyped from tail DNA using PCR protocols involving three primer as previously
described for the Nfl n31 (Jacks et al., 1994)and p53A (Jacks et al., 1994) mutations.
Southern analysis of tumor DNAs.
Tumor tissues were excised and DNA prepared by standard methods. LOH analysis of Nfl status,
tumor DNA was digested with NcoI and HindIII and hybridized with a probe derived from a Ncol-
PstI genomic fragment from intron 31 of the murine Nfl gene (probe B, Jacks et al., 1994). p53
status was evaluated by digesting tumor DNA with EcoR1 and Stul and hybridizing with a 3'
cDNA probe (probe B, Jacks et al., 1994).
Histopathology.
Analysis was performed as described (Jacks et al., 1992; Jacks et al., 1994). Tissues were
surgically removed and fixed in either 10% formalin or 4% freshly-prepared paraformaldehyde,
dehydrated, embedded in paraffin, sectioned at 6 mm and stained with hematoxylin and eosin prior
to microscopic analysis.
Immunohistochemistry and immunofluorescence.
Analysis was performed on unstained histological sections prepared as described above. For o-
sarcomeric actin antibody (Sigma) analysis, sections were permeabilized with IF buffer (0.1%
triton X-100 in PBS containing 5% horse serum and 1% goat serum), incubated with dilute
antisera (1:500), immunostained using Vectastain ABC kit and visualized by diaminobenzidine
(DAB) reaction. For myelin basic protein (MBP) analysis (Dako), sections were treated with
blocking buffer (BB: 10% goat serum, 0.05% Tween-20 and 0.02% sodium azide in PBS),
hybridized with dilute antisera (1:200), and visualized with Vectastain ABC and DAB kits. For S-
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100 (Dako) immunofluorescence detection (1:200 dilution of primary antibody), sections were
incubated in BB buffer, and a FITC-conjugated goat anti-rabbit antibody (Jackson
ImmunoResearch, used at 1:75 dilution) was used as the secondary antibody. Signal was detected
using an immunofluorescence scope.
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Results
Separately, the Nfl and p53 mutations predispose mice to cancer. Nfl heterozygous animals are
prone to the development of pheochromocytomas and myeloid leukemia between twelve to
eighteen months of age (Figure 4.1) (Jacks et al., 1994). p5 3 heterozygous animals exhibit similar
kinetics of cancer development (Figure 4.1), but succumb to lesions distinct from the Nfl
heterozygotes, including sarcomas and lymphomas (Table 4.1) (Jacks et al., 1994, Harvey et al.,
1993). Consistent with the tumor suppressor hypothesis, cancerous tissues arising in both mutant
strains exhibit loss-of-heterozygosity (LOH) at the Nfl (Jacks et al., 1994) or p53 (Jacks et al.,
1994, Harvey et al., 1993) locus. Moreover, p53 null animals show a significantly accelerated rate
of tumor formation, with over 90% mortality by 3-6 months of age (Figure 4.1). It is not possible
to generate Nfl-null adult animals, since Nfl-deficiency results in mid-gestation embryonic
lethality due to abnormal cardiac development (Brannan et al., 1994; Jacks et al., 1994).
Generation of animals through Mitotic Recombination
In order to study cooperative effects between Nfl and p53 on tumor development, three novel
strains of mice were created. First, mice heterozygous for the two mutations on separate
chromosomes (in 'trans') were created. Second, mice constitutionally heterozygous for the two
mutations carried on the same chromosome (in 'cis') were generated as described below. Finally,
animals heterozygous for the Nfl mutation on a p53 null background ('het-mutant', or 'H-M')
were generated from appropriate crosses.
'Trans' animals were generated and identified by PCR genotyping. These animals represent
approximately 50% of the progeny derived from matings between Nfl +/- and p53 -/- parents.
However, since the two gene loci are tightly linked on mouse chromosome 11 (5 centimorgans
(cM) apart), a chromosome containing both mutant genes was needed to generate the 'cis' and 'H-
M' strains of mice. Instead of re-targeting single-mutant ES cells, we decided to take advantage of
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Figure 4.1. Survival of mice with mutations in p53 and Nfl.
Graph summarizing the lifespan of 51 'trans' animals; 34 'cis' animals; 49 'H-M' animals; 19
wild-type animals; 37 Nfl +/- animals; and 41 p53 +/- animals. The p53 -/- survival curve was not
shown, but closely follows that of the 'cis' curve. The mean age of survival (the point at which
50% of the animals had died) was 14 months for the 'trans' animals; 5 months for the 'cis'
animals; and about 4 months for the 'H-M' animals. At 20 months, over 50% of the Nfl and p53
heterozygous animals remained alive and about 90% of the wild-type animals were still alive at 25
months of age.
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the spontaneous meiotic cross-over events that occur between homologous chromosomes in germ
cell precursors. If such a reciprocal recombination event took place between the Nfl and p53 loci
of a 'trans' parent (as depicted in Figure 4.2), the animal would theoretically produce equivalent
numbers of zygotes containing either (1) wild-type copies or (2) mutant copies of both genes. The
frequency of this desired cross-over event depends on the chromosomal distance between the two
genes. To this end, 'trans' animals were mated to wild-type or p53 null mice. Genotypic analysis
of animals from these matings identified thirty-two (32) cross-over events in the 283 animals
generated. This gives an empirical cross-over distance of 4.2 cM, a value consistent with the
previously reported 5 (Buchberg et al., 1992). Of the 32 mice inheriting recombinant
chromosomes, only 4 were of the 'cis' configuration. The other 28 recombinant mice were wild-
type for both tumor suppressor gene mutations. These 4 mice were then used to generate the other
'cis' mice and were mated to p53 mutant mice to generate the 'H-M' mice.
In order to assess the effect of these mutational configurations on the adult mouse, we followed
cohorts of different groups over time and analyzed the resulting tumor spectrum. Animals were
carefully monitored and sacrificed at first signs of illness or significant tumor burden.
Analysis of Nfl +/-;p53+/- 'trans' mice
The mean age of survival (defined as the age at which 50% of the animals had died) of the 'trans'
animals was slightly reduced compared to Nfl or p53 heterozygous alone (Figure 4.1). The
'trans' animals exhibited similar tumor spectra to those found in either single heterozygotes (Table
4.1), including lymphomas, various sarcomas, myeloid leukemia and hemangiomas.
For each genotype indicated, the number of animals analyzed is found at the bottom of the column.
Most of these tumors could be found by gross necropsy as abnormal enlargements or growths.
Rhabdomyosarcomas, fibrosarcomas and anaplastic sarcomas are combined into one category due
to the variable morphology among the tumors. Note the predominance of sarcoma development in
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Figure 4.2. Meiotic cross-over was required between two closely-linked tumor suppressor loci.
Generation of Nfl-p53 a 'cis' chromosome containing both mutant alleles heterozygotes was
achieved by a cross-over event between homologous chromosomes in germ cell precursor cells.
The reported chromosomal distance between Nfl and p53 was 5 cM. This study found the
chromosomal distance to be 4.3 cM.
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'cis' animals. 'H-M' animals developed a combination of p53-related (thymic lymphoma) 'cis'-
related (sarcoma) lesions. An uterine tumor was found in a 'cis' mouse. Due to the gender-
specificity of this tumor, the actual incidence could be underestimated.
Table 4.1: Incidence of tumor types in mice with various combination of Nfl and p53 mutations
Tumor/lesion Nfl +/- p53 +/- p53 -/- 2x trans 2x cis Nfl +/-/p53 -/-
lymphomas 25% 25% 71% 36% 5% 42%
rhabdomyosarcoma/fi 5% 57%) 21% 36% 81% 54%
brosarcoma
osteosarcomas 0% 0% 18% 0% 4%
myeloid leukemia 16% 0% 0% 9% 0% 4%
hemangioma 0% 0% 0% 9% 14% 17%
epithelial 0% 0% 0% 0% 0% 4%
neuroblastoma
lung adenocarcinoma 16% 0% 0% 0% 0% 0%
pheochromocytoma 21% 0% 0% 0% 0% 0%
hepatocarcinoma 9% 0% 0% 0% 0% 0%
brain tumor 0% 0% 0% 0% 5% 0%
uterine tumor 0% 0% 0% 0% 5% 0%
(n=) 57 44 56 11 21 24
Southern blot analysis of the tumor DNA
p53 becoming wild-type at both alleles),
(Figure 4.3). This result suggests one of
(n=6) revealed LOH of either the Nfl mutant locus (with
or the p53 mutant locus (with two functional Nfl alleles)
two possible mechanisms for LOH: (1) the tight linkage
of the two loci does not allow cross-over between Nfl and p53 or (2) the loss of the entire
chromosome 11 and its subsequent duplication from the remaining template, which has a mutant
allele as well as a wild-type allele for the two tumor suppressor genes, respectively. In fact, in the
two 'trans' fibrosarcomas and two osteosarcomas analyzed, one of each showed LOH to Nfl
while the other was found to have LOH to p53. Despite the different genetic events, the tumors
did not appear histologically different upon examination. The one case of myeloid leukemia, a
condition primarily associated with Nfl deficiency, showed LOH at the Nfl locus.
Analysis of Nfl+/-;p53+/- 'cis' mice
As shown in Figure 4.1, mice inheriting both mutations on the same chromosome showed a
dramatic increase in tumor predisposition. The mean survival age for this group of animals is 5
158
months (similar to the p53 -/- animals, with closely matching survival curves; p53-/- survival curve
not shown). This is substantially lower than the 14 months for the 'trans' population.
Furthermore, none of the 'cis' animals lived past 10 months of age. The 'cis' mice typically
develop a single, large subcutaneous tumor, ranging in size from 1 centimeter (cm) to 4 cm in
diameter. Overall, 80% of tumors seen in 'cis' animals are of this type (Table 4.1).
Histological analysis of these tumors revealed that they were sarcomas exhibiting varying degrees
of differentiation. As shown in Figure 4.4, the tumors range from undifferentiated fibrosarcomas
to clear rhabdomyosarcomas with the associated muscular striations. In addition, a new class of
pleomorphic 'anaplastic' sarcomas was found, composed of an extremely heterogeneous cell
population (Figure 4.4). Many of these tumors contain at least two distinct regions of cellular
morphology, one comprised of compact, spindle-shaped cells and the other of pleomorphic,
irregularly-shaped cells and nuclei, usually with abundant cytoplasm. The tumors are reminiscent
of malignant soft tissue sarcomas found in humans in terms of the high mitotic index, infiltration
into adjacent tissues (as seen by the trapped normal muscle fibers in Figure 4.4A), necrotic core,
high ploidy nuclei, and rapid rates of growth. Consistent with the tight linkage of Nfl and p53,
100% of all sarcomas analyzed by Southern blot showed simultaneous LOH at both loci (Figure
4.3). Since none of the 'trans' animals were able to lose both loci, the absence of such anaplastic
sarcomas seems to suggest a crucial role for the combined Nfl- and p53-deficiency in the
development of these novel mouse tumors.
Analysis of Nfl+/-;p53-/- 'het-mutant' animals
The 'H-M' mice exhibited significant decrease in tumor latency, with a mean survival age of just
over 4 months. This represents a shift of survival curve to the left of both the 'cis' (see Figure
4.1) and p53 -/- curves (previously published data; Jacks et al., 1994). The tumors observed in
this population included those associated with p53 deficiency (42% thymic lymphomas) as well as
tumors seen in the 'cis' mice (54% sarcomas). These sarcomas exhibited similar ranges of cellular
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Figure 4.3. LOH in Nfl-p53 mouse sarcomas.
Status of Nfl and p53 in genomic (G) and tumor (T) tissues of various mutation combinations. Ti
'trans" fibrosarcoma; T2 'trans' osteosarcoma; T3 'trans' myeloid leukemia; T4 'cis' anaplastic
sarcoma; T5 'cis' brain tumor; T6 'H-M' fibrosarcoma; T7 'H-M' thymic lymphoma. 'trans'
tumors T1 and T2 show LOH to p53 (with Nfl locus reverting back to wild-type), but the myeloid
leukemia showed loss to Nfl. T4 and T5 show simultaneous loss of both mutant alleles. Note the
LOH to Nfl in the 'H-M' fibrosarcoma (T6) but not in the 'H-M' thymic lymphoma (T7). Most
tumors were well-vascularized, hence the extracted tumor tissues were contaminated with genomic
DNA (blood and skin).
160
Figure 4.3
NP 'trans' NP 'cis' NP 'H-M'
G T1 T2 T3 G T4 T5 G T6 T7
Nfl MUT --
Nfl WT -
p53 MUT --
p53 WT --
pseudo-gene
differentiation and pleomorphism as their 'cis' counterparts (Figure 4.4).
In contrast to the 100% LOH at the Nfl and p53 loci for the 'cis' tumors, only about 50% (4/8) of
the H-M fibrosarcomas and rhabdomyosarcomas showed loss of Nfl (Figure 4.3, some tumor
samples not shown). In contrast, 4 out of 5 (80%) anaplastic sarcomas exhibited loss of the wild-
type Nfl allele. This suggests that p53-deficiency is required for the development of sarcomas,
but that loss of Nfl function generates a selective growth advantage during tumor progression.
The wild-type alleles of Nfl were never lost in any of the thymic lymphomas analyzed (Figure
4.3), suggesting that Nfl deficiency confers no selective advantage in the progression of this
tumor type.
Immunohistochemical analysis of anaplastic sarcomas
In order to better understand the anaplastic sarcomas seen in the 'cis' and 'H-M' mice, we
performed extensive immunohistochemical analysis to determine the cell types present in the
tumors. An cx-sarcomeric actin antibody was chosen to confirm the presence of muscle cells in
rhabdomyosarcomas. Their presence was further verified by Mallory's Phosphotungstic Acid
Hematoxylin (PTAH) chemical staining method (not shown). In addition, to determine the
similarities between these sarcomas and the class of NFl-related tumors called malignant peripheral
nerve sheath tumors (MPNSTs), Schwann cell markers (S-100 and myelin basic protein) were
used. The results of these analyses are shown in Figure 4.5, where adjacent sections of
representative tumors were stained with the panel of antibodies described above. Care was taken
to distinguish positive staining from background staining due to endogenous peroxidase activity,
particularly in red blood cells and necrotic regions within the lesions (regions of necrosis are often
found in the core of these large tumor masses). Results of the immunohistochemical profile are
summarized in Table 4.2.
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Figure 4.4. Tumor pathology of 'cis' and 'H-M' tumors (H&E).
(A) 'cis' rhabdomyosarcoma (400x magnification). Note the characteristic muscle striations in the
tumor (arrowheads). (B) 'cis' fibrosarcoma (400x). Tumor exhibit compact, spindle-shaped cells
with "streaming" morphology, indicative of fibroblastic fascicles. (C) 'H-M' anaplatsic sarcoma
(400x). Pleomorphic appearance including cells with abundant cytoplasm, irregularly-shaped
nuclei and variable ploidy counts. (D) 'H-M' rhabdomyosarcoma (400x). Note the two distinct
cell populations in the tumor as distinguished by the intercellular spacing and the variable size of
the nucleus (poly-ploidy) in the bottom half of (D). All these tumors are solitary and
subcutaneous. Rapid growth and necrosis in the tumor core are common traits among the
sarcomas.
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Figure 4.4
Approximately a third of the sarcomas stained positive only for skeletal muscle markers. In
comparison, 21% of the sarcomas were found to be positive for Schwann cell markers, while only
12% of the lesions stained positive for both markers. These staining patterns are consistent with
the varied range of differentiation as seen by H&E staining. In the double positive lesions, a
careful comparison between the size and morphology of each cell type showed that these tumors
comprised of a mixture of Schwann and muscle cells, rather than cells expressing both markers
simultaneously (Figure 4.5). In summary, the 'cis' and 'H-m' sarcomas show a variegated pattern
of staining with respect to the various nerve sheath markers, and do not always correspond to the
expected morphological features. These lesions are reminiscent of the MPNSTs, with a subset of
the tumors resembling "Triton Tumors" with its expression of both Schwann and muscle surface
markers. Triton tumors are found to be highly associated with patients constitutionally
heterozygous for the NFI mutation.
Table 4.2. Immunohistochemical results for 'cis' and 'H-M' sarcomas.
n= Schwann (+) Muscle(+) Double (+)
'cis' 21 4 5 3
'H-M' 13 3 6 1
Total 34 7 11 4%* 1 21% 32% 12%
*Some tumors were negative for both markers
Table 4.2. Approximately one-third of the tumors stained positive for c-sarcomeric actin.
Twenty-one percent of the tumors stained positive for either S-100 or MBP, or both. In addition,
12% of the tumors were positive for both types of markers. The different combination of Nfl and
p53 mutant allele did not seem to bias the development and differentiation of cell types in these
tumors. *Some of the tumors did not stain with either marker (9 'cis' and 3 'H-M' tumors).
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Figure 4.5. Immunohistochemical analysis of representative sarcomas in 'cis' and 'H-M'
animals.
Anaplastic sarcoma sections from each genotype are tested for markers against a-sarcomeric actin,
S-100 and MBP (not shown). (A) 'cis' rhabdomyosarcoma. Note positive a-sarcomeric actin
staining in normal muscle staining as well as neoplastic regions. Only background S-100 staining
is seen (magnification 40x); (B) 'cis' anaplastic sarcoma. Tumor has infiltrated into surrounding
muscle, displacing individual muscle fibers. Cells extending processes stain positive for S-100
(magnification 400x); (C) 'H-M' anaplastic sarcoma. H&E staining show combination of spindle-
shaped and pleomorphic cells. Note that the tumor comprise of a mixture of S-100 and ca-
sarcomeric actin-positive cells (magnification 100x); (D) 'H-M' rhabdomyosarcoma. a-sarcomeric
actin stains striations in rhabdoid cells (magnification 400x).
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Discussion
The data presented in this paper illustrates that the Nfl and p53 tumor suppressor genes act
synergistically to exacerbate the tumor phenotype and decrease survival. We generated two distinct
in vivo murine models that were useful in assaying for the effects of simultaneously losing both
gene functions. One novel phenotype produced in the models was a set of lesions reminiscent of
human malignant peripheral nerve sheath tumors (MPNST), a condition known to be strongly
associated with the inherited NF1 disease. This is consistent with data in humans suggesting that
p53 loss contributes toward the progression of neurofibromas to neurofibrosarcomas (Menon et
al., 1990). Furthermore, this study represents the first demonstration of the simultaneous loss of
two linked tumor suppressor genes and its effect on tumorigenesis.
Concomitant loss of two linked tumor suppressor genes
The concomitant loss of both the Nfl and p53 genes observed in tumor DNA samples was not
surprising given the tight linkage of the two loci on mouse chromosome 11 (Figure 4.2). Several
molecular mechanisms may explain the LOH event, including inactivating mutation, mitotic
recombination, gene conversion, large deletion, or chromosomal loss followed by duplication.
However, due to the proximity of the two loci, several of these mechanisms could result in the
observed LOH. We favor the chromosomal loss mechanism for several reasons: First, 100% of
the LOH observed in the sarcomas demonstrated the loss of the wild-type allele, ruling out the
possibility of point mutations or small deletions. Furthermore, by analyzing simple sequence
length polymorphism (SSLP) markers that are well-defined for many mouse strains, it has been
observed by several groups that LOH associated with neoplasia is usually accompanied by loss of
polymorphic markers on the entire chromosome (Luongo & Dove, 1996; McClatchey, submitted).
However, since the mouse population used in this study is derived from several generations of
backcrossing mixed 129SV and C57BL/6 parents, the resulting randomization of strain-specific
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SSLP markers did not allow us to utilize such markers to clarify the mechanism of loss in the
sarcomas.
It was documented that the 'trans' and 'cis' mice develop tumors with clear LOH at the tumor
suppressor loci (Figure 4.3). However, the fact that 'cis' tumors appear at a much earlier age
(mean survival age of 5 months compared to 14 months for the 'trans' population) suggest that the
configuration of these two linked tumor suppressor genes may confer great advantage toward
tumor transformation. There are two mechanistic explanations for the early onset of tumors: (1) in
'trans' animals, LOH at the tumor suppressor loci occur at the same rate as the 'cis' animals, but
additional genetic events are required for tumor progression; (2) the 'cis' configuration increased
the likelihood of LOH, possibly through greater genomic instability.
Cooperativity between tumor suppressor genes
Previous studies on genetic cooperativity in mouse models of tumorigenesis provide insights into
the development of malignant sarcomas in the Nfl-p53 mice. For example, by combining these
genetic mutations, the sarcomas appear earlier with increased pleomorphic morphology. This is
reminiscent of the faster progression to malignancy of skin tumors resulting from breeding the H-
ras mutation into a mutant p53 background (Kemp et al., 1993). The development of a novel
lesion in the 'cis' and 'H-M' mice which is similar to the human Triton tumor suggests that Nfl
and p53 might play a role in the differentiation pathways of such precursor cell types (see below
for further discussion on the etiology of Triton tumors). Williams et al. (1994) found the
appearance of several novel tumors in Rb mutant mice after crossing the mutation onto the p53-
deficient background. These include the rare pinealoblastomas and islet cell tumors. In addition,
studies combining the Wnt-1 transgene with the p53-mutation found an earlier onset of the same
tumor type, mammary adenocarcinomas. However, the tumors appear less differentiated with
more cells showing aneuploidy (Donehower et al., 1995). This was attributed to p53's role in
promoting genomic instability and cellular proliferation. Furthermore, it was found that the tumor
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promotion seems to be unrelated to decreased level of apoptosis as a result of p53 deficiency
(Jones et al., 1997). Sometimes, combining specific gene mutations may serve to promote the
development of one tumor type but not the others. For example, the p53 and Apc double mutant
mice showed higher pancreatic tumor risk but did not exhibit increased intestinal abnormalities
(Clarke et al., 1995). Given the predicted involvement of both genes in colorectal cancer
progression, this result suggest that p53 and Apc mutations alone may not be sufficient to induce
intestinal cancer.
The ras gene is often seen as the counterpart of p53 in the area of oncogenes because of the
frequency of mutations (30%) found in human cancers. In fact, ras has been implicated in many
types of cancer (review Bos, 1989), and most notably has been included as a pre-malignancy
mutational event in the multi-step model of colorectal cancer development (Fearon & Vogelstein,
1990). The ras signaling pathway is also one of the most well-defined in all of biology, with
upstream molecules such as tyrosine kinases, GRB2 and mSOS and downstream effectors
including -- but not limited to -- Raf, MEK, and the rest of the MAP Kinase pathway (review Egan
& Weinberg, 1993). Neurofibromin is one of two well-defined negative regulators of mammalian
ras, the other being the GAP (review Bollag and McCormick, 1992). It is therefore reasonable to
hypothesize that activated ras contributed toward the tumor progression seen in the Nfl-p53
animals. For example, increased levels of ras signaling could provide the necessary mitogenic
signals to drive tumor cells through the cell cycle (provided that the necessary nutrients are
available). Furthermore, the effect of activated ras differs widely in different cell types, inducing
proliferation in NIH 3T3 and fibroblasts, while promoting differentiation and growth inhibition in
cells such as the cultured pheochromocytoma line PC12 (Greene and Tischler, 1976). Nfl
deficiency in nerve sheath precursor cells might confer growth advantages or survival factors
similar to that of an activating ras mutation. Interestingly, mice inheriting mutations in Nfl, p53
and GAP are predisposed to the development of hemangiosarcomas (T.S. Shih, unpublished
results). This could be due to the action of these genes in cells comprising of the vasculature, as
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suggested by the development of a vascular phenotype observed in embryos deficient in Nfl and
GAP (Henkemeyer et al., 1995).
Effect of the Nfl and p53 mutations in 'trans'
A statistical comparison revealed that the 'trans' animals had a lower survival curve when
compared to a theoretical kill curve (not shown). This hypothesized kill curve was constructed by
taking into account the statistical likelihood of 'trans' animals to die from either the Nfl or p53
mutation alone, i.e. without synergistic effects toward tumor progression. Such evidence suggest
a slight cooperative effect of combining germline mutations in Nfl and p53, even in the 'trans'
configuration. It is possible that heterozygosity for fl increases the level of activated ras in
certain crucial cell types, or that p53 heterozygosity predisposes the same cells to chromosomal
aberrations, resulting in decreased tumor latency.
Developmental effect of Nfl and p53 mutations in 'cis'
Furthermore, in our attempt to generate the 'cis' chromosome by breeding, only 12% of the
progeny carrying recombinant chromosomes were of the 'cis' configuration. This suggests that
either the gametes or the developing animals carrying the 'cis' chromosome are somehow selected
against. The mechanism underlying this reduction in developmental fitness is not clear at the
present time. However, it is interesting to note that the male/female ratio for the four founder 'cis'
mice as well as their subsequent progeny was close to 1:1. This result argues against a selection
pressure based on gender.
MPNST and NF1
The histopathology of sarcomas seen in the Nfl-p53 'cis' and 'H-M' mice closely resemble those
of human tumors classified as malignant peripheral nerve sheath tumors (MPNSTs). MPNSTs
account for approximately 5-10% of all soft tissue sarcomas in human (Hashimoto, 1995; Fletcher,
1995), and are defined as aggressive neoplasm typically, but not exclusively, occurring in major
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trunks of the peripheral nerve or benign neurofibromas of NF1 patients. Traditionally,
Schwannomas, neurofibrosarcomas, perineuriomas, as well as other less-differentiated lesions are
included in this category. MPNSTs often contain a heterogeneous cell populations, with the two
most common being (1) compact, spindle-shaped cells arranged in interlacing fascicles, usually
expressing Schwann cell markers such as S-100 and MBP and (2) pleomorphic cells with varying
amounts of eosinophilic cytoplasm. In recent years, the advent of immunohistochemical
techniques and electron microscopy have become crucial in the diagnosis of MPNSTs.
Ultrastructural studies indicate that the predominant cell types in MPNSTs are Schwann cells,
fibroblasts and perineurial cells (reviews Fletcher, 1995; Hirose 1992). Johnson and colleagues
(1988) found that approximately 60% of MPNSTs expressed the S-100 protein (17/28).
However, the same study stressed that the immunohistochemical profiles of MPNSTs do not
always correlate exactly with the cell morphology or pathological patterns. This histopathological
description resembles that of the set of sarcomas found in the 'cis' and 'H-M' animals. A subset
(approximately 10%) of MPNSTs contain heterologous elements, or cells displaying differentiation
distinct from the nerve sheath (Fletcher, 1995). The most commonly observed differentiation
pattern is rhabdomyoblastic, called "Malignant Triton tumors," are defined as malignant nerve
sheath tumors or Schwannomas with rhabdomyosarcomatous differentiation (Brooks, 1988;
Woodruff, 1996). Triton tumors account for approximately 16% of all MPNSTs, and typically
represent much worse clinical prognosis than MPNST in general (Brooks, 1988; Woodruff,
1996). The designation of "Triton" came from experiments conducted in Triton salamanders
(genus Triturus) where sciatic nerve transplants evolved both neural and muscular elements
(Masson, 1932). Hallmark traits of Triton tumors include (1) the presence of two distinct cellular
regions (spindle and pleomorphic) in the same tumor, (2) skeletal muscle actin striation in
differentiated rhabdoid cells, and (3) immunohistochemical confirmation of muscle-specific
markers such as a-sarcomeric actin and myoglobin.
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A clear involvement of the NF1 mutation in MPNSTs and Triton tumors is has been established in
clinical studies, as evidenced by studies noting the predominance of Triton tumor patients with
family histories of NF1 (Sordillo et al., 1981; DeWit et al., 1986; Ducatman et al., 1986, Hruban
et al., 1990). In addition, the human NF1 population exhibit an increased frequency of Triton
tumor development (1-4%) (Fletcher 1995; Doom et al., 1995). Sporadic MPNSTs arise in
humans at the mean age of 40 years, while the NFl-associated MPNSTs become apparent on
average 10 years earlier in life (Fletcher 1995). Lastly, NF1 mutations have been found in a subset
of MPNSTs previously defined as neurofibrosarcomas (Legius, 1993). The correlation of p53
mutations in MPNSTs has also been demonstrated by the occasional LOH at that genetic locus on
chromosome 17p (Legius, 1994; Jhanwar, 1994, Lothe, 1995), loss of p53 expression in
MPNSTs (Lothe et al., 1995) or by the overexpression of the presumed mutant p53 protein in
MPNSTs but not benign PNSTs (Kindblom et al., 1995).
In mice, the effect of the Nfl mutation has been studied in both Schwann cells and fibroblasts.
Nfl-deficient Schwann cells show properties consistent with an activated ras mutation, i.e.
decreased cell division in response to glial growth factor 2 (Kim et al., 1995). This suggests that
mutations in Nfl are required, but not sufficient, for abnormal Schwann cell growth in tumors,
and that the p53 mutation may be a necessary second mutation for proliferation. Nfl-deficient
fibroblasts exhibit only slight increases in growth properties, and a failure to form perineurium in
cultured conditions (Rosenbaum et al., 1995). Again, the lack of a drastic effect on nerve sheath
proliferation suggest that another mutation is needed in addition to Nfl for tumor transformation,
as is the case in the 'cis' and 'H-M' animals.
Triton tumors
Several theories have been put forth to explain the divergent differentiation observed in Triton
tumors. Some theories such as (1) induction by endoneural cells (Masson et al., 1932), (2) de-
differentiation due to some type of teratoid influence (Shuangshoti et al., 1979), or (3) a specific
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type of "collision tumor" of Schwann and rhabdoid elements (Naka et al., 1975), all have little
scientific support. The most widely accepted theory, called the "ectomesenchymal theory," was
developed from the neural crest precursor cell concept initiated by Horstadius (Woodruff, et al.,
1973, Karcioglu et al, 1977; Ducatman et al., 1984). According to this theory, neuroectodermal
structures evolve from migrating neural crest cells, a transient cell population existing only in early
development. These neuroectodermal structures include neurons, nerve sheath cells, melanocytes,
ganglion cells, as well as mesenchymal tissues such as bone, cartilage and muscle. A few of these
cells, such as the Schwann cell, are known to possess the ability to differentiate into other tissues.
The ectomesenchymal theory draws upon such pluripotent characteristics to suggest that
neuroectodermal tumors, especially of the peripheral nerve sheath, may recapitulate the
developmental lineage of neural crest cells. In fact, it has been suggested that Schwann cells may
possess the innate program to de-differentiate and the "trans-differentiate" into rhabdomyoblastic
cells (Nathanson, 1986). MPNSTs, therefore, are tumors of the "ectomesenchymal" type
dominated by Schwann or rhabdoid elements. This theory corresponds well with the involvement
of the Nfl mutation in the murine models, because human NF1 lesions occur primarily in tissue
types derived from the neural crest lineage (melanocytes, peripheral nerve sheaths, facial bone,
etc.) (Le Douarin, 1982). The p53 mutation may serve to promote tumors in cell types
predisposed to abnormal growth by the Nfl mutation.
Finally, we believe that the murine models described here provide a reproducible --and previously
unavailable -- solid tumor model associated with mutations in not only in the NF1, but thep53.
tumor suppressor gene as well. Such models are suitable for screening therapeutic agents aimed at
either (or both) of these molecular targets. Furthermore, this model not only affords the
opportunity to study the in vivo tumor response, but also in vitro assays using cell lines derived
from these lesions. This is particularly exciting since the sarcomas found in the Nfl-p53 animals
share growth and histopathological features with the lesions belonging to the important clinical
classification of MPNSTs.
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Chapter 5
Summary and Implications
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By the time this thesis project was initiated, the human NF1 gene had been identified and cloned
for less than two years. In the years since, relatively little was known about the precise function of
the gene and its protein product, despite a flourish of reports documenting the gene's mutational
spectrum and patterns of expression. To summarize the findings: It has been established -- across
several species -- that NF1 is expressed ubiquitously in early development, and becomes
progressively restricted to various neural crest-derived tissues beginning in mid-gestation and
through adulthood. The adult tissues showing high levels of NF1 expression were consistent with
many of the tissues affected in NF1 patients, the most striking of which being neural crest-derived
tissues (peripheral nerve sheath, melanocytes, adrenal chromaffin cells, etc.). To date, the only
clearly assigned function to the NFI protein (neurofibromin) is its ability to downregulate the
p2ras oncogene signaling pathway. This anti-oncogenic activity, together with the frequent loss
of heterozygosity (LOH) at the NF1 locus in human tumors, suggest that NF1 normally functions
as a tumor suppressor gene.
Yet, the progress toward understanding of the NF1 disease has remained stagnant over the past
several years. The lack of progress may be attributed to the large size of the gene's coding
domain, the difficulty to express and develop functional assays using the entire protein, and the
extremely variable disease severity found across the human patient population. Of these, the
inability to address even the most basic functions of NF1 in normal and diseased cellular processes
has been frustrating, given the prevalence of NF1 and the potentially debilitating symptoms
associated with the disease. In my efforts to create a mouse model of Nfl, I focused on trying to
answer the following questions:
* What role does Nfl play in development?
* What are the crucial cell type(s) in neurofibromas?
* What genetic events are required for the development of neurofibromas?
* What additional events are needed for malignant progression of these lesions?
* What genetic and environmental factors modulate the expressivity of the NF1 disease?
* What functional role does neurofibromin play in influencing various disease pathways?
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* Are there other functional domains on neurofibromin?
* What are the upstream regulators and downstream effectors of neurofibromin?
* Can we develop a good set of biological reagents to better answer these questions?
This thesis attempts to (1) understand the genetic basis for the NF1 disease and (2) utilizing that
knowledge to generate mouse model that accurately recapitulate the various lesions found in human
NF1 patients and (3) eventually use that model to help develop effective treatments for NF1
complications. Mouse models are ideal for this type of analysis given the ability to modify and
introduce various gene sequences in vivo and in vitro. Furthermore, clinically-relevant animal
disease models are often ideal candidates for pharmaceutical companies to assess the preclinical
drug safety and efficacy profiles prior to human trials. I will discuss below one such compound
with the potential to treat NF1 patients. Therefore, in this final chapter, I intend to summarize the
progress I have made toward each of those goals, describe the implication of those findings, and
then raise issues that have not been adequately addressed.
Gene targeting
When the germline Nfl mutation was created in mice via homologous recombination (Chapter 2),
many other mouse genes have already been functionally disrupted using similar techniques. Most
targeting vectors included the insertion of a selectable marker, the neomycin resistance gene (neo),
in the opposite transcriptional orientation relative to the gene of interest. This selectable marker
was important for both disrupting the gene function as well as identifying cells with the appropriate
homologous gene integration. In an effort to provide a detailed characterization on the
molecular/splicing effect of the neo gene insertion, we determined that the neo coding sequences,
when inserted in the opposite orientation, provides a set of very efficient splice donor and acceptor
sites. As a result, the mutant transcript from the neo-disrupted Nfl allele included a 473 nucleotide
stretch of antisense neo sequence (Jacks et al., 1994), instead of a series of potential translational
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stop codons expected with this type of insertional mutagenesis events. In fact, all mutant alleles
constructed in this manner should be expected to generate such aberrant transcripts, which may
result in the production of proteins with unexpected functions. This has potentially significant
implications in the design of targeting vectors for homologous recombination, given the explosion
of knockout mouse strains in the years since the publication of our report.
Role of Nfl in development
Neurofibromin is expressed at high levels in every cell type in early embryogenesis, and becomes
increasingly restricted to the PNS, white blood cells and the adrenal medulla after mid-gestation.
Given the ubiquitous expression early in development, it was surprising to find that Nfl-deficient
embryos were able to survive up to day 13.5 of gestation. One possible explanation for the lack of
an Nfl phenotype prior to mid-gestation (despite high levels of gene expression) is that of
functional redundancy, i.e. the existence of other proteins which may compensate for the loss of
the Nfl protein. In fact, based on the proposed function of neurofibromin as a GTPase activating
protein (GAP), it is likely that other GAP proteins are active early in embryogenesis in addition to
Nfl .
The cause of death was a restriction of blood flow due to the combination of abnormal heart
development (double outlet right ventricle) and a thickening of endocardial cushion tissues in the
cardiac outflow tracts (i.e. the aorta and pulmonary artery). These features provided further
support for the involvement of neural crest tissues in the NF1 disease tissues, largely because of
previous observations made in avian neural crest experiments: laser ablation of neural crest cells in
birds resulted in cardiac defects reminiscent of the mouse Nfl mutant phenotype, but the
endocardial cushion hyperplasia was noticeably absent. Thus, the cushion defect may be a specific
functional consequence of Nfl deficiency in these cell types. A second explanation for the cardiac
phenotype may be related to the onset of Type III neurofibromin isoform expression in cardiac
183
muscle during mid-gestation (Gutmann et al., 1995a). Perhaps Type III neurofibromin confers the
predominant GAP activity in the embryonic heart, without which the cells lining the outflow tracts
fail to cease proliferation (Chapter 2).
A separate developmental phenotype associated with the loss of Nfl function was described in
neonatal DKO chimeras -- this time affecting another neural crest-derived tissue: the adrenal
medulla. It appears that Nfl-deficient chromaffin precursors are either unable to migrate
completely into the adrenal primordium, and differentiated ectopically into adrenal chromaffin cells
(Chapter 3). An alternative scenario is the abnormal growth and metastasis of chromaffin cells into
the surrounding tissues. In either case, the adrenal medullary defect most likely resulted in
neonatal lethality by causing dysregulation of epinephrine and norepinephrine production in mice.
Neurofibromin may play a role in signals required for migration, due to its physiological
association with microtubules (Gregory et al., 1993). However, it does not appear that Nfl
function is required for proper differentiation of adrenal chromaffin cells.
Nfl in benign lesions
Despite being two of the most common lesions of human the NF1 disease, the development of
cafe-au-lait spots and Lisch nodules have not been detected in the mouse mutant Nfl models. This
was true both in the case of the Nfl heterozygous mice as well as the Nfl DKO chimeras (positive
contribution of Nfl-deficient ES cells to the iris and skin has been suggested by GPI analysis
and/or X-gal staining). The absence of these two benign phenotypes may be attributable to the
inability of the Nfl mutant locus to undergo LOH (a possible rate-limiting step required for
abnormal tissue growth). To address whether Nfl deficiency is necessary in the initiation of
benign growths, it would be interesting to quantify the extent of Nfl LOH in iris and skin
melanocytes of Nfl +/- adult mice without cafe-au-lait spots or Lisch nodules (these experiments
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are now feasible due to improvements in single-cell PCR and trace DNA isolation techniques). If
no LOH is detected even in aging animal tissues, it may suggest iris cells and skin melanocytes
have high genomic stability, or that the mouse susceptible "target cell" population is too small for
any meaningful LOH to occur during the animals' lifetime.
On the other hand, intrinsic physiological differences between mice and human in these two cell
types may preclude the development (or detection) of cafe-au-lait spots and Lisch nodules. For
example, mouse skin normally undergoes wave-like patterns of continuous hair follicle and
melanocyte regeneration, which then induces high levels of natural melanin production throughout
their lifetime. Therefore, it may be impossible to differentiate between normal skin
hyperpigmentation and cafe-au-lait spots arising from Nfl-deficient melanocytes.
Role of Nfl in tumor suppression
Consistent with the Knudson model of tumor suppressor genes (Knudson, 1971), our work
suggests that the loss of both Nfl alleles is a step toward tumorigenesis in at least four tumor
types: pheochromocytoma, myeloid leukemia, neurofibroma and malignant peripheral nerve
sheath tumors (MPNSTs).
Pheochromocytoma
Animals inheriting one mutant copy of Nfl are prone to developing tumors (unilateral or bilateral)
of the adrenal medulla (pheochromocytoma), albeit late in their normal life expectancy (Chapter 2).
Pheochromocytoma is another component of the Nfl-related neurocristopathy proposed for the
involvement of various neural crest derivatives in NF1 lesions. Our analyses concur with human
studies in suggesting that loss of NF1 function is required for the onset of malignant
pheochromocytomas in patients with or without other NF1 clinical features (Xu et al., 1992;
Gutmann et al., 1995b). Functionally, this provides an argument for neurofibromin as a
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downstream effector of ras: It has been established that transient activation of ras causes
proliferation while constitutively activated ras induces differentiation and inhibit proliferation of
neuronal and PC12 cells, a rat pheochromocytoma cell line (Greene and Tischler, 1976).
Therefore, since the loss of NFI is expected to result in prolonged ras activation, it suggests that
neurofibromin is functioning as an effector in the differentiative signaling pathway of ras.
Myeloid leukemia
Benign myeloid hyperproliferative disorders were seen in both the DKO chimeras and Nfl
heterozygous animals (Chapters 3 and 2, respectively). Consistent with the human genotypic
analyses of NFl-related juvenile chronic myeloid leukemia (JCML) (Shannon et al., 1994), both
of these murine myeloid tumor models are accompanied by clear LOH at the Nfl locus (Chapter
2). Pathologically, the murine tumors are reminiscent of human myeloid disorders due to the
presence of predominantly well-differentiated cells in the myeloid lineage, suggesting a benign
lesion rather than a full blown leukemia. Biochemical assays show these murine cells to have
abnormally high ras-GTP levels, and are hypersensitive to GM-CSF stimulation -- a pathway
known to signal through ras (Largaespada et al., 1996). Therefore, neurofibromin seems to be a
classic negative regulator of ras signaling in response to growth factor stimulation, and that the loss
of one or both alleles of NF1 may accordingly lower the proliferative stimulation threshold for the
myeloid lineage.
Modifier Gene Effects?
One of the more curious aspects about the NF1 disease is the variable expressivity of phenotypes
across the human population. Two explanations have often been proposed as the underlying
causes for such variability, including the presence of modifier genes and other ectopic factors, such
as environmental influences.
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It has long been assumed that environmental effects, while playing a potentially important role in
the regulation of the disease phenotype, are not easily isolated or quantifiable from the study of the
human NF1 population (due to the inability to control many such conditions among human
patients). On the other hand, attempts to link disease severity to specific gene mutations have
revealed subtle correlations at best (Cnossen et al., 1997). In fact, it has been demonstrated
consistently that NF1 patients inheriting identical gene mutation can develop vastly different
symptoms. The only known genotypic-phenotypic relationship has come from studies of
monozygotic twins (with identical DNA contents), who tend to exhibit a more similar (though not
the same) spectrum of lesions than more distantly-related NF1 individuals, such as dizygotic twins
(Easton et al., 1993). To date, the human data can be used only to implicate the involvement of
environmental and genetic components in regulating the onset of various NF lesions, but fall well
short of suggesting the identity or extent of such influences. Lastly, given the diversity of its
genome through randomized breeding, the human model does not provide an easy reagent from
which to clone and identify modifier genes involved in the NF1 disease.
We believe that the Nfl mouse tumor models may yet prove valuable in providing the necessary in
vivo tools to elucidate some of the genetic components affecting NF1 disease onset and
development. First of all, we were able to minimize the impact of environmental variabilities by
maintaining our mouse study population under strictly-controlled laboratory conditions. Secondly,
because the Nfl mice show tumor development in a strain-dependent manner (Chapters 2 and 3), it
therefore suggests the existence of strain-specific modifier genes which serve to modulate the onset
of certain tumor types. In fact, myeloid proliferative disorders have been found only in 129sv
inbred Nfl +/- mice or in DKO chimeras generated from 129sv inbred Nfl -/- ES cells. On the
other hand, pheochromocytomas were exclusively detected in the 129sv x C57BL/6 mixed
background animals (both in animals inheriting germline mutations as well as DKO chimeras).
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Evidence supporting a genetic component in (1) the modulation of disease predisposition as well as
(2) drug efficacy in patients from various genetic backgrounds has led to the emergence of a field
in modern medicine that focuses on establishing genetic "profiles" of patients. The goal of genetic
profiling is to identify a set of genetic markers that determines why some patients develop a certain
set of malignancies and, more importantly, why only a percentage of patients respond to a
particular treatment, while the same treatment show little efficacy on others (also known as
"pharmacogenomics"). Researchers in this field intend to use the power of genomics research and
high-throughput screening to identify these modifier genes. Eventually, this genetic data will be
used to improve disease management protocols in healthcare, be it interventional or prophylactic.
The cancer genetics data shown in Chapters 2 and 3 is critical to this area of research because it
provides an in vivo situation showing clear-cut divergence of NF I clinical symptom based on
genetic differences. Therefore, such a model may be used to identify and clone individual modifier
genes in mice that influence the development of each NFl-related phenotypes -- by extending the
same type of genetic/phenotypic analysis across other Nfl inbred mouse strains. If modifier gene
candidates were confirmed in the Nfl murine models, the study of their human homologs may
eventually be useful in (1) determining the predisposition of certain patient segments to succumb to
various NF1 malignancies and (2) defining other players in the genetic pathways of the disease. A
prime example of this type of research is the cloning of Mom-i, a modifier locus of the intestinal
polyp numbers in Apcmin mice (Dietrich et al., 1993). More recently, the phospholipase A2 gene
was suggested as the actual modifier gene residing in the Mom-i locus (MacPhee et al., 1995).
Mechanistically, the differences in tumor spectrum may be a result of (1) slight variations in how
the neurofibromin signaling pathways are regulated (e.g. mixed background animals may have
redundant GAP functions in myeloid cell lineages, which prevents the cells from abnormal
proliferation) or (2) differential regulation of neurofibromin activity (e.g. lower expression or
higher rate of turnover of neurofibromin in 129sv chromaffin cells such that the physiological level
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of active p2 ras remains higher relative to other strains). As opposed to myeloid leukemia and
pheochromocytoma, the development of neurofibromas (in timing, size and number) does not
seem to vary across these two strains. This either suggests that (1) modifier genes required for
neurofibroma development is present in both murine strains examined in this thesis or (2) the
presence of an Nfl mutation alone may be sufficient to induce neurofibroma formation without the
influence of modifier genes. If the latter case was true, it may explain why neurofibromas are so
prevalent in the human NF1 population. To address these questions, the Nfl mutation is currently
being bred onto different inbred mouse backgrounds. If any of these different mutant Nfl strains
show definitive changes in the presentation of NFl-related lesions, a full-scale search will
commence for possible modifier genes, using the densely-mapped (and commercially-available)
chromosomal markers.
Neurofibroma associated with simple NF1 LOH?
Ever since the cloning of the NF1 gene, the question of whether NF1 LOH is required for
neurofibroma formation has remained unresolved. This is partly because the search for the
inactivation of the second NF1 allele in these benign lesions has produced mostly negative results,
with only a few recent reports demonstrating LOH in some lesions (Colman et al., 1995; Sawada
et al., 1996; Serra et al., 1997). Despite this ambiguity of data, there is little doubt that NF1
heterozygosity is a prerequisite toward the development of neurofibromas, given that all NF1
patients are constitutionally heterozygous for the NFI mutation. It is worth noting again,
however, that in human NF1 clinical studies, the inability to control for genetic and other
environmental variables makes it extremely difficult to identify and/or rule out the involvement of
other factors which may promote neurofibroma formation.
With this in mind, it was nonetheless a surprising observation that no neurofibromas were ever
found in heterozygous Nfl mice (Chapter 2). Perhaps the absence of only one Nfl allele was
insufficient to induce tumor growth -- and that additional genetic events or environmental factors
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are required (during the animal's lifetime) for initiation. In Chapter 3, we described the detection
and characterization of multiple plexiform neurofibromas in Nfl DKO chimeras, a mouse model in
which a number of Nfl deficient cells are randomly introduced into various adult tissues. In fact,
increased numbers and size, as well as earlier onset of neurofibromas are correlated with higher
levels of Nfl -/- cell contribution. Given the early onset of these peripheral nerve lesions (as early
as 2.5 months of age), it is unlikely that the cells responsible for neurofibroma formation have had
enough time to incur a number of other mutations. Taken together, these observations extends the
current thinking about neurofibroma etiology by implying that simple Nfl deficiency may be
sufficient to initiate and promote neurofibroma growth. However, additional data will be needed to
validate this hypothesis. One such direct proof includes demonstrating the presence of Nfl
deficient cells in these murine lesions. Hopefully, this evidence will become available in the near
future using the ROSA-26 transgene as a molecular marker in Nfl -/- ES cells (Chapter 3).
Cellular composition of neurofibromas
The murine neurofibromas appear to lack the variable cellular composition relative to their human
counterparts. In humans, approximately 40-85% of the neurofibroma cells are believed to be of
the Schwann cell origin (Stefansson et al., 1982), although the recorded range vary significantly
between individuals and from study to study. In contrast, our murine neurofibromas are almost
entirely perineurial in nature, as determined by immunohistochemical and ultrastructural evidence
(Chapter 3). Does this observation imply intrinsic differences between the human and mouse
tumorigenic pathways? Indeed, it is possible that the particular exon 31 mutation we generated in
mice specifically caused the hyperplasia of perineurial cells. As mentioned previously, however,
such phenotype-genotype correlation has not been conclusively demonstrated in humans.
Furthermore, the mouse neurofibromas may lack the cell type variability because, contrary to
studies using human subjects, we were able to more closely control (and alter) the genetic
background and environmental influences in our mouse population.
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The difference in cell type composition may also be explained by a major discrepancy between the
genetics of the mouse and human disease systems: In the adult DKO chimeras, Nfl null cells are
typically surrounded by wild-type (+/+) cells. In the human case, however, these Nfl null cells
would be surrounded by cells heterozygous (+/-) for the Nfl mutation (every human NF1 patient
is born constitutionally heterozygous for the NF1 mutation). A simple and elegant way to
recapitulate the human condition in mice is to inject Nfl null ES cells into blastocysts heterozygous
for the same mutation, hence the resulting chimeras would be strictly composed of Nfl +/- or -/-
cells. It is possible that haploinsufficiency in Nfl function is critical to the development of
neurofibromas in addition to the LOH event, for example, in providing appropriate environment
cues (e.g. cell surface molecules) or increasing certain cell types' sensitivities to various growth
factors.
As mentioned previously, one of the unanswered questions is the identity of the Nfl-deficient cell
type(s) responsible for the tumor growth. So far, our attempts at identifying the Nfl DKO ES
cells in the mouse lesions have fallen short (in situ hybridization, in situ PCR, etc.) However,
only recently were we able to observe the development of neurofibromas in a ROSA-26 DKO
chimera, which could finally render the visualization of null cells in neurofibromas technically
feasible. The potential drawbacks to this approach are (1) the variability in P-gal staining patterns
in control PNS tissue sections and (2) the problem of X-gal penetration into the tumor (Chapter 3).
However, preliminary data suggest that the current staining protocol may be able to yield specific
staining patterns in the cell types involved. This should be one of the top short-term priorities for
the project.
The neurofibroma is the only benign lesion associated with NF1 with the potential to progress into
MPNSTs. Such malignancies are both painful and generally lead to poor patient prognosis. The
findings presented here will hopefully provide a framework that defines the minimal genetic
alterations that are necessary and sufficient for the development of neurofibromas, and will
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subsequently lead to rational disease management -- and possibly therapeutic -- protocols for the
NF1 patients.
MPNST
Malignant lesions associated with NF1 include neurofibrosarcomas, Schwannomas,
rhabdomyosarcomas, fibrosarcomas, as well as other undifferentiated sarcomas. There is evidence
implicating the p53 tumor suppressor gene in malignant transformation of peripheral nerve sheath
lesions (Menon et al., 1990). This was the underlying rationale for the experiments in Chapter 4,
which described three mouse models inheriting various combinations of germline Nfl and p53
mutations. Two of these mouse strains, the 'cis' (Nfl-p53 double heterozygotes on the same
chromosome) and the 'H-M' (Nfl +/- and p53 -/-) were prone to developing large, solitary
sarcomas within five months of birth.
In the mouse genome, the Nfl and p53 loci are closely linked (5 cM). Therefore, in both the 'cis'
and 'H-M' mice, the LOH of the two mutant alleles was found to occur simultaneously. The data
from these mice complement previous studies that simply document the detection of Nfl and p53
mutations in MPNSTs. In fact, the kinetics of tumor formation provide strong (and direct)
evidence that Nfl and p53 alone are sufficient to induce malignant transformation of tumors. Since
the lack of p53 confers resistance to a variety of therapeutic protocols, this is a particularly good
model for testing cancer drugs because it will also show whether the compound can cause tumor
regression in a p53-independent manner.
Histological and immunohistochemical analysis showed a wide range of differentiation and
pleomorphic features among the tumors -- and frequently within individual tumors -- features that
are strongly indicative of MPNSTs (Fletcher, 1995). However, the fact that some tumors are
clearly undifferentiated fibrosarcomas while others resemble differentiated rhabdomyosarcomas
raises an interesting point: Do these tumors share a common nerve sheath origin, or do they
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represent a collection of tumors arising from several different, terminally-differentiated, cell types?
This answer to this question is central in understanding the etiology of the tumor model.
However, there may not be a clear answer, given (1) the frequent disagreements among
pathologists as to what constitutes an MPNST and (2) a lack of strong correlation between genetic
mutations and cellular composition in such lesions. The situation is further complicated by the
rapid accumulation of chromosomal aberrations and the activation of multiple signaling pathways
that usually occur in rapidly-dividing tumor cells. We are hoping to address this question in the
short-term by obtaining ultrastructural and additional immunohistochemical data on this set of
tumors.
Past and present collaborations
Given the advantages of our mouse model as a well-defined biological reagent, we have initiated
collaborative efforts with several principal investigators to study the role of Nfl in various
biological pathways.
* Nfl signaling in the myeloid lineage to modulate proliferation and differentiation (Dr. Kevin
Shannon of UCSF, Dr. Wade Clapp of the University of Indiana Medical School, and Dr. Gideon
Bollag of Onyx Pharmaceuticals). Nfl-deficient bone marrow cells were used to reconstitute the
hematopoietic cells in lethally-irradiated mice. Results show the development of myeloproliferative
disorders in these mice (Bollag et al., 1996), which are currently being treated with the farnesyl
transferase inhibitor (described below).
* Immunohistochemical analysis of pheochromocytoma and attempted derivation of cell lines (Dr.
Arthur Tischler, New England Medical Center in Boston). Pheochromocytomas derived from the
Nfl mice maintained normal chromaffin differentiation in culture and were found to express
epinephrine (Tischler et al., 1995). Since Rb DKO chimeras also tend to develop
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pheochromocytomas, we decided to study the cooperative effects of the Nfl and Rb germline
mutations on tumor development. Preliminary data suggest that these animals show an early onset
of multifocal pheochromocytoma in the adrenal medulla (unpublished results).
* Cooperative effects between Nfl and p120 GAP (Dr. Mark Henkemeyer and Dr. Tony Pawson
at the Mt. Sinai Hospital, Toronto). The combination of GAP and Nfl mutations in development
led to an early stage embryonic lethality associated with vascular defects and hyperproliferation in
the developing nervous system (Henkemeyer et al., 1995). These two mutations cooperated in
adult mice to induce a preponderance of hemangiosarcomas (unpublished results).
* A putative role of Nfl in B cell proliferation mediated through a tyrosine kinases (Dr. Shiv Pillai
of the Massachusetts General Hospital in Charlestown). The isolation of bone marrow cells for
biochemical studies on the signaling and proliferative effects of Nfl-deficiency.
* The role of Nfl in learning and memory (Dr. Alcino Silva of Cold Spring Harbor Labs). The
combination of Nfl and other synaptic function mutations (e.g. NMDAR 1, a glutamate gated
calcium channel) caused deficits in learning and long-term potentiation. Published data suggest a
significant alteration of brain signaling and memory, which may begin to explain the mental
retardation and learning disability associated with some NF1 patients (Silva et al., 1997).
* The effect of Nfl deficiency in the neural crest lineage (Dr. Hubert Schorle and Dr. Rudolph
Jaenisch at the Whitehead Institute in Cambridge). Nfl-deficient neural crest cells were cultured
and transplanted back into murine hosts. In the few animals tested, the detection of melanin-
producing cells in lung and muscle tissues suggest that Nfl null neural crest cells may be defective
in migration and differentiation.
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* The role of Nfl heterozygosity in skin melanocytes (Dr. Dieter Kaufmann and Dr. Winfried
Krone, Universitat Ulm, Germany). Skin melanocyte cultures were established from Nfl
heterozygous animals for biochemical and functional analysis.
Long-term goals
Despite the progress we have made in understanding the genetic and functional pathways involving
Nfl, a number of the outstanding questions still remain pertaining to the onset and growth of
neurofibromas. Given the limitation of current mouse models, we see a necessity to build better
mouse models to address these questions.
Conditional knock-outs
The cell type responsible for the formation of neurofibromas may be identified by using the cre-
loxP conditional knockout technique described in Chapter 1. Briefly, this model allows for tissue-
specific inactivation of gene function by expressing the cre recombinase in a restricted set of cell
types. Therefore, by disrupting Nfl function only in Schwann cells, neurons or perineurial cells
in mice, the appearance of neurofibromas can be clearly affiliated with the loss of Nfl function in a
particular cell type.
Neurofibromin domain-function analysis
Since the cloning of the NFI gene in 1990, only a few domains of neurofibromin have been
assigned putative functions. Given the large size of the protein and the various signal transduction
pathways in which neurofibromin has been implicated, the identification of these domains would
move the NF1 field forward considerably. To this end, we suggest using a yeast artificial
chromosome to introduce the entire Nfl genomic fragment into DKO ES cells. The advantages to
this approach include the ability to propagate up to a megabase of mammalian genomic DNA,
making it possible to clone the entire mouse NF1 gene (300 kb genomic region) into a single YAC.
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In fact, a YAC encompassing the entire human NF1 gene has been constructed (Marchuk et al.,
1992). However, frequent rearrangements of genes cloned into YACs (especially large fragments)
may limit the usefulness of this approach. To avoid this difficulty, a good restriction
map/fingerprint of the cloned gene must be available in order to detect a wide range of mutations
that might occur during the propagation and transfer of the YACs.
Because the DKO ES cells are functionally null for Nfl function, any mutant allele brought in by
YACs will become the exclusive source of neurofibromin in these cells. Previous reports have
documented successful introduction and expression from YAC DNA fragments in mammalian cells
(Pachnis et al., 1990; Strauss and Jaenisch, 1992; Choi et al., 1993; Schedl et al., 1993; Montoliu
et al., 1994; Huxley et al., 1996; Matsuura et al., 1996; Li et al., 1997; Maas et al., 1997; Manson
et al., 1997). This will constitute a quick and clean system to study the consequences of various
NFI mutations in vivo. Mutagenesis and manipulation of the large Nfl gene can be greatly
facilitated by the powerful recombination machinery in yeast (reviewed in Lamb and Gearhart,
1995). Precise point mutations, insertions and deletions of YAC DNA can be easily made by
homologous recombination. Therefore, we envision this approach as an effective screen for
functional domains of neurofibromin -- by selectively mutating various regions of neurofibromin
(highly-conserved domains as well as the regulatory elements, embedded genes, or the 5'- and 3'-
UTR). The resulting phenotype of the YAC chimeras may provide clues to other unknown Nfl
functions.
Another advantage of this system is the short time frame required to screen for a specific mutation.
After generating the mutant Nfl YAC construct, it should be a matter of months before a chimera
can be obtained and its phenotype analyzed. Furthermore, if a mouse strain reliably succumbs to
NF1 lesion (such as neurofibromas, pheochromocytomas, or connective tissue abnormalities), not
only have we generated additional mouse models of the NF1 disease, we might also be able to
attribute such lesions to a specific domain mutated in the Nfl gene. This mutagenesis data may be
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helpful in identifying potential binding partners of neurofibromin, and clarifying the biochemical
pathways giving rise to NF1 phenotypes as well as the particular cell types in which they act.
Genetic studies of a neurofibromin homolog (60% protein identity) in D. melanogaster has
provided evidence for an additional ras-independent signaling pathway. Flies deficient for this
protein show reduced size and the noticeable absence of a K current upon stimulation by
neuropeptides. Interestingly, these phenotypes can be rescued by increased signaling through the
cAMP-PKA -- but not the Ras 1 -- pathway (The et al., 1997). Such evidence suggest that human
neurofibromin may also possess domains which interact with players in the PKA-mediated signal
transduction pathway. Clinically, it is possible that NF1 deficiency may lead symptoms resulting
from the abnormal regulation of the PKA pathway, such as learning deficiencies. The YAC
transgenesis system may be used to quickly map the protein domains involved in this, as well as
other, signaling pathways.
It has been suggested that an expression vector driving the Nfl cDNA may be a simpler way to
generate such mouse models of NFl. However, several lines of evidence argue for using the YAC
approach: First, the YAC vector will supposedly contain the physiological promoter driving Nfl
expression, as well as its nearby regulatory elements (i.e. enhancers and repressors). Second, and
probably more importantly, if intronic sequences are crucial to the function and regulation of Nfl
(e.g. alternatively spliced forms of Nfl or embedded genes), then a cDNA will not be able to
recapitulate normal Nfl function.
Therapeutic models of NF1
As mentioned previously, one of the reasons for creating these mouse models of cancer is their
utility as animal disease models to be used during preclinical drug testing. Given that the various
Nfl knockout mice exhibit subsets of the NF1 disease phenotype (within a genetically-defined
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system), pharmaceutical companies will be able to pinpoint the design of their drug development
trials toward very specific therapeutic indications by using one or more of these models. This is
particularly important given the competitive nature of the pharmaceutical industry, the high cost of
entering into full-blown clinical trials, and the necessity to demonstrate efficacy toward alleviating
well-defined disease symptoms.
One obvious candidate for the treatment of NF 1 is a class of compounds called farnesyl protein
transferase inhibitors (FPTI) (reviewed in Khosravi-Far et al., 1992). These small molecule drugs
act by inhibiting the farnesyl transferase, an enzyme that confers ras activity by anchoring active
ras proteins to the cell membrane. In fact, various forms of FPTI competitively inhibit the active
binding site on the protein and, by definition, act as general inhibitor of the ras signaling pathway.
Currently, over ten pharmaceutical and biotechnology companies have FPTI research programs,
with Merck, Schering Plough and Janssen pharmaceuticals being the closest to filing an
investigational new drug application (IND) for the compound (Janssen filed the IND in October of
1997).
This potentially exciting drug has been successfully used to treat activated ras tumor cell lines (Yan
et al., 1995) as well as in vivo mouse cancer models harboring oncogenic ras mutations (Kohl et
al., 1995). Despite early concerns that FPTI may cause serious side effects, given that farnesyl
transferase proteins normally function in the retina, skeletal muscle as well as rapidly-dividing
tissues (Khosravi-Far et al., 1992), these drugs have shown good clinical efficacy in reducing
tumor mass, while including relatively few deleterious features in animal tests (within the
therapeutic dose). This lack of serious side effects prompted investigators to examine the
mechanism and specificity of FPTI's. In fact, it was recently determined that H-ras protein
prenylation is highly sensitive to farnesyl transferase inhibitors, while N- and K-ras are
alternatively prenylated by geranylgeranyl transferase-1 (GGTase 1) in the presence of FPTIs
(Whyte et al., 1997). This was due to the fact that GGTasel are 100 fold less sensitive to FPTI
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inhibition than FTase proteins. In addition, it was found that K-ras4B (the predominant isoform)
can be modified by both GGTasel and FTase in vivo and in vitro (James et al., 1995; Lerner et
al., 1995). That evidence suggest a mechanism where FPTI efficiently shuts down signaling
through oncogenic H-ras mutants, but normal cellular signaling through N- and/or K-ras still
persists in non-transformed cells at concentrations sufficient to revert malignant phenotypes.
Therefore, depending on the type of oncogenic ras (H-, N- or K-ras) proteins found in the tumors,
the FPTI specificity toward cancer cells (and non-toxic effects toward normal cells) may be
explained by the fact that geranylgeranylation is highly resistant to their inhibitory effects, and may
indeed keep physiological ras signaling pathways functioning.
As a side note, it is known that modified Ras is very stable (half-life of 24 hours) (Ulsh and Shih,
1984). Therefore, it is curious that FTase inhibition takes effect much more rapidly than can be
explained by simple ras signal depletion alone. A consistent explanation for this type of drug
kinetics is an effect on the cellular cytoskeleton, namely the induction of actin stress fiber
formation. This observation suggest the Rho-subfamily of proteins as targets of FPTI. In fact,
RhoB is modified by both GGTase and FTase with a half life of approximately two hours
(Adamson et al., 1992; Lebowitz et al., 1995). Another likely FPTI target could be the RhoE
GTPase, which is normally GTP-bound and exclusively farnesylated (Foster et al., 1996).
Furthermore, dominant negative mutants of Rho were able to impair transformation by oncogenic
ras, similar to FPTI (Qiu et al., 1995). Lastly, Lebowitz et al. (1995) demonstrated that FPTI can
suppress ras transformed phenotype by interfering with Rho function.
Together, the effect of FPTI in reducing tumor mass revealed mechanistic implications that were
not ras-dependent, as originally assumed by researchers. Subsequent findings on the effect of
FPTI showed the reasons behind its efficacy and lack of toxicity, which potentially involves other
farnesylated proteins that may be crucial in tumor development. This sort of seredipitous
observation, followed by exhaustive mechanistic studies, will eventually help to refine cancer drug
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targets. Such detailed understanding of drug action will be especially helpful given the current
trend of combining multiple drug therapies (cocktails) simultaneously targeting the various genetic
defects implicated in one cancer type.
Biological Models of NF 1
In summary, this thesis work had not only been an exercise in the generation of a tumor
suppressor mutant mouse strain via homologous recombination. Aside from the creation and
detailed characterization of murine myeloid leukemia, pheochromocytoma and neurofibroma
models, I believe we have, in fact, opened the door to understanding the tumorigenic and signaling
mechanisms of the Nfl gene:
First of all, the mouse model has provided powerful in vivo and in vitro systems to study the
function, signaling pathway and mutational consequences of Nfl: We now have the ability to
systematically manipulate genetic and environmental factors which may be relevant to Nfl tumor
development. Concrete experimental protocols can be quickly established to test each of these
variables alone and in combination. We also have the tools to address the multi-factorial and multi-
step nature of neurofibromas, and how such cues would lead to tumor initiation, promotion and
progression to malignancy (growth factors, physical trauma, diet, stress, etc.). One way to
accomplish this is to study the effect of two or more cancer genes acting in concert, be it in a
synergistic or complementary context/pathway. We now have the ability to be able to follow a
large number of animals in order to assess the effects of a particular mutation across different
genetic backgrounds -- a sort of controlled cancer population study that has previously been
deemed unfeasible for the NF1 disease. Such a study can be crucial in defining the complex
genetic and environmental factors leading to the variable expressivity of the disease. Finally, using
the YAC transgene approach, we now have an efficient screen for functional domains of
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neurofibromin, be it as a negative regulator or effector of the ras pathway, for the identification of
binding domains and partners, or other yet unrevealed functional protein regions.
Yet, equally important to the scientific pursuits outlined above, these Nfl murine models can be
applied toward developing more effective therapeutic protocols for human NF1 patients. In
contrast to previous Nfl animal models, most of which have ill-defined etiology or the inclusion of
broadly-acting oncogenes, we now have several clearly-defined mammalian tumor models
exhibiting various features of the NF1 disease (both benign and malignant). Expanding the genetic
analysis (as described above) on our existing models may eventually help to determine the critical
genetic profiles for human NF1 patients -- in order to better define disease predisposition/risk and
for drug response profiles.
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